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ABSTRACT 
 
ROBERT N. SCHUCK: Translational Characterization of Arachidonic Acid Metabolism in 
Vascular Inflammation and Cardiovascular Disease 
 (Under the direction of Craig R. Lee, Pharm.D., Ph.D.) 
 
 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the 
United States and novel therapeutic approaches are needed to prevent its development and 
progression. It is well-established that inflammation is integral to the pathogenesis of 
coronary artery disease (CAD); therefore, inhibition of the inflammatory response has 
enormous therapeutic potential to prevent CAD development and progression.  
Cytochrome P450 (CYP) enzymes metabolize arachidonic acid to biologically active 
eicosanoids, and modulation of CYP-mediated arachidonic acid metabolism has emerged 
as a potential therapeutic target for the treatment of CAD. CYP epoxygenases from the 
CYP2C and CYP2J subfamilies metabolize arachidonic acid to epoxyeicosatrienoic acids 
(EETs), which have potent anti-inflammatory effects, and are rapidly hydrolyzed by soluble 
epoxide hydrolase (sEH) to less biologically active dihydroxyeicosatrienoic acids (DHETs). 
In contrast, CYP ω-hydroxylase enzymes from the CYP4F and CYP4A subfamilies catalyze 
the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) which 
exhibits potent pro-inflammatory effects. Accumulating evidence indicates that CYP-derived 
eicosanoids are key regulators of inflammation and endothelial function; however, the 
functional association between CYP-mediated eicosanoid metabolism, inflammation and 
endothelial dysfunction, and CAD remains poorly understood.  
Therefore, the aim of this dissertation is to characterize the functional contribution of 
CYP-mediated eicosanoid metabolism to the regulation of systemic and vascular 
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inflammation within the clinical context of CAD. Using an integrated combination of systems 
wide and candidate pathway approaches in humans, and pharmacologic and genetic 
approaches in mice, our findings demonstrate that genes regulating the inflammatory 
response associate with the presence and severity of CAD. Moreover, we identified a subset 
of stable CAD patients with enhanced CYP ω-hydroxylase and sEH metabolic function who 
had advanced endothelial dysfunction and vascular inflammation. In addition, our preclinical 
studies demonstrated that fatty liver disease-associated inflammation suppressed hepatic 
CYP epoxygenase activity, and genetic disruption of sEH restored EET levels, and 
attenuated hepatic and systemic inflammation. Collectively, this dissertation demonstrates 
that targeted therapeutic strategies that modulate CYP-mediated arachidonic acid 
metabolism represent a rational anti-inflammatory approach for the treatment of CAD, and 
thus lays a critical foundation for future studies that directly evaluate the therapeutic effects 
of modulating CYP-mediated eicosanoid metabolism in CAD patients. 
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CHAPTER I 
INTRODUCTION 
 
Clinical Problem 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the 
United States and novel therapeutic approaches are needed to prevent its development and 
progression. In 2008, over 800,000 individuals died from cardiovascular causes in the 
United States, which accounts for 1 in every 3 deaths.1 Coronary artery disease (CAD) is 
defined as the buildup of atherosclerotic plaque in the vessel wall of the coronary arteries. 
The progression of CAD results in narrowing of the vessel lumen, plaque instability, and 
ultimately plaque rupture and an acute coronary syndrome (ACS) clinical event. Over 1.2 
million people in the United States will experience a new or recurrent ACS event each year, 
making it a substantial burden on the healthcare system.1 In recent decades considerable 
progress has been made in the development of therapeutics for the treatment of CAD; 
however, mortality remains high and over 36% of men and 47% of women will die within 5 
years following a myocardial infarction (MI).1 The extensive morbidity and mortality 
associated with CAD highlights the need for new therapies that target biological pathways 
integral to the pathogenesis and progression of CAD. However, a more thorough 
understanding of the mechanisms underlying the progression of CAD is necessary to 
facilitate the development of new therapeutic strategies that mitigate CAD progression, 
prevent ACS clinical events and cardiovascular death, and improve public health.  
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Inflammation is a Key Pathological Mediator of CAD 
Atherosclerosis is a chronic disease that begins with the recruitment of monocytes to the 
coronary artery wall leading to the infiltration of macrophages, development of foam cells 
and formation of plaque, proliferation of the atherosclerotic lesion, and ultimately plaque 
rupture and ACS clinical events.2 The pathogenesis of CAD is complex, involving intricate 
interactions between the vessel wall and circulating blood cells; however, it is clear that 
innate immune system-mediated inflammatory responses play a key pathological role in all 
stages of atherogenesis.3 Most notably, activation of the transcription factor nuclear factor-
kappa B (NF-κB) through toll-like receptors (TLRs) and its downstream signaling is central to 
the regulation of inflammation and the pathogenesis and progression of atherosclerosis. 
 
Vascular Inflammation  
Vascular inflammation is integral to the development and progression of CAD.4 In the 
early stages of atherosclerosis, activation of NF-κB results in endothelial activation and 
increased expression of key pro-inflammatory cytokines (i.e., interleukin-6 [IL-6] and tumor 
necrosis factor alpha [TNFα]), chemokines (i.e., monocyte chemoattractant protein-1 [MCP-
1]), and cellular adhesion molecules (CAMs; i.e., intracellular adhesion molecule [ICAM]-1 
and vascular cellular adhesion molecule [VCAM]-1) on the endothelium.
5
 Cytokines are pro-
inflammatory signaling molecules that drive the inflammatory response,6 chemokines are 
chemoattractant cytokines that recruit leukocytes to the vessel wall7 and CAMs mediate 
leukocyte adherence to the endothelium.8 Collectively, these pro-inflammatory mediators 
facilitate the migration, adherence and infiltration of monocytes into the vessel wall where 
they differentiate into macrophages and engulf lipoproteins to form foam cells, a key step in 
the development of the atherosclerotic lesion.9 Circulating IL-6 promotes the release C-
reactive protein (hs-CRP) from the liver, initiating a systemic inflammatory response that 
propagates the vascular inflammatory response (Figure 1.1).9 These inflammatory 
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processes also contribute to plaque instability by breaking down the extracellular matrix; 
ultimately resulting in plaque rupture, formation of a thrombus, occlusion of the vessel, and 
an ACS clinical event.2  
Recent studies using preclinical models have demonstrated that inhibition of vascular 
inflammation may be a viable therapeutic strategy to prevent the development and 
progression of atherosclerosis. For example, LDL receptor knockout mice lacking the 
chemokine MCP-1 (Ldlr-/-/MCP-1-/-) develop significantly less atherosclerosis than Ldlr-/- mice 
wild-type (WT) for MCP-1.10 Similarly, mice deficient in both apolipoprotein E (ApoE-/-) and 
the CAMs ICAM-1 (ApoE-/-/ICAM-1/-), E-selectin (ApoE-/-/E-selectin-/-), or P-selectin 
(ApoE-/-/P-selectin-/-) have significantly lower atherosclerotic plaque lesion areas than ApoE-/- 
littermates.11 Collectively, these data indicate that endothelial activation and the subsequent 
increase in chemokines and CAMs are integral to the development and progression of CAD, 
and anti-inflammatory therapeutic strategies that attenuate NF-κB mediated vascular 
inflammation, may attenuate the development and progression of CAD. 
In humans, it has become well-established that circulating biomarkers of systemic and 
vascular inflammation are predictive of CAD risk, as well as prognosis in patients with 
established CAD. For example, higher circulating levels of CAMs, including VCAM-1, ICAM-
1 and E-selectin, are predictive of death from cardiovascular causes12 Similarly, elevated 
MCP-1 levels are associated with higher risk of all-cause mortality in patients with 
established CAD.13 The role of neutrophils in atherosclerosis has recently become 
appreciated,14 leading to the study of neutrophil chemokines including epithelial neutrophil 
activating protein (ENA)-7815 as potential mediators of vascular inflammation in patients with 
CAD. Genetic variation in ENA-78 has been associated with higher plasma ENA-78 levels16 
and higher rates of all-cause mortality in ACS patients.17 Collectively, these data 
demonstrate that biomarkers of vascular inflammation are critical in the pathogenesis and 
progression of CAD and are valuable phenotypic endpoints in pre-clinical and human 
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studies. Consequently, adjunct therapies that attenuate vascular inflammation have 
enormous therapeutic potential to prevent the progression of atherosclerosis and improve 
prognosis in CAD patients. 
 
Endothelial Dysfunction 
Endothelial dysfunction is a physiologic manifestation of vascular inflammation 
secondary to increased oxidative stress and impaired nitric oxide (NO) availability and 
function. Endothelial activation, and the subsequent macrophage infiltration into the vascular 
wall during the early stages of atherogenesis, results in increased production of reactive 
oxygen species (ROS) within the endothelium. Under conditions of oxidative stress NO· and 
O2·
- react to produce peroxynitrite (ONOO-) which diminishes levels of tetrahydrobiopterin 
(BH4).
18 BH4 is an essential cofactor for the enzyme endothelial nitric oxide synthase 
(eNOS), the main source of NO in the vasculature, and insufficient levels result in eNOS 
producing O2·
- rather than NO.18 This process is referred to as eNOS uncoupling and results 
in further reduction of NO availability, ultimately leading to endothelial dysfunction.19 
Impaired physiologic measures of endothelial function, most notably brachial artery flow-
mediated dilation (FMD), are associated with future cardiovascular events in multiple patient 
populations.20, 21 Moreover, CAD patients with persistently impaired FMD despite optimized 
therapy have a higher risk of cardiovascular events.22 Collectively, these studies illustrate 
that endothelial dysfunction is a key pathological mediator of CAD, and suggest that adjunct 
therapies that attenuate vascular inflammation and/or improve FMD may subsequently 
improve prognosis. 
 
Systemic and Hepatic Inflammation 
Vascular inflammation mediated by cytokines, chemokines, and CAMs leads to 
endothelial dysfunction and is a key pathological mediator of CAD. However, systemic 
 5 
 
inflammation can propagate the inflammatory response in the vasculature by increasing 
circulating levels of pro-inflammatory cytokines leading to more advanced vascular 
inflammation and endothelial dysfunction (Figure 1.1). Hepatocytes play a key pathological 
role in the propagation of the inflammatory response by releasing numerous pro-
inflammatory mediators into the systemic circulation including cytokines, chemokines and 
acute-phase reactants.23 Most notably, circulating IL-6 signals the liver to synthesize hs-
CRP, a potent acute-phase reactant that initiates and propagates a potent inflammatory 
cascade.9 Elevated hs-CRP is associated with increased risk of CAD development, 
recurrent MI and death from cardiovascular causes in individuals  with established CAD, and 
is used clinically to assess cardiovascular risk and guide treatment,4, 24, 25 indicating that the 
systemic inflammatory response is important in the development and progression of CAD 
and therapeutic strategies that mitigate the systemic inflammatory response may improve 
prognosis in CAD patients.  
 
Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis 
The liver is a key mediator of the initiation and propagation of the systemic inflammatory 
response and regulation of cholesterol homeostasis. Given the integral role of hepatocytes 
in the inflammatory response, and the potent pro-inflammatory effects of cholesterol, it has 
recently become appreciated that patients with chronic liver disease also have enhanced 
systemic and vascular inflammation.26 Non-alcoholic fatty liver disease (NAFLD) effects 
approximately 30% of the population, and ranges from simple steatosis to steatosis 
combined with inflammation (non-alcoholic steatohepatitis [NASH]), and may progress to 
cirrhosis and fibrosis of the liver.27 The severity of NAFLD has been associated with higher 
CVD risk, and the presence of hepatic inflammation (NASH) confers the highest CVD risk in 
both male and female subjects.28 Importantly, the association between NAFLD and CVD risk 
persists after adjusting for cardiovascular risk factors including age, sex, smoking history, 
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diabetes duration, HbA1c, LDL cholesterol, liver enzymes, medication use, and the 
metabolic syndrome, suggesting the presence of a pathological link between NAFLD and 
CVD rather than simply shared risk factors.29 Since inflammation plays a key role in the 
development and progression of both NAFLD and CVD, it is hypothesized that increased 
oxidative stress and NF-κB activation secondary to the presence of fatty liver disease drives 
vascular inflammation, endothelial dysfunction and the subsequent development and 
progression of CAD.30 This pathological link between NAFLD and CAD is supported by 
interventional studies in preclinical models and humans demonstrating that direct 
administration of free fatty acids increased plasma free fatty acid levels (a hallmark of 
NAFLD), resulted in NF-κB activation and impaired NO production in endothelial cells and 
elevated circulating levels of ICAM-1 and VCAM-1.31, 32 This direct functional interaction 
between fatty liver disease-associated systemic and vascular inflammation and CVD in 
preclinical models and humans suggests that novel therapeutic strategies that attenuate 
fatty liver disease-associated inflammatory response have enormous therapeutic potential to 
subsequently attenuate systemic and vascular inflammation and the development and 
progression of CAD. 
  
Summary and Significance  
Systemic and vascular inflammation, and the subsequent development of endothelial 
dysfunction, are integral to the pathogenesis and progression of CAD. Consequently, 
biomarkers of inflammation and endothelial function that are predictive of prognosis are 
valuable phenotypic endpoints in pre-clinical and human studies, and therapeutic strategies 
that decrease systemic or vascular inflammation and improve endothelial function have 
enormous potential to slow disease progression and improve outcomes in CAD patients. 
However, recent failures in drug development indicate that new therapeutics are unlikely to 
be effective in broadly defined populations. Therefore, identification and rigorous 
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characterization of the pathways central to the regulation of NF-κB dependent vascular and 
hepatic inflammatory responses in preclinical models and humans will be critical to facilitate 
the development of novel anti-inflammatory therapeutic strategies for the treatment of CAD, 
and identify putative responders to these therapeutic strategies.   
 
Arachidonic Acid Metabolism 
Metabolism of arachidonic acid to biologically active eicosanoids is critical in the 
regulation of numerous biological processes including inflammation.33, 34 Arachidonic acid is 
obtained through dietary sources or synthesized from linoleic acid and stored in cell 
membrane phospholipids where it is subsequently released by cytosolic phospholipase A2, 
the key regulator of free arachidonic acid levels.35 Free arachidonic acid is metabolized by 
the cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) enzyme 
families to bioactive fatty acids known as eicosanoids (Figure 1.2).36  
 
Cyclooxygenase Pathway 
The most widely studied pathway of arachidonic acid metabolism is the COX pathway, 
which plays a role in the regulation of inflammation and other biological processes.37 COX-1 
is expressed on platelets where, in conjunction with thromboxane A2 (TXA2) synthase, it 
metabolizes arachidonic acid to TXA2, a potent inducer of platelet aggregation.
38, 39 Inhibition 
of COX-1 with low-dose aspirin prevents arachidonic acid induced platelet aggregation, 
reduces risk of cardiovascular death, MI and stroke, and therefore is standard of care in 
CAD patients.40, 41 
COX-2 is expressed in the vasculature and on macrophages and metabolizes 
arachidonic acid to pro-inflammatory prostaglandin E2 (PGE2) and anti-inflammatory 
prostaglandin I2 (PGI2).
37, 42 Inhibition of COX-2 has yielded conflicting effects on 
cardiovascular inflammatory responses and atherosclerosis in pre-clinical models.42 For 
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example, the COX-2 inhibitor celecoxib increased TNFα expression in macrophages treated 
with lipopolysaccharide (LPS), and increased atherosclerotic lesion area in ApoE-/- mice 
treated with LPS.43 Conversely, genetic disruption of COX-2 in macrophages attenuated 
LPS induced expression of MCP-1 and TNFα, and the COX-2 inhibitors rofecoxib and NS-
398 reduced early atherosclerotic lesion formation in female ApoE-/- mice.44 These 
preclinical findings highlight the complex role of COX metabolism and prostaglandin 
signaling in the regulation of inflammation and CVD development and progression. 
Importantly, data in humans have clearly shown that selective inhibition of COX-2, 
significantly increases the risk of thrombosis and CAD clinical events,45-47 whereas non-
selective inhibition of COX-1/2 with non-steroidal anti-inflammatory drugs (NSAIDs) is not 
associated with clear evidence of protection or harm in CVD patients.48 Therefore, selective 
inhibition of COX-2 is relatively contraindicated, and routine use of non-selective NSAIDs is 
not recommended, in CAD patients secondary to increased risk of cardiovascular events 
and the associated morbidity and mortality.49 The complex role of COX-mediated eicosanoid 
metabolism in CVD, and the established role of low-dose aspirin in the secondary 
prevention of CAD, highlights the need for better understanding of parallel pathways of 
arachidonic acid metabolism in CAD. 
 
5-Lipoxygenase Pathway 
The LOX pathway metabolizes arachidonic acid to biologically active eicosanoids, 
including leukotrienes.34 5-lipoxygeanse (5-LO) and its activating protein (FLAP) are highly 
expressed in leukocytes and in the liver, and both enzymes are required to metabolize the 
conversion of arachidonic acid to leukotriene A4.
50 Leukotriene A4 is subsequently converted 
to LTB4, a potent leukocyte activator and chemoattractant, or cysteinyl leukotrienes, which 
mediate bronchoconstriction and have other biological effects.51 In contrast to COX derived 
eicosanoids, which have both pro- and anti-inflammatory effects, leukotrienes are clearly 
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pro-inflammatory in both acute and chronic models of inflammation. Mice with genetic 
disruption of the gene encoding 5-LO (Alox5-/-) have attenuated induction of inflammation 
and reduced organ damage following LPS administration.52 Similarly, ApoE-/-/Alox5-/- double-
knockout mice demonstrate reduced hepatic inflammation compared to ApoE-/- control 
mice53 and pharmacologic inhibition of FLAP attenuated adipose tissue inflammation in 
response to a high-fat diet.54 Despite the clear role of 5-LO pathway in the pathogenesis of 
inflammation, inhibition of 5-LO mediated LTB4 biosynthesis has yielded conflicting results in 
preclinical models of atherosclerosis.55 Initial reports demonstrated that mice heterozygous 
for the 5-LO null mutation on an Ldlr-/- background (Alox5-/+/Ldlr-/-) had reduced 
atherosclerotic lesion area;56 however, larger subsequent studies of Alox5-/- mice on Ldlr-/- 
and ApoE-/- backgrounds failed to replicate this finding.57, 58 Similarly, pharmacologic 
inhibition of the 5-LO pathway has produced inconsistent effects on atherosclerotic lesion 
development.58, 59 Consistent with preclinical data, initial findings that genetic polymorphisms 
in the 5-LO pathway were associated with subclinical CAD60 have not been shown to be 
associated with clinical events,61 and clinical trials evaluating 5-LO pathway inhibition have 
produced only modest effects on biomarkers of inflammation in CAD patients.62, 63 
Collectively, these data support a modest role for the 5-LO pathway in the pathogenesis of 
CAD, and further demonstrate the need for better understanding of parallel pathways of 
arachidonic acid metabolism in CAD 
 
Cytochrome P450 pathway 
CYP enzymes are predominately expressed in the liver where they catalyze the 
oxidative biotransformation of most exogenous drugs and other xenobiotics.64 Regulation of 
CYP expression and metabolic activity are impacted by genetic polymorphisms, hormones, 
the presence of certain disease states, and pro-inflammatory cytokines.64 In addition to their 
important role in xenobiotic metabolism in the liver, certain CYP isoforms are expressed in 
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extrahepatic tissues and metabolize endogenous substrates including arachidonic acid.65 
This “3rd pathway” of arachidonic acid metabolism catalyzes the conversion of arachidonic 
acid to biologically active eicosanoids in multiple tissues and cell types.  
 
CYP Epoxygenase pathway 
CYP epoxygenase enzymes from the CYP2C and CYP2J subfamilies are expressed in 
endothelial cells, cardiomyocytes and hepatocytes where they metabolize arachidonic acid 
to the biologically active 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid (EET) 
regioisomers; however, EETs are quickly hydrolyzed by soluble epoxide hydrolase (sEH) to 
their corresponding dihydroxyeicosatrienoic acids (DHETs), which have much less biological 
activity.66 CYP epoxygenase derived EETs elicit vasodilatory,67, 68 fibrinolytic,69 pro-
angiogenic,70 anti-apoptotic,71 and cardioprotective effects72, 73 by a variety of mechanisms.  
Most notably, EETs exert potent anti-inflammatory effects in the cardiovascular 
system.74 A seminal paper published by Node, et. al. in 1999 was the first to demonstrate 
that pretreatment of human umbilical vein endothelial cells with 11,12-EET attenuated the 
TNFα induced increase in expression of ICAM-1, VCAM-1, and E-selectin.75 Additional in 
vitro studies have demonstrated that direct administration of EETs attenuates endothelial 
activation via decreased activation of the key pro-inflammatory transcription factor NF-κB by 
inhibiting IκB kinase (IKK) activity and the subsequent phosphorylation and ubiquitination of 
inhibitor κB-α (IκB-α) and translocation of NF-κB to the nucleus.74 In addition, several studies 
indicate that potentiation of the CYP epoxygenase pathway may represent an effective anti-
inflammatory therapeutic strategy in vivo. Following LPS administration, mice treated with 
the sEH inhibitor AUDA-BE had lower plasma levels of IL-6 and TNFα as well as monocyte 
chemoattractant protein-5 compared to vehicle treated control mice.76 Similarly, we 
observed that endothelial over-expression of human CYP2J2 or CYP2C8 or global 
disruption of murine Ephx2, attenuates the LPS-mediated induction of pro-inflammatory 
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cytokine (IL-6 and IL-1β), chemokine (MCP-1 and ENA-78) and CAM (E-selectin) 
expression, and neutrophil infiltration into lung tissue, in mice via decreased activation of 
NF-κB.77 Inhibition of sEH has also exhibited protective effects in chronic models of CVD. 
ApoE-/- mice infused with angiotensin II had lower rates of abdominal aortic aneurysm 
formation and reduced atherosclerotic lesion area when treated with a sEH inhibitor 
(AR9276).78 Notably, these effects were associated with reduced aortic expression of 
cytokines and CAMs, and circulating levels of inflammatory biomarkers, suggesting they 
were mediated by the anti-inflammatory properties of sEH inhibition. The vasodilatory and 
anti-inflammatory properties of EETs have led to the development of pharmacologic 
inhibitors of sEH for the treatment of human CVD.79 Importantly, the protective effects of 
EETs in preclinical models of atherosclerosis and inflammation suggest that pharmacologic 
inhibition of sEH may have clinical utility as an adjunct anti-inflammatory therapeutic strategy 
for the treatment of CAD.  
Genetic polymorphisms in the CYP epoxygenase pathway have been associated with 
CAD risk in humans.80 For example, a polymorphism in EPHX2 (K55R) is associated with 
higher epoxide hydrolase activity in vivo (lower EETs) and higher risk of CAD.81 In addition, 
we observed that the EPHX2 K55R polymorphism is associated with endothelial dysfunction 
in Caucasians.82 Similarly, a CYP2J2 promoter polymorphism (CYP2J2 -50G>T) is 
associated with lower CYP2J2 promoter activity in vitro, lower circulating DHETs and higher 
risk of CAD in humans;83 and, the CYP2C8 K399R variant allele has lower CYP 
epoxygenase activity in vitro84 and is associated with higher risk of ACS clinical events.85 
However, the strength of associations between genetic variants in CYP-mediated 
eicosanoid metabolism and risk of CAD development is not consistent across all studies,80 
suggesting that the relationship between CYP-mediated arachidonic acid metabolism and 
CAD is complex, and likely most profound in certain subsets of the population. Moreover, we 
recently reported that clinical factors including obesity, age, diabetes, and cigarette smoking 
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are associated with CYP epoxygenase and sEH metabolic function, indicating that non-
genetic factors may also impact the relationship between CYP-mediated eicosanoid 
metabolism and CAD risk. Despite these initial observations in humans, the contribution of 
inter-individual variation in CYP epoxygenase and sEH metabolic function to inflammation 
and endothelial dysfunction in CAD patients remains poorly understood and requires 
rigorous evaluation. 
 
CYP ω-hydroxylase Pathway 
In contrast to the vascular-protective effects of the CYP epoxygenase pathway, human 
CYP ω-hydroxylase enzymes from the CYP4F and CYP4A subfamilies catalyze the 
conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE)86 which 
exhibits potent vasoconstrictive and pro-inflammatory effects in preclinical models.86 For 
example, the addition of 20-HETE to endothelial cells results in the activation of NF-κB, 
increased production of pro-inflammatory CAMs, and increased superoxide and decreased 
NO production secondary to eNOS uncoupling.87, 88 In rat renal interlobar arteries 20-HETE 
impairs acetylcholine induced vasorelaxation and the CYP ω-hydroxylase inhibitor HET0016 
improves vasorelaxation in 5α-dihydrotestosterone treated animals via increased NO 
bioavailability.89 In addition, in vivo studies have demonstrated that endothelial over-
expression of CYP4A2 in Sprague-Dawley rats results in increased blood pressure and 
impaired vasorelaxation in response to acetylcholine via increased 20-HETE biosynthesis.90 
Furthermore, the putative 20-HETE receptor antagonist 20-6,15-HEDE attenuates the 5α-
dihydrotestosterone induced decrease in acetylcholine-induced vasorelaxation and increase 
in NF-κB activation in renal interlobar arteries.91 
In humans, genetic epidemiology studies have demonstrated that the CYP ω-
hydroxylase pathway is associated with CVD risk. For instance, presence of the CYP4F2 
V433M minor allele is associated with higher renal excretion of 20-HETE and higher 
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incidence of hypertension and ischemic stroke, indicating that 20-HETE may be an 
important mediator of vascular tone in humans.92, 93 Similarly, higher urinary excretion of 20-
HETE has also been associated with lower FMD in a subjects without known CAD.94 Despite 
these initial observations in humans, the functional relationship between inter-individual 
variation in CYP ω-hydroxylase mediated eicosanoid metabolism and inflammation and 
endothelial dysfunction has not been rigorously evaluated, and requires further study. 
 
Summary and Significance 
Emerging evidence has demonstrated that CYP-derived eicosanoids are key regulators 
of inflammation and endothelial function in preclinical models. Pharmacologic agents that 
increase EETs or decrease 20-HETE elicit potent protective effects in the cardiovascular 
system, and represent potentially promising adjunct anti-inflammatory therapeutic strategies 
for the treatment of CAD. However, the functional role of CYP-mediated eicosanoid 
metabolism in fatty liver disease-associated inflammatory responses, which are increasingly 
recognized as key contributors to the pathogenesis and progression of CAD, remains 
unknown. Therefore, preclinical studies are necessary to define the contribution of CYP-
mediated eicosanoid metabolism to fatty liver disease-associated systemic and vascular 
inflammation. 
Furthermore, although genetic epidemiology studies suggest that CYP-mediated 
arachidonic acid metabolism may be important in the pathogenesis of CAD in humans, the 
functional contribution of CYP-derived eicosanoids to the regulation of biological processes 
underlying the pathogenesis and progression of CAD in humans remains largely unknown. 
Therefore, studies evaluating the association between inter-individual variation in CYP-
mediated eicosanoid metabolism and biological processes integral to the pathogenesis and 
progression of CAD, including inflammation and endothelial dysfunction, are necessary to 
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provide further insight into the functional relevance of CYP-mediated eicosanoid metabolism 
in humans and its contribution to the pathogenesis and progression of CAD.  
 
Perspective 
The significant morbidity and mortality associated with CAD highlights the need to better 
understand the mechanisms underlying the pathogenesis and progression of 
atherosclerosis in order to facilitate the development of novel therapeutic strategies that 
mitigate these key pathological mechanisms, and thus offer the potential to improve 
outcomes. Accumulating evidence clearly indicates that systemic and vascular inflammation 
drive the pathogenesis and progression of CAD. Therefore, discovery and rigorous 
characterization of the key mechanisms underlying this fundamental pathological process, in 
both preclinical models and humans, offers enormous potential to develop rational 
therapeutic strategies that are likely to improve clinical outcomes. Based on emerging 
evidence indicating CYP-derived eicosanoids are key regulators of inflammation and 
endothelial function, we hypothesize that modulation of CYP-mediated eicosanoid 
metabolism offers enormous therapeutic potential in CAD patients. However, the functional 
association between CYP-mediated eicosanoid metabolism, inflammation and endothelial 
dysfunction, and CAD remains poorly understood, and requires rigorous investigation in 
preclinical models and humans.  
Thus, the overall aim of this dissertation is to characterize the functional contribution of 
CYP-mediated eicosanoid metabolism to the regulation of systemic and vascular 
inflammation within the clinical context of CAD. We seek to accomplish this aim using an 
integrated combination of systems biology (Specific Aim I) and candidate pathway (Specific 
Aim II) approaches in humans with CAD and pharmacologic and genetic approaches in mice 
(Specific Aim III) following induction of a systemic and vascular inflammatory response 
relevant to human CAD. 
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Completion of this dissertation will serve to improve our understanding of  the functional 
role of CYP-mediated eicosanoid metabolism in the pathogenesis and progression of CAD, 
provide further mechanistic insight into the impact of therapeutic strategies that modulate 
CYP-mediated arachidonic acid metabolism on systemic and vascular inflammation, and 
thus lay a critical foundation for future studies that directly evaluate the therapeutic effects of 
modulating CYP-mediated eicosanoid metabolism in CAD patients. Furthermore, these 
studies offer enormous potential to identify a population of putative responders to anti-
inflammatory therapeutic strategies that modulate CYP-mediated eicosanoid metabolism.  
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Specific Aims 
1) Utilize a global systems biology approach to identify the key biological processes 
that underlie the development and progression of obstructive CAD in humans. 
Overall Hypothesis: Global gene expression analyses in peripheral blood mononuclear 
cells (PBMCs) will demonstrate that pathways involved in innate immune-mediated 
inflammatory responses are the most important biological processes in the development and 
progression of obstructive CAD in humans 
Specific Hypotheses: 
a) Expression of genes that mediate the innate immune response in PBMCs will be 
dysregulated in humans with obstructive CAD. 
b) Expression of genes that metabolize arachidonic acid to biologically active eicosanoids 
in PBMCs will be dysregulated in humans with obstructive CAD. 
 
2) Utilize a candidate pathway approach to characterize the functional relationship 
between inter-individual variation in CYP-mediated eicosanoid metabolism and 
endothelial dysfunction, vascular inflammation, and systemic inflammation in stable 
obstructive CAD patients. 
Overall Hypothesis: CYP-mediated eicosanoid metabolism is important in the regulation of 
endothelial dysfunction and vascular and systemic inflammation in stable, obstructive CAD 
patients. 
Specific Hypotheses: 
a) Impaired CYP epoxygenase and enhanced sEH metabolic function (i.e. lower EETs) is 
associated with endothelial dysfunction, advanced vascular inflammation, and 
advanced systemic inflammation in patients with stable, obstructive CAD. 
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b) Enhanced CYP ω-hydroxylase metabolic function (i.e. higher 20-HETE) is associated 
with endothelial dysfunction, advanced vascular inflammation, and advanced systemic 
inflammation in patients with stable, obstructive CAD. 
 
3) Utilize a preclinical approach to define the contribution of CYP-mediated 
eicosanoid metabolism to the regulation of non-alcoholic fatty liver disease-
associated systemic and vascular inflammation in mice. 
Overall Hypothesis: CYP-mediated eicosanoid metabolism is an integral mediator of fatty 
liver disease-associated systemic and vascular inflammation in vivo. 
Specific Hypotheses: 
a) Induction of fatty liver disease will significantly suppress CYP epoxygenase-mediated 
EET biosynthesis in vivo via activation of the innate immune system and suppression 
of hepatic CYP epoxygenase expression. 
b) Inhibition of sEH mediated EET hydrolysis will restore EET levels and attenuate fatty 
liver disease-associated systemic and vascular inflammation in vivo. 
 
 
  
 18 
 
Figures 
 
 
Figure 1.1. Interaction between hepatic, systemic, and vascular inflammation.  
The innate immune response is initially activated in the liver secondary to cholesterol and 
lipid accumulation or in the vasculature by macrophages following TLR activation. Upon 
activation of the innate immune response, a positive feedback loop is created in which IL-6 
that is formed in the vasculature is released into systemic circulation, and signals the liver to 
synthesize acute-phase reactants (e.g. C-reactive protein) and additional and cytokines (e.g. 
IL-6), chemokines (e.g. MCP-1), and CAMs (e.g. ICAM-1). Release of these pro-
inflammatory mediators from the liver propagates the inflammatory response in the 
vasculature through further activation of NF-κB and drives endothelial activation, increased 
biosynthesis of cytokines, chemokines, and CAMs, and the subsequent development and 
progression of atherosclerosis.   
↑ IL-6
↑ Acute phase 
reactants 
↑ Cytokines
Liver Vasculature
NF-kB
↑Chemokines
↑CAMs
↑Cytokines
TLR
Activation
↑ NF-kB
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Figure 1.2. Overview of arachidonic acid metabolism.  
(A) After release from the cell membrane by cytosolic phospholipase A2, free arachidonic 
acid is metabolized by enzymes from the COX, LOX, and CYP pathways to biologically 
active eicosanoids. 
(B) Arachidonic acid is metabolized by CYP ω-hydroxylases from the CYP4A and CYP4F 
subfamilies to 20-HETE or by CYP epoxygenases from the CYP2C and CYP2J subfamilies 
to one of four EET regioisomers (5,6-, 8,9-, 11,12-, and 14,15-EET). The EETs (epoxides) 
are subsequently hydrolyzed by sEH to their corresponding DHET (diol) metabolites, which 
generally have less biological activity. Structures for the 14,15-EET regioisomer, the 
preferred EET substrate for sEH, and the 14,15-DHET metabolite are provided since the 
14,15-EET:DHET (epoxide:diol) ratio is an established biomarker of sEH metabolic function. 
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CHAPTER II 
INFLAMMATORY BIOMARKERS AND GLOBAL GENE EXPRESSION IN 
OBSTRUCTIVE CORONARY ARTERY DISEASE 
 
Introduction 
It is well-established that age is associated with cardiovascular disease (CVD) risk. 
Epidemiology studies have demonstrated that the lifetime risk for CVD remains high in older 
individuals and increases dramatically in the presence of multiple risk factors.95 In addition, 
older individuals who experience an acute coronary syndrome (ACS) suffer poorer 
prognosis compared to the general population. For example, in patients age 65 or older, the 
five year mortality rate following a myocardial infarction (MI) is 46-58% and chances of 
death, recurrent MI or fatal coronary heart disease, and stroke are all higher compared to 
younger individuals.1  However, older patients are frequently under-represented in clinical 
trials and the pathophysiology underlying the development and progression of 
atherosclerotic coronary artery disease (CAD) has not been rigorously evaluated in this 
population. Increasing age is associated with pathophysiological changes in the vasculature 
including increased carotid intima-media thickness, arterial stiffening, endothelial 
dysfunction, and elevated systolic blood pressure.96 While it is well-established that systemic 
and vascular inflammation are important in the development and progression of CAD in the 
general population,4, 9 studies in older patient populations have not consistently 
demonstrated that elevated biomarkers of inflammation are associated with poorer 
outcomes.97, 98 These findings suggest that the pathophysiology underlying CAD in older 
individuals may be distinct from that in younger individuals. Therefore, identification of the 
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key biological processes underlying the development and progression of CAD in this high-
risk patient population may facilitate the development of novel therapeutic strategies to 
improve prognosis.  
Systems biology studies have identified global gene expression signatures in peripheral 
blood mononuclear cells (PBMCs) that are predictive of the presence and extent of coronary 
artery atherosclerosis,99, 100 suggesting that evaluation of gene expression in PBMCs may 
provide insight into the key biological processes underlying the development and 
progression of CAD. In addition, gene expression changes that occur in peripheral blood 
have been reported to mirror gene expression changes in atherosclerotic arteries.100 
Therefore, evaluation of global gene expression changes in PBMCs, and application of 
functional annotation tools to identify the key biological processes dysregulated in the 
presence of CAD, represents a non-biased approach to elucidate the key mechanisms 
underlying the development and progression of CAD.  
Although elevated circulating biomarkers of inflammation including C-reactive protein 
(hs-CRP), monocyte chemoattractant protein-1 (MCP-1) and cellular adhesion molecules 
(CAMs) have been repeatedly associated with the development and progression of CAD in 
the general population,9 and poor prognosis in patients with established CAD,12, 13, 24 the 
relationship between inflammation and CAD risk is less clear in older adults. Furthermore, 
the key biological processes underlying the pathogenesis and progression of CAD in older 
individuals, including the contribution of circulating inflammatory biomarkers, remains 
unknown. Therefore, in order to improve our understanding of the pathogenesis and 
progression of CAD in older adults, we utilized a 1) candidate biomarker approach to 
determine if the presence and severity of obstructive CAD is associated with elevated 
circulating biomarkers of inflammation and 2) systems biology approach to identify gene 
expression changes and dysregulated biological pathways in PBMCs that are associated 
with the presence and severity of obstructive CAD in older adults. 
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Methods 
Study Population 
The Supporting A Multidisciplinary Approach to Researching Atherosclerosis (SAMARA) 
study enrolled consecutive individuals who were at least 65 years of age and undergoing 
diagnostic cardiac catheterization as part of their routine care. Between March 2007 and 
February 2009 we enrolled 143 individuals from the University of North Carolina (UNC) 
Cardiac Catheterization Laboratory. Individuals with HIV or HCV infection, lymphoma, 
leukemia, anemia, history of rheumatoid arthritis or lupus, history of solid organ 
transplantation and individuals undergoing current cancer treatment or chronic 
immunosuppressive therapy were not eligible to participate. Participants were interviewed to 
obtain pertinent medical information including previous medical history, current medication 
use, family medical history, and smoking status. This study was approved by the UNC 
Institutional Review Board and conducted according to institutional guidelines; all 
participants provided written informed consent. 
 
CAD Severity 
Subjects underwent diagnostic left-heart catheterization as part of their routine medical 
care. Following the procedure, CAD severity was quantified in each subject by coronary 
angiography by calculating a CAD score as follows: 0 (<10% stenosis in all major coronary 
arteries); 1 (10-70% stenosis in at least one vessel); 2 (>70% stenosis in one vessel); 3 
(>70% stenosis in two vessels); and, 4 (>70% stenosis in 3 vessels or >70% stenosis in the 
left-main coronary artery).  
Obstructive CAD was defined as >70% stenosis in ≥1 major epicardial coronary artery 
(CAD score 2-4). Subjects with ≤70% occlusion in any vessel (CAD score 0-1) were 
considered free of obstructive CAD and thus were utilized as the comparator group. 
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Sample Collection and Processing 
All catheterizations took place in the morning following an overnight fast; at the start of 
the procedure 30 mL of blood was drawn from the femoral artery into Na-EDTA Vacutainer 
tubes (Becton, Dickinson and Co., Cockeysville, MD). Following blood collection RNA and 
DNA were isolated from PBMCs as described.101 RNA was purified using the RNeasy mini-
kit (Qiagen, Valencia, CA). RNA quantity, purity and integrity were assessed by 
spectrophotometry and microcapillary electrophoresis on an Agilent BioAnalyzer 2100 
(Agilent Technologies, Inc., Santa Clara, CA). Only RNA with an A260/280 ratio of ≥ 1.8, 
and an electrophoretic profile consistent with only minimal degradation was considered 
acceptable for use. An additional 8 mL of blood collected in tubes containing EDTA and 
proteinase inhibitor was processed to plasma, aliquoted, and stored at -80ºC pending 
analysis. 
 
Gene Expression Profiling 
RNA was co-hybridized to Agilent G4112A Whole Human Genome 44K oligonucleotide 
arrays in the presence of Cyanine-3 labeled Universal Human Reference RNA (UHRR, 
Stratagene, LaJolla, CA) for array normalization, as described.101 Slides were hybridized 
and washed, then scanned on an Axon 4000b microarray scanner; data were processed 
using Agilent software. Only probes flagged “detected” in at least 85% of all samples were 
included, resulting in 18,411 probes in the final dataset. In addition, only samples with at 
least 90% of probes flagged detected were included in the analyses. Missing data were 
imputed using the k-nearest neighbor algorithm (k=10). MIAME-compliant datasets were 
deposited with the Gene Expression Omnibus of the National Center for Biotechnology 
Information (GEO Series accession number GSE12959). 
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Microarray expression data was corrected to account for scan-date batch effects using 
the remove batch-effect feature in Partek Genomics Suite v6.6. Unsupervised analyses 
determined the primary signal contributing to gene expression was gender. In addition, 
diabetes was found to be a potential confounder to CAD severity. Therefore we conditioned 
the dataset using an analysis of variance (ANOVA) linear model to account for gender and 
diabetes in order to identify potential probes that correlated with CAD severity. 
 
Quantification of Circulating Biomarkers of Inflammation 
Plasma concentrations of CAMs (E-selectin, P-selectin, intracellular adhesion molecule 
[ICAM]-1, and vascular cellular adhesion molecule [VCAM]-1) and neutrophil (epithelial 
neutrophil-activating protein-[ENA]-78) and monocyte (MCP-1) chemokines were quantified 
using the Human Adhesion Molecule and Human Cytokine Fluorokine® Multi-Analyte 
Profiling Kits (R&D Systems, Minneapolis, MN), respectively. hs-CRP was quantified using 
the Human C-Reactive Protein Fluorokine® MAP kit for use in Cardiac Panel B. All analytes 
were quantified with fluorescence detection on the Bio-Plex 200 System (Bio-Rad, Hercules, 
CA) according to the manufacturer’s instructions.  
 
Comparison of Functional Pathways to Independent CAD Cohorts 
In order to compare the gene expression signatures identified in our analysis to those 
previously identified in CAD patients, we accessed the published list of 655 genes that were 
associated with CAD in the case:control analyses from both the CATHGEN102 and 
Personalized Risk Evaluation and Diagnosis in the Coronary Tree (PREDICT)103 cohorts.104 
The CATHGEN cohort identified 87 CAD cases (defined as ≥75% stenosis in one major 
coronary vessel or ≥50% stenosis in two major coronary vessels) who were 63 ± 10 years of 
age and 108 control subjects (defined as <25% stenosis in all major coronary vessels) who 
were 55 ± 11 years of age. The PREDICT cohort enrolled only non-diabetic individuals and 
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identified 99 CAD cases (defined as ≥50% stenosis in at least one major coronary artery) 
who were 62 ±11 years of age and 99 age and gender matched controls (defined as <50% 
stenosis in all major vessels) who were 55 ± 12 years of age. The association between gene 
expression and case:control status in these studies was assessed using logistic regression 
for the CATHGEN cohort and conditional logistic regression for the PREDICT cohort. 
 
Statistical Analysis 
Circulating Biomarkers of Inflammation 
Demographic and clinical characteristics were compared in subjects with and without 
obstructive CAD using regression for continuous variables and chi-squared analysis for 
categorical variables. All variables that were not normally distributed were log-transformed 
prior to analysis. Since hs-CRP was above the limit of detection in 53 (37%) of the samples 
analyzed, a value of 15.2 mg/L (1.5-fold higher than the highest standard) was imputed for 
each sample above the upper limit of detection.  
Spearman’s rank correlation was used to determine the correlation among circulating 
biomarkers of inflammation. Multiple CAMs were significantly correlated (data not shown); 
therefore, in order to minimize redundancy in our analysis, a consolidated ‘CAM score’ 
phenotype was calculated in each individual, as described,105 by summing the z-scores of E-
selectin, P-selectin, ICAM-1, and VCAM-1. None of the remaining biomarkers of 
inflammation (hs-CRP, MCP-1, ENA-78, CAM score) were significantly correlated.  
The association between plasma levels of the selected inflammatory biomarkers and 
CAD score was evaluated using an unadjusted regression model and a model that adjusted 
for potential demographic (age, race, gender) and clinical (obesity, diabetes mellitus, 
hyperlipidemia, statin use) confounders that associated with biomarkers of inflammation or 
obstructive CAD status in the SAMARA cohort. Similarly, plasma levels of these 
inflammatory biomarkers were compared in subjects with and without obstructive CAD using 
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both the unadjusted and adjusted regression models. A secondary analysis compared the 
proportion of subjects with high (>median) or low (≤median) inflammatory biomarker levels 
in individuals with and without obstructive CAD using a Chi-square analysis. For hs-CRP, an 
additional analysis was conducted comparing the proportion of individuals with and without 
obstructive CAD who had hs-CRP levels >3 mg/L, the clinically relevant threshold that 
confers higher risk of CAD.106 All statistical analyses were conducted using SAS Version 9.3 
(SAS, Cary, NC). 
 
Global Gene Expression Profiling 
Spearman rank correlation was utilized to generate a list of genes that correlated with 
the CAD score (0-4) with a predefined cutoff of rs ≥0.25 or rs ≤-0.25 using Partek Genomics 
Suite (Partek Incorporated, St. Louis, MO). Pathway enrichment was determined using the 
National Institutes of Health (NIH) Database for Annotation, Visualization and Integrated 
Discovery (DAVID) Version 6.7, which uses a modified Fisher’s Exact Test to calculate an 
“Enrichment Score” for each functional annotation cluster.107, 108 Biological Process Terms 
and Molecular Function Terms were included as Gene Ontologies, and the Classification 
Stringency was set to high; all other default parameters were unchanged. The gene list 
obtained from our correlation analysis was uploaded to DAVID and compared to the human 
genome reference to generate a list of functional pathways that were over-represented with 
increasing CAD severity. P-values were calculated by computing 10-Enrichment Score, with 
p<0.05 (Enrichment Score >1.3) considered statistically significant. A similar analysis was 
conducted using the list of 655 genes that were differentially expressed in subjects with and 
without CAD in both the CATHGEN and PREDICT studies.104 This allowed us to compare 
the functional pathways identified in our analysis of older individuals in the SAMARA cohort 
to the functional pathways from previously published cohorts. 
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Results 
Study Population 
The study population characteristics stratified by obstructive CAD status are shown in 
Table 2.1. A total of 93 subjects (65%) had obstructive CAD while 50 (35%) did not have 
obstructive CAD. In both groups the majority of subjects were Caucasian, and had multiple 
comorbidities including hyperlipidemia and hypertension. A significantly higher proportion of 
those diagnosed with obstructive CAD were male, had a previous diagnosis of 
hyperlipidemia and myocardial infarction, and were taking medications for the treatment of 
cardiovascular disease including statins, aspirin, and clopidogrel (Table 2.1). 
 
Candidate Biomarkers of Inflammation (plasma) 
Plasma concentrations of hs-CRP and MCP-1, and the CAM score, were not 
significantly associated with CAD score (Table 2.2). Moreover, when analyzed by the 
presence or absence of obstructive CAD, no significant differences in hs-CRP, MCP-1, and 
CAM score were observed in subjects with obstructive CAD compared to subjects without 
obstructive CAD in either the unadjusted or adjusted models (Table 2.3). In contrast, ENA-
78 levels were inversely associated with CAD score (Table 2.2), and were significantly lower 
in subjects with obstructive CAD in both the unadjusted and adjusted models (Table 2.3, 
Figure 2.1). Similarly, the proportion of subjects with high (above the median) levels of hs-
CRP, MCP-1, and CAMs was not significantly different in subjects with and without 
obstructive CAD, while subjects with obstructive CAD were significantly more likely to have 
low ENA-78 levels (Table 2.4). In addition, individuals with obstructive CAD were not 
significantly more likely to have hs-CRP levels greater than 3 mg/L (Table 2.4).  
Since we did not observe a significant positive association between any of the candidate 
biomarkers of inflammation and either CAD score or the presence of obstructive CAD, we 
sought to develop a more comprehensive phenotypic index of inflammation by integrating 
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hs-CRP, MCP-1, and ICAM-1 into a single ‘inflammation score’ phenotype (Appendix I). 
Clear differences in this ‘inflammation score’ were observed between a cohort of patients 
with angiographically-confirmed CAD and healthy volunteers at low risk for CAD, and thus 
enabled us to more completely assess the association between presence and severity of 
obstructive CAD and inflammation in the SAMARA cohort. Similar to the analysis of 
individual inflammatory biomarkers, however, the ‘inflammation score’ was not significantly 
associated with CAD score or the presence of obstructive CAD in the SAMARA cohort 
(Appendix I).  
 
Global Gene Expression (PBMCs) 
Our global gene expression analysis identified 708 probes that significantly correlated 
with CAD severity (CAD score 0-4) with rs≥0.25 or rs≤-0.25 (Figure 2.2). The absolute 
correlation coefficient (rs) of ≥0.25 corresponded to a p-value ≤0.0026 in our analysis; only 
48 probes would pass this threshold based on chance, indicating only a small proportion of 
our findings are likely due to chance. Of the 708 probes, 364 were positively correlated with 
CAD score while 344 were inversely correlated, indicating that increasing severity of CAD is 
associated with higher expression of certain genes in PBMCs, but lower expression of 
others. The 708 probes identified in our analysis corresponded to 512 unique annotated 
genes (Gene List 1). Functional analysis using DAVID identified 28 annotation clusters that 
were significantly enriched (p<0.05) in our list of 512 unique annotated genes. The 10 
functional annotation clusters with the highest enrichment scores are presented in Table 2.5. 
A description of each functional annotation cluster “representative annotation terms” and the 
number of genes in each functional annotation cluster that were included in the gene list are 
provided. The fold enrichment (number of genes in the functional annotation cluster relative 
to the number that would be expected by chance) of each functional annotation cluster in 
the gene list and the p-value are provided.  
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The top annotation cluster represented genes involving immune system development. 
Fifteen genes from this pathway were positively correlated with the CAD score while 5 were 
inversely correlated with the CAD score (Figure 2.3), indicating that genes involved in 
immune system development were expressed at higher levels in subjects with more severe 
CAD. Other highly enriched annotation clusters included antigen and protein processing, 
actin related genes, and processes involved in the regulation of transcription (Table 2.5); the 
majority of genes from these pathways were positively correlated with the CAD score 
(Figure 2.3). Of the 512 unique annotated genes that were correlated with the CAD score, 
89 were a component of at least one functional annotation cluster (Gene List 2). A heat map 
displaying the association between CAD score and each of the 89 genes included in the 
functional annotation clusters is displayed in Figure 2.4. 
 
Comparison of Functional Pathways to Independent CAD Cohorts 
We compared our list of 512 unique annotated genes to the 655 genes that significantly 
associated with CAD in the case:control analyses from both the CATHGEN and PREDICT 
studies. There were 45 genes identified in our study that were also identified in both the 
CATHGEN and PREDICT cohort, which is 2.7-fold greater than the number of overlapping 
genes expected by chance (p<0.001), indicating that we were able to identify gene 
expression changes in our cohort of older individuals that are similar to previously validated 
gene expression changes in younger populations (Gene List 3). Our functional analysis of 
the gene list from the CATHGEN and PREDICT studies identified 23 annotation clusters that 
were significantly enriched (p<0.05). The 10 functional annotation clusters from the 
CATHGEN/PREDICT analysis with the highest enrichment scores are presented in Table 
2.6. Although no identical annotation clusters were represented in top 10 processes from 
both the CATHGEN/PREDICT analysis and the analysis of the SAMARA cohort, clusters 
representing pathways involved in regulation of the immune response were represented in 
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both analyses. Three annotation clusters representing genes involved in the regulation of 
apoptosis were also identified in the top 10 functional annotation clusters from the 
CATHGEN/PREDICT analysis. 
 
Discussion 
Inflammation is integral to the development and progression of CAD in the general 
population; however, the role of inflammation in the pathophysiology underlying the 
development and progression of CAD in older patient populations has remained largely 
unexplored. Our analysis of candidate circulating inflammatory biomarkers, which are critical 
mediators of systemic and vascular inflammation and capture the inflammatory response at 
multiple levels, did not demonstrate a significant association between higher levels of 
inflammation and the presence and severity of obstructive CAD in older individuals. 
However, our global gene expression analysis in PBMCs revealed that genes regulating the 
immune response are expressed at higher levels in subjects with more severe CAD. These 
findings suggest that although elevated circulating candidate biomarkers of inflammation 
were not significantly associated with the presence and severity of obstructive CAD in older 
individuals, inflammation signaling is a key pathological factor underlying the pathogenesis 
and progression of CAD in this patient population. Moreover, global gene expression 
changes in PBMCs may be more reflective of the underlying pathology of CAD in older 
individuals than circulating protein levels, suggesting that circulating biomarkers of 
inflammation may have less clinical utility for assessment of cardiovascular risk and 
prognosis in this patient population. 
In order to characterize the role of systemic and vascular inflammation in the 
pathophysiology of CAD in older individuals, we first evaluated the association between the 
presence of obstructive CAD and well-established circulating mediators of inflammation (hs-
CRP, CAMs, MCP-1, and ENA-78) that have been associated with higher CAD incidence in 
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the general population,109-111 and higher mortality in patients with established CAD.12, 13, 17, 24 
Our analysis demonstrated that hs-CRP (an acute phase reactant reflective of systemic 
inflammation), MCP-1 (a chemokine synthesized in monocytes and endothelial cells that 
drives monocyte recruitment to the vascular wall), and CAMs (inflammatory mediators 
expressed on endothelial cells that mediate leukocyte and platelet adhesion) were not 
associated with the presence or severity of obstructive CAD in a population of older adults 
presenting for coronary angiography. Although circulating biomarkers of inflammation are 
frequently elevated in CAD patients compared to healthy individuals and are associated with 
CAD incidence,4 the association between inflammatory biomarkers and CAD in older 
individuals is less clear. For example, an analysis of over 4,500 individuals over 65 years of 
age demonstrated only a modest association between hs-CRP levels and CVD events 
(hazard ratio of 1.13, 95% confidence interval 1.05-1.21 for every standard deviation 
increase).112 Moreover, a study of more than 1,200 individuals over 65 years of age showed 
that changes in hs-CRP levels over three years, but not baseline levels, were associated 
with all-cause mortality.97 Collectively, these data indicate that circulating biomarkers of 
inflammation have insufficient power to differentiate between older adults with and without 
obstructive CAD, and to predict prognosis in older patients with established CAD, 
suggesting a limited role in risk assessment of older individuals.  
Surprisingly, the neutrophil chemokine ENA-78 was inversely associated with CAD 
score, and ENA-78 levels were significantly lower in subjects with obstructive CAD 
compared to subjects without obstructive CAD. Although genetic predisposition to higher 
ENA-78 levels has been associated with poorer survival in ACS patients, the association 
between plasma ENA-78 levels and the presence of obstructive CAD in humans has not 
been evaluated to date. Our findings demonstrate that elevated ENA-78 levels in older 
individuals are not associated with the presence and severity of obstructive CAD. Given the 
association between genetic predisposition to higher ENA-78 levels and higher mortality in 
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ACS patients,17 and preclinical studies demonstrating that neutrophil recruitment to the 
vascular wall promotes atherosclerotic plaque formation in mice,113 it is possible that ENA-
78 is suppressed in obstructive CAD patients via a compensatory response. However, less 
is known about the role of neutrophil chemokines in the development and progression of 
atherosclerotic CAD in humans, and future studies evaluating the contribution of neutrophil 
recruitment to the vascular wall to the pathogenesis and progression of CAD in older adults 
are warranted.  
Our candidate biomarker analysis has limitations that must be acknowledged. Although 
the circulating biomarkers of inflammation that we quantified have been associated with 
CAD risk in younger patient populations, and each captures different processes in the 
pathology of inflammation (i.e., CAMs, chemokines, acute phase reactant), we were only 
able to evaluate a limited number of inflammatory mediators. Therefore, it is possible that 
circulating inflammatory biomarkers not represented in our panel may be more important in 
the pathophysiology of CAD in older adults. Moreover, the cross-sectional design of our 
study precludes us from directly evaluating the association between circulating biomarkers 
of inflammation and incident CAD, or prognosis in individuals with established CAD. In 
addition, circulating biomarkers of inflammation are a surrogate for the biological processes 
taking place at the site of the lesion, and may not capture all biological processes that are 
relevant to the development and progression of CAD. The absence of a significant 
association between higher circulating levels of seemingly established individual 
inflammatory biomarkers (hs-CRP, MCP-1, CAMs) and the presence and severity of 
obstructive CAD, and the inverse association with a less well understood inflammatory 
biomarker (ENA-78), highlights the complex pathophysiology of CAD development and 
progression in this patient population, and the need for more advanced and unbiased 
methods to identify key processes underlying the development and progression of 
obstructive CAD. 
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Systems biology studies have demonstrated that gene expression signatures in PBMCs 
are predictive of the presence and extent of coronary atherosclerosis, and gene expression 
changes in PBMCs mirror gene expression changes in the atherosclerotic lesion.99, 100 In 
addition, PBMCs are integral mediators of vascular inflammation and express signaling 
molecules that drive monocyte recruitment and infiltration into the vessel (including 
cytokines, chemokines, and CAMs), ultimately leading to plaque development and 
obstructive CAD.114 Therefore, we took a systems biology approach to characterize the 
association between global gene expression changes in PBMCs and the presence and 
severity of CAD. Our global gene expression analysis revealed 512 genes that were 
significantly correlated with CAD severity. The observed differential regulation of gene 
expression in PBMCs is consistent with a previous report of individuals undergoing coronary 
angiography (age range 42-82 years) that identified 526 genes with at least 1.3-fold 
differential expression in 27 CAD cases (defined as ≥70% stenosis in one or ≥50% stenosis 
in two major coronary vessels) compared to 14 controls (defined as 0% stenosis in all 
vessels).99 Our findings indicate that PBMC gene expression in older individuals is 
dysregulated in the presence of obstructive CAD, and may provide insight into the key 
mechanisms underlying the development and progression of CAD.  
Functional annotation of genes dysregulated in the presence of obstructive CAD 
revealed that the most highly enriched annotation cluster included genes key in the 
regulation of inflammation. Interestingly, multiple genes that were positively correlated with 
CAD score in our global analysis have been implicated in the nuclear factor-kappa B (NF-
κB) mediated inflammatory response; NF-κB is the central transcriptional regulator of 
vascular inflammation, and has previously been implicated in CAD.115 For example, CHUK 
and PRDX3 are integral to the activation of NF-κB.116, 117 Similarly, JAK2 is activated by NF-
κB responsive genes,118 and NF-κB has been shown to regulate FAS mediated apoptosis.119 
The association between key genes involved in the innate-immune mediated inflammatory 
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response and CAD is consistent with a previous study in individuals <65 years of age that 
identified 160 genes that correlated with CAD severity, many of which were involved in the 
inflammatory response and apoptosis;100 however, we are the first to utilize global gene 
expression analyses to identify key biological processes that are enriched in the 
development and progression of CAD in older individuals.  
Similarly, in their development of a gene expression algorithm for assessment of 
obstructive CAD, Elashoff, et. al. identified 655 genes that were associated with the 
presence of CAD in both the CATHGEN registry and the PREDICT study, which reflected 
the processes of inflammation, immune cell differentiation, and apoptosis.104 In order to 
more directly compare gene ontologies from genes identified in the CATHGEN/PREDICT 
analysis to the SAMARA study, we repeated our DAVID analysis using the 655 overlapping 
genes from the CATHGEN and PREDICT analyses, which similarly identified genes involved 
in inflammation and apoptosis as the most highly enriched biological processes. Genes 
identified in both analyses include CASP4, which has been implicated in both inflammation 
and apoptosis,120 HLA-E, which regulates endothelial activation121 and MAPK14, a member 
of the mitogen-activated protein kinase family, which has previously been implicated in 
inflammation and CVD.122 Our findings indicate that expression of these genes in PBMCs, 
all of which are involved in the inflammatory response, is consistently associated with the 
presence CAD. Future studies are warranted to define their direct functional role in the 
pathogenesis and progression of CAD, and to rigorously evaluate the role of upstream 
pathways that regulate inflammation signaling, and thus CAD development and progression. 
Our global gene expression analysis is limited by the use of PBMC RNA expression as a 
surrogate for capturing biological processes taking place at the site of the atherosclerotic 
lesion. Although this is a limitation of our analysis, PBMC gene expression has been shown 
to reflect atherosclerotic lesion gene expression, and the relative ease of obtaining PBMC 
samples allowed us to recruit a large study cohort to conduct the analysis. Importantly, 
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microarray technologies are vulnerable to false-positive findings, and validation of key genes 
by quantitative real time-polymerase chain reaction (qRT-PCR), and replication in an 
independent cohort remain necessary. Similarly, functional annotation tools such as DAVID 
cluster genes into functional groups based on their association with multiple biological 
processes, allowing a more insightful biological interpretation of large gene lists; however, 
the results from such analyses can be impacted by multiple factors and must be interpreted 
cautiously. Lastly, although our gene expression analysis took a non-biased global approach 
to identify the key biological processes underlying the development and progression of CAD, 
such systems biology approaches are limited to pre-defined pathways and biological 
processes. Therefore, follow-up studies using candidate pathway approaches provide the 
means to rigorously characterize upstream pathways hypothesized to be important 
regulators of systemic and vascular inflammation, and evaluate their potential utility as 
therapeutic targets. 
 
Conclusions 
In summary, our analysis of circulating inflammatory mediators did not demonstrate that 
plasma levels of established systemic or vascular inflammatory biomarkers are elevated in 
older patients with obstructive CAD. However, a functional analysis of genes associated with 
the presence and severity of obstructive CAD reflected differential expression of genes 
regulating multiple processes. Most notably, key genes regulating the inflammatory 
response were associated with the presence and severity of CAD. Future studies remain 
necessary to identify the key upstream pathways regulating the development and 
progression of obstructive CAD and advanced inflammation in this population, and ultimately 
evaluate the efficacy of novel anti-inflammatory therapeutic strategies that modulate these 
pathways.   
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Tables 
Table 2.1. Study population characteristics by obstructive CAD status. 
Characteristic Obstructive CAD No Obstructive CAD P 
N  93  50   
Age (years) 74±6.3  73±6.2  0.220 
Male gender (%) 57 (61%) 18 (36%) 0.004 
Caucasian (%) 74 (80%) 37 (74%) 0.446 
Body mass index (kg/m2) 29±6.3 30±7.1  0.323 
Current smoker (%) 4 (4%)  3 (6%) 0.653 
Diabetes (%) 38 (41%) 17 (34%) 0.421 
Hyperlipidemia (%) 74 (80%) 28 (56%) 0.003 
Hypertension (%) 82 (88%) 44 (88%) 0.976 
Previous myocardial infarction (%)  41 (44%) 3 (6%) <0.001 
Multivessel disease (%) 62 (67%) 0 (0%) <0.001 
Systolic blood pressure (mmHg) 143±20 141±20  0.573 
Diastolic blood pressure (mmHg) 77±13 78±12  0.588 
Statin use (%) 74 (80%) 23 (46%) <0.001 
Aspirin use (%) 78 (84%) 33 (66%)  0.015 
Clopidogrel use (%) 33 (36%) 6 (12%) 0.003 
Data presented as mean ± standard deviation or count (proportion). 
Age, body mass index, and diastolic blood pressure were not normally distributed and were 
log-transformed prior to analysis. 
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Table 2.2. Association between plasma inflammatory biomarker levels and CAD 
score. 
Analyte Parameter Standard Partial R2 P 
  Estimate Error 
hsCRP* 
 Unadjusted 0.095 0.068 0.014 0.164 
 Adjusted 0.133 0.077 0.022  0.088 
MCP-1 
 Unadjusted -0.010 0.031 0.001 0.748 
 Adjusted -0.015 0.035 0.001 0.673 
ENA-78 
 Unadjusted -0.145  0.046 0.065 0.002 
 Adjusted -0.114  0.052 0.035  0.029 
CAM Score 
 Unadjusted 0.145 0.131 0.009 0.270 
 Adjusted 0.104 0.151 0.003 0.495 
Following log-transformation, associations between each analyte and CAD score were 
evaluated by regression.  
Adjusted model: adjusted for age, race, gender, obesity, diabetes mellitus, hyperlipidemia, 
statin use. 
*53 (37%) of values were above the limit of detection and imputed to a value of 15.2 mg/L 
(1.5-fold higher than the highest standard). 
 
  
3
8
 
Table 2.3. Comparison of plasma inflammatory biomarker levels between subjects with obstructive CAD and subjects 
without obstructive CAD. 
Analyte Obstructive CAD No Obstructive CAD Unadjusted P Adjusted P*  
hsCRP^ (mg/L) 5.7 (13) 4.6 (14) 0.198  0.108 
MCP-1 (pg/mL) 122 (57) 115 (46) 0.663 0.512  
ENA-78 (pg/mL) 998 (923) 1638 (1380) 0.002 0.028 
CAM Score  0.10 (2.6) -0.07 (2.8) 0.489 0.748 
Data presented as median (interquartile range). Following log-transformation, plasma levels of each analyte were compared by 
regression.  
*Adjusted model: adjusted for age, race, gender, obesity, diabetes mellitus, hyperlipidemia, statin use. 
^53 (37%) of values were above the limit of detection and imputed to a value of 15.2 mg/L (1.5-fold higher than the highest standard). 
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Table 2.4. Proportion of subjects with high (>median) or low (≤median) levels of 
inflammatory biomarkers by obstructive CAD status. 
Analyte Obstructive CAD No Obstructive CAD P  
hsCRP 49 (53%) 22 (44%) 0.322  
hsCRP >3 mg/L 71 (76%) 32 (64%) 0.117 
MCP-1 49 (53%) 22 (44%) 0.322  
ENA-78 39 (42%) 32 (64%) 0.012  
CAM Score 47 (51%) 24 (48%) 0.772 
Data presented as N (%) above median in each group.  
Chi-square p-value is presented. 
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Table 2.5. Functional classification of genes that associated with the severity of CAD 
in SAMARA. 
Annotation  Representative Genes Fold Enrichment P 
Cluster  Annotation Terms 
1  Immune System Development 20 2.6 0.0006 
2 Antigen Processing 9 10.0 0.0007 
3  Positive Regulation Protein Processing 17 2.6 0.0019 
4  Actin Related  6 7.3 0.0024 
5 Negative Regulation of Transcription 8 5.0 0.0025 
6 Ras GTPase 13 3.0 0.0032 
7 Ubiquitin Regulation 13 3.8 0.0046 
8 Regulation of DNA Binding 12 3.1 0.0047 
9 Antigen Presentation 9 9.0 0.0058 
10 RNA Splicing 21 2.1 0.0081 
The 10 functional annotation clusters with the highest enrichment scores are presented in 
rank order.  
“Representative Annotation Terms” provides a description of each functional cluster. 
“Genes” indicates the number of genes from the SAMARA gene list that were included in 
each annotation cluster. 
“Fold enrichment” indicates the number of genes in each functional annotation cluster 
relative to the number that would be expected by chance. 
The p-value for each annotation cluster is provided.   
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Table 2.6. Functional classification of genes differentially expressed in CAD patients 
in the CATHGEN and PREDICT studies. 
Annotation  Representative Genes Fold Enrichment P 
Cluster Annotation Terms 
1 Ribosome Component 20 4.56 <0.0001 
2 Regulation of Apoptosis 54 1.94 <0.0001 
3  Positive Regulation of Apoptosis 35 2.43 <0.0001 
4  Immune Activation 25 2.84 <0.0001 
5 Immune Differentiation  20 2.89 0.0004 
6 Negative Regulation of Apoptosis 25 2.04 0.0013 
7 Positive Immune Regulation 15 2.95 0.0016 
8 Immune Proliferation 10 3.49 0.0022 
9 Histone H2A 5 8.25 0.0026 
10 Phosphorylation 50 1.56 0.0035 
The 10 functional annotation clusters with the highest enrichment scores are presented in 
rank order.  
“Representative Annotation Terms” provides a description of each functional cluster. 
“Genes” indicates the number of genes from the SAMARA gene list that were included in 
each annotation cluster. 
“Fold enrichment” indicates the number of genes in each functional annotation cluster 
relative to the number that would be expected by chance. 
The p-value for each annotation cluster is provided.   
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Figures 
 
 
Figure 2.1. Plasma ENA-78 levels by obstructive CAD status.  
The distribution of plasma ENA-78 levels is displayed in subjects with (n=93) and without 
(n=50) obstructive CAD. The horizontal line within the box represents the median, the edges 
of the box represent the 25th and 75th percentiles, and the error bars represent the 10th 
and 90th percentiles. *P<0.05 compared to subjects with obstructive CAD in both the 
unadjusted and adjusted models.  
  
E
N
A
-7
8
 (
p
g
/m
L
)
0
1000
2000
3000
4000
5000
Plasma ENA-78 Levels
No 
Obstructive 
CAD
Obstructive 
CAD
*
 43 
 
 
Figure 2.2. Heat-map displaying the 708 probes that were significantly correlated with 
CAD score with absolute correlation coefficient (rs) of ≥0.25.  
Each column represents one subject; the first row displays the CAD score; darker boxes 
represent more severe CAD. Individual gene expression profiles are represented in rows, 
red indicates a positive correlation with CAD score and blue indicates an inverse association 
with CAD score with the color scale designating the relative expression (log2) of each gene.   
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Figure 2.3. Number of genes from each of the top 10 functional annotation clusters 
identified by DAVID. 
The number of genes from each of the top 10 functional annotation clusters identified by 
DAVID is displayed. The number of genes positively correlated with the CAD score are 
represented in black and the number of genes negatively correlated with the CAD score are 
represented in gray. Overall, 67 (75%) of genes in these pathways were positively 
correlated with the CAD score. 
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Figure 2.4. (Preceding page) Heat map displaying genes correlated with presence and 
severity of CAD that were represented in the top 10 functional pathways from DAVID. 
The red-blue heat map (left) represents the relative expression (log2) of a subset of 
microarray probes (rows) identified in the top 10 categories of pathway enrichment by 
DAVID analysis. As shown in Figure 2, the gene expression of subjects (columns) clustered 
generally according to CAD classification, increasing from left to right. The green heat map 
(middle) indicates the DAVID category of each probe and is represented by the fold-
enrichment (antilog2) of the functional category. The functional clusters of gene expression 
are indicated by color (right).  
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Gene Lists 
Gene List 1. List of 512 unique genes that correlate with CAD score with absolute 
correlation coefficient (rs) of ≥0.25 
Gene Symbol r p-value(correlation) 
PHOSPHO2 -0.380723 2.72E-06 
LOC100287628 -0.370113 5.37E-06 
NSUN5P1 -0.363053 8.33E-06 
PDE8B -0.356918 1.21E-05 
PMS2L1 -0.341573 2.98E-05 
LRDD -0.341141 3.05E-05 
AZI1 -0.330346 5.59E-05 
AGK -0.32976 5.77E-05 
PMS2 -0.328076 6.33E-05 
LOC100289173 -0.326178 7.02E-05 
SSNA1 -0.320579 9.48E-05 
DMAP1 -0.318288 0.000107 
LRRC56 -0.316948 0.000115 
PDDC1 -0.31586 0.000122 
RG9MTD3 -0.315461 0.000124 
FAM128B -0.314821 0.000128 
BCL7A -0.312254 0.000147 
NSUN5 -0.309186 0.000172 
FIS1 -0.307483 0.000187 
APBB1 -0.306803 0.000194 
SNHG10 -0.306109 0.000201 
SARM1 -0.305626 0.000206 
SPG7 -0.303997 0.000223 
TCTN1 -0.30393 0.000224 
PEMT -0.30294 0.000235 
LOC642346 -0.302004 0.000247 
CHD1L -0.301706 0.00025 
PI4KA -0.300811 0.000262 
NOSIP -0.300801 0.000262 
EIF3L -0.300093 0.000271 
ZCCHC7 -0.299291 0.000282 
IPO5 -0.298768 0.000289 
LRRC58 -0.297993 0.000301 
POP5 -0.297802 0.000304 
BTF3 -0.297781 0.000304 
RBM19 -0.297768 0.000304 
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DNAJA3 -0.296821 0.000318 
PMS2L11 -0.293494 0.000374 
ICAM4 -0.293459 0.000375 
KIAA1407 -0.293196 0.00038 
CHD9 -0.292245 0.000398 
ACOT1 -0.29185 0.000405 
EFNB1 -0.290846 0.000425 
SEC31B -0.290756 0.000427 
RFTN1 -0.290151 0.000439 
RPAIN -0.289555 0.000452 
PAOX -0.289307 0.000457 
HIST1H4C -0.28925 0.000459 
TRAIP -0.289019 0.000464 
DNAJC27 -0.288904 0.000466 
C11ORF2 -0.288868 0.000467 
RPL3 -0.287526 0.000498 
RSAD1 -0.287234 0.000505 
SEPT6 -0.286738 0.000517 
NELF -0.286699 0.000518 
ESF1 -0.286549 0.000521 
RPL12P6 -0.286071 0.000533 
XPNPEP1 -0.28564 0.000544 
MRPL10 -0.285592 0.000545 
ELAC2 -0.285449 0.000549 
STAG3L2 -0.284399 0.000576 
EXOSC7 -0.284302 0.000579 
ASXL1 -0.284097 0.000585 
C13ORF15 -0.283059 0.000614 
COQ4 -0.282866 0.000619 
WDR92 -0.281829 0.00065 
KIAA1191 -0.281759 0.000652 
MTF2 -0.281753 0.000652 
HARS -0.281648 0.000655 
DIDO1 -0.281631 0.000656 
NKTR -0.281499 0.00066 
MCM7 -0.280695 0.000685 
SUSD3 -0.280348 0.000696 
LOC152217 -0.280014 0.000706 
HNRNPA3 -0.279411 0.000726 
LOC100287580 -0.279155 0.000735 
WDR59 -0.278758 0.000748 
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SLC22A23 -0.278242 0.000766 
EEF1D -0.277013 0.00081 
GLTSCR2 -0.276717 0.000821 
HSD17B10 -0.276713 0.000821 
ZNF544 -0.276509 0.000829 
QRSL1 -0.276184 0.000841 
PNPLA4 -0.275892 0.000852 
ABI2 -0.275654 0.000862 
LOC400987 -0.274663 0.000901 
RPL34 -0.274657 0.000901 
TRMU -0.274516 0.000907 
TAF1C -0.274331 0.000915 
ZCCHC17 -0.273676 0.000942 
SCARNA15 -0.272891 0.000976 
LOC100128355 -0.272884 0.000976 
ZNF783 -0.272664 0.000986 
IMP4 -0.272406 0.000997 
RPSAP52 -0.272204 0.001006 
SAMM50 -0.271713 0.001028 
OGFOD1 -0.271353 0.001045 
NEURL4 -0.271015 0.001061 
GTF2H4 -0.270961 0.001063 
CEBPZ -0.27052 0.001084 
NDRG2 -0.270158 0.001102 
BCL11A -0.269978 0.001111 
FBL -0.269814 0.001119 
TRAPPC6A -0.269654 0.001127 
LOC648771 -0.269333 0.001143 
CHAF1A -0.268751 0.001172 
MYO19 -0.268688 0.001176 
PYGO2 -0.268632 0.001179 
RBM17 -0.268516 0.001185 
SEC63 -0.268478 0.001187 
BAT3 -0.268405 0.00119 
ACOT2 -0.268359 0.001193 
ATF7IP2 -0.268134 0.001205 
DDX51 -0.267958 0.001214 
MARCH9 -0.267878 0.001218 
EIF3D -0.267338 0.001247 
METTL2B -0.267136 0.001259 
FAM160B2 -0.267065 0.001262 
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ZBTB5 -0.266542 0.001292 
RSL1D1 -0.265307 0.001363 
PMPCA -0.264789 0.001394 
HADH -0.264713 0.001399 
TRPT1 -0.264425 0.001416 
LOC100132364 -0.264402 0.001418 
LRPPRC -0.264373 0.001419 
PPIAL3 -0.264058 0.001439 
PET112L -0.263928 0.001447 
PRPF31 -0.263926 0.001447 
CD79A -0.263663 0.001464 
AKAP1 -0.263594 0.001468 
RRP1B -0.263268 0.001489 
C18ORF22 -0.263203 0.001493 
TMEM223 -0.262947 0.00151 
ZG16B -0.262938 0.00151 
FAM195A -0.262875 0.001514 
ZNHIT2 -0.262821 0.001518 
HAX1 -0.262812 0.001518 
AFG3L1 -0.262521 0.001538 
SMYD3 -0.261951 0.001576 
TRIB2 -0.261838 0.001583 
GCDH -0.261632 0.001597 
PCCA -0.261607 0.001599 
DHX30 -0.26083 0.001653 
EIF1AX -0.260553 0.001673 
TTC17 -0.260116 0.001704 
SNRPN -0.260089 0.001706 
PRPF8 -0.259952 0.001716 
SGSM3 -0.25957 0.001744 
ZNF10 -0.259431 0.001755 
LNPEP -0.259146 0.001776 
MBD3 -0.259146 0.001776 
UBE2Q2P1 -0.259144 0.001776 
MUTYH -0.258747 0.001807 
NHP2L1 -0.258659 0.001813 
SFRS14 -0.258545 0.001822 
CXORF57 -0.258446 0.00183 
ZIK1 -0.258253 0.001845 
RPL15P18 -0.257888 0.001873 
LOC442454 -0.257837 0.001877 
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LOC399804 -0.257793 0.001881 
THEM4 -0.257682 0.00189 
SHMT2 -0.257594 0.001897 
RBM25 -0.257522 0.001903 
UTP14A -0.25735 0.001916 
ZNF91 -0.257312 0.001919 
MRPS2 -0.257241 0.001925 
PMEPA1 -0.257067 0.001939 
ZNF439 -0.256951 0.001949 
DGCR6L -0.25689 0.001954 
TMC8 -0.256831 0.001959 
DDT -0.256806 0.001961 
IL11RA -0.256638 0.001975 
EVL -0.256122 0.002018 
ZNF500 -0.256096 0.00202 
ING5 -0.255857 0.002041 
LOC283663 -0.255704 0.002054 
C19ORF29 -0.255674 0.002056 
ELP2 -0.255492 0.002072 
XRCC1 -0.255116 0.002105 
NDUFV1 -0.254893 0.002125 
EGFL8 -0.254582 0.002152 
ANKRD36 -0.254482 0.002161 
RPS10 -0.254454 0.002164 
CC2D2B -0.254368 0.002172 
ZNF335 -0.254316 0.002176 
DDX27 -0.254213 0.002186 
FLJ10038 -0.254057 0.0022 
P4HTM -0.253959 0.002209 
LOC338799 -0.253875 0.002217 
NCAPH2 -0.253616 0.002241 
ZNF571 -0.253532 0.002249 
C5ORF45 -0.253488 0.002253 
WDR74 -0.253383 0.002263 
GRASP -0.253314 0.002269 
FAM82B -0.252999 0.002299 
RPS15AP12 -0.252875 0.002311 
GEMIN4 -0.252438 0.002353 
WDR54 -0.252306 0.002366 
ZNF232 -0.252203 0.002376 
ITM2C -0.251943 0.002402 
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SETDB2 -0.251806 0.002415 
MRPL41 -0.251651 0.002431 
ALG10B -0.251628 0.002433 
DYRK4 -0.251569 0.002439 
C12ORF65 -0.25134 0.002462 
FCRLA -0.251252 0.002471 
LOC389901 -0.25114 0.002482 
PRMT1 -0.251094 0.002487 
ADAT2 -0.25079 0.002518 
PRKAB2 -0.250731 0.002525 
CD1C -0.250706 0.002527 
CLN8 -0.250697 0.002528 
GPATCH1 -0.250685 0.002529 
ZNF446 -0.250622 0.002536 
WDR73 -0.25055 0.002543 
INTS10 -0.25022 0.002578 
RBM42 -0.250105 0.00259 
R3HDM2 0.250157 0.002585 
IER2 0.250739 0.002524 
NFE2 0.250767 0.002521 
PSMA6 0.250903 0.002507 
RAC2 0.250928 0.002504 
CREG1 0.250932 0.002504 
FCHSD2 0.250977 0.002499 
KPNA4 0.251151 0.002481 
NMI 0.251155 0.002481 
CMTM3 0.251184 0.002478 
MKRN1 0.251434 0.002452 
RAB10 0.251523 0.002444 
KIAA0240 0.251611 0.002435 
CNIH4 0.251733 0.002422 
ARNT 0.251745 0.002421 
RAB11A 0.251959 0.0024 
SQRDL 0.252258 0.002371 
FTLP2 0.252535 0.002344 
LIMD2 0.252879 0.00231 
OAZ1 0.252913 0.002307 
GRB10 0.252957 0.002303 
C6ORF150 0.252969 0.002302 
SMURF1 0.252997 0.002299 
TMEM167A 0.253171 0.002283 
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SLC39A11 0.253272 0.002273 
RGS19 0.25345 0.002256 
ME2 0.25407 0.002199 
MPP1 0.254215 0.002186 
LCP1 0.254253 0.002182 
ASTN2 0.254274 0.00218 
IRF9 0.254303 0.002178 
MYL6 0.254318 0.002176 
HLA-H 0.254332 0.002175 
PGK1 0.254332 0.002175 
LPCAT2 0.254622 0.002149 
HARBI1 0.254643 0.002147 
FLI1 0.254658 0.002146 
PLBD1 0.254881 0.002126 
ARF6 0.254912 0.002123 
COTL1 0.25496 0.002119 
ARPC3 0.255204 0.002097 
CAPZA1 0.255374 0.002082 
C16ORF70 0.255794 0.002046 
CD274 0.255853 0.002041 
GMFG 0.25591 0.002036 
LOC150786 0.256099 0.00202 
SLK 0.256227 0.002009 
CTSA 0.256229 0.002009 
UBC 0.256489 0.001987 
SLC44A1 0.256493 0.001987 
TALDO1 0.256684 0.001971 
ATF7 0.256808 0.001961 
ADM 0.256827 0.001959 
MGC4473 0.256899 0.001953 
WDR20 0.256983 0.001946 
RNF10 0.256985 0.001946 
CHD7 0.257088 0.001938 
LAMP1 0.257447 0.001909 
C4ORF34 0.25805 0.001861 
CALM2 0.258764 0.001805 
ZNF24 0.258789 0.001803 
HLA-E 0.25894 0.001792 
BPGM 0.25899 0.001788 
LMO2 0.259079 0.001781 
JAK2 0.25915 0.001776 
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TTRAP 0.259196 0.001772 
AIF1 0.259236 0.001769 
NOTCH2 0.259524 0.001748 
KRCC1 0.25961 0.001742 
SLC38A2 0.259618 0.001741 
ATP5L 0.259849 0.001724 
GOLGA7 0.2599 0.00172 
C1ORF63 0.259967 0.001715 
ERBB2IP 0.259997 0.001713 
FAM100B 0.260166 0.001701 
C20ORF24 0.260219 0.001697 
PPP4R2 0.260282 0.001692 
TPM3 0.260681 0.001664 
UPF1 0.260759 0.001658 
RRAGC 0.260763 0.001658 
DEGS1 0.260872 0.00165 
CRADD 0.260985 0.001642 
YWHAZ 0.261023 0.00164 
ATP11B 0.26103 0.001639 
PCBP1 0.26104 0.001638 
TMEM140 0.261198 0.001627 
FAU 0.261229 0.001625 
UBE2D3P 0.261414 0.001612 
VCPIP1 0.261735 0.00159 
S100P 0.261949 0.001576 
MCL1 0.261972 0.001574 
HLA-C 0.262117 0.001565 
MAFG 0.26225 0.001556 
FAM104A 0.262256 0.001555 
YOD1 0.262542 0.001536 
GSR 0.262571 0.001534 
LOC647252 0.262707 0.001525 
ERO1L 0.262756 0.001522 
TAP1 0.262838 0.001517 
SMAD2 0.263371 0.001482 
LOC220594 0.263501 0.001474 
CDC42SE1 0.264274 0.001426 
TMSL1 0.26428 0.001425 
LRPAP1 0.264591 0.001406 
NBN 0.264633 0.001404 
SAP18 0.264673 0.001401 
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LOC728875 0.264742 0.001397 
SLC37A3 0.264791 0.001394 
CD63 0.265314 0.001363 
CRNKL1 0.265564 0.001348 
ZNF93 0.265645 0.001343 
HLA-J 0.265809 0.001334 
RAB35 0.265874 0.00133 
TSC22D2 0.265971 0.001324 
SUMO1P3 0.266049 0.00132 
THRAP3 0.266288 0.001306 
SEC22B 0.266584 0.001289 
SCYL2 0.266603 0.001288 
PSMC6 0.266704 0.001283 
TOR1AIP2 0.266889 0.001272 
GLRX 0.266937 0.00127 
ZC3H11A 0.266937 0.00127 
CASP4 0.267019 0.001265 
TGFBR2 0.267269 0.001251 
SRPK1 0.2673 0.00125 
FAS 0.267399 0.001244 
IFI16 0.267439 0.001242 
PRR13 0.267563 0.001235 
LOC644063 0.267683 0.001229 
TAB3 0.267731 0.001226 
LOC100133398 0.267775 0.001224 
NBPF14 0.267941 0.001215 
ADAR 0.268058 0.001209 
CNTNAP3 0.268145 0.001204 
HINT3 0.268491 0.001186 
ACTR3 0.268506 0.001185 
TXN 0.26873 0.001173 
UPP1 0.26877 0.001171 
SRP14 0.26905 0.001157 
ACPL2 0.269062 0.001156 
C14ORF43 0.269144 0.001152 
TXNIP 0.269491 0.001135 
CXCR4 0.269493 0.001135 
PSME1 0.269583 0.00113 
CD46 0.269728 0.001123 
FAM27C 0.269829 0.001118 
FBXO30 0.270083 0.001105 
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PRDX3 0.270333 0.001093 
LSM14B 0.270696 0.001076 
VIM 0.270828 0.00107 
KPNB1 0.270847 0.001069 
MIER1 0.271566 0.001035 
GNB4 0.271773 0.001025 
TMBIM6 0.272034 0.001014 
RIT1 0.272088 0.001011 
LOC644101 0.272198 0.001006 
TOP1P2 0.272601 0.000988 
NACC1 0.272628 0.000987 
TMED5 0.27283 0.000978 
KCNE1L 0.273012 0.00097 
FAM199X 0.273061 0.000968 
POTEKP 0.273141 0.000965 
KIDINS220 0.273243 0.00096 
SMCHD1 0.273254 0.00096 
CENPB 0.273319 0.000957 
ACTB 0.273504 0.000949 
RABAC1 0.273846 0.000935 
UBE2H 0.274063 0.000926 
ELF4 0.274109 0.000924 
SPDYA 0.274153 0.000922 
PPP3CB 0.274199 0.00092 
ZEB2 0.274405 0.000912 
RBM7 0.274928 0.00089 
LGALS8 0.275087 0.000884 
MSL3 0.275522 0.000867 
CLIC1 0.275593 0.000864 
WIPI1 0.275785 0.000857 
LCE1A 0.276242 0.000839 
B4GALT1 0.276417 0.000832 
LOC100294179 0.276562 0.000827 
TADA3 0.276591 0.000826 
SERPINB1 0.276658 0.000823 
NBR1 0.276908 0.000814 
AFF1 0.277406 0.000796 
ARHGDIB 0.277612 0.000788 
NPTN 0.277677 0.000786 
SLC30A5 0.277941 0.000777 
EXOC6 0.278017 0.000774 
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KIAA1609 0.27834 0.000763 
TOR1A 0.278773 0.000748 
ADAM9 0.279527 0.000722 
AGFG1 0.279581 0.00072 
PPP1R10 0.279676 0.000717 
CYB5R3 0.279686 0.000717 
P704P 0.279836 0.000712 
PLEKHH3 0.279857 0.000711 
ANAPC11 0.279949 0.000708 
TMEM131 0.280201 0.0007 
HDAC4 0.280251 0.000699 
PSMD12 0.280974 0.000676 
CHUK 0.281215 0.000668 
C1GALT1C1 0.281272 0.000667 
DISC1 0.281969 0.000645 
GATAD2A 0.282106 0.000641 
DEDD 0.282463 0.000631 
LOC541471 0.282616 0.000626 
CHIC2 0.282683 0.000624 
TRIP12 0.283729 0.000595 
MOBKL1B 0.284265 0.00058 
CHMP5 0.284449 0.000575 
SAMSN1 0.284758 0.000567 
ACTR2 0.284783 0.000566 
ARL6IP6 0.28479 0.000566 
LYRM1 0.284794 0.000566 
YIPF1 0.284951 0.000562 
PSMC1 0.285193 0.000555 
CDC5L 0.285348 0.000551 
ZC3H4 0.285546 0.000546 
RBMS1 0.285569 0.000546 
ZBTB47 0.285739 0.000541 
MORF4L1 0.286104 0.000532 
SGMS1 0.287062 0.000509 
CNBP 0.287398 0.000501 
GNAI3 0.287675 0.000494 
LOC730144 0.287763 0.000492 
DYNLT1 0.288181 0.000483 
PSMD4 0.288263 0.000481 
ETS2 0.288666 0.000472 
EVI2A 0.288836 0.000468 
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ACTG1 0.289179 0.00046 
HTATIP2 0.289443 0.000455 
WAC 0.289826 0.000446 
MSL3L2 0.28987 0.000445 
SPATA13 0.289874 0.000445 
VEZF1 0.290061 0.000441 
ZBTB2 0.290502 0.000432 
GRN 0.291029 0.000421 
GADD45A 0.29176 0.000407 
SP100 0.294742 0.000352 
DPYD 0.294754 0.000352 
EIF1B 0.295567 0.000339 
KIAA1949 0.295771 0.000335 
NEDD8 0.296075 0.00033 
TBC1D5 0.296399 0.000325 
ADAM17 0.296686 0.000321 
ELF1 0.296783 0.000319 
MYL12B 0.296819 0.000319 
C16ORF57 0.297249 0.000312 
GYG1 0.299087 0.000285 
EAF1 0.299624 0.000278 
PGM2 0.300948 0.00026 
MAPK14 0.30129 0.000256 
S100A6 0.301584 0.000252 
SNX6 0.303058 0.000234 
DCUN1D1 0.303457 0.000229 
TRIM21 0.304923 0.000213 
RAB8B 0.307382 0.000188 
TOR1AIP1 0.309659 0.000168 
ITPR2 0.310984 0.000157 
DENND1B 0.311007 0.000156 
CDC42 0.311383 0.000153 
MAP3K5 0.311429 0.000153 
ATP6V1C1 0.311458 0.000153 
ABR 0.311685 0.000151 
HLA-G 0.312401 0.000146 
RAP2C 0.313802 0.000135 
SHISA5 0.314539 0.00013 
NSUN3 0.314743 0.000129 
UBA3 0.314829 0.000128 
LOC100292967 0.315604 0.000123 
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DNAJA1 0.317194 0.000113 
RHOT1 0.317996 0.000109 
IDH1 0.318034 0.000109 
NFKBIA 0.318363 0.000107 
HLA-B 0.318876 0.000104 
METTL9 0.3196 9.99E-05 
SNX3 0.320938 9.3E-05 
BRD2 0.322421 8.6E-05 
PPT1 0.323086 8.29E-05 
NBPF3 0.32329 8.2E-05 
ZMYM5 0.323605 8.07E-05 
TMEM165 0.323685 8.03E-05 
UBQLN2 0.324174 7.82E-05 
TMSL3 0.32476 7.58E-05 
B2M 0.325663 7.22E-05 
TMEM167B 0.327413 6.57E-05 
RNF146 0.328173 6.3E-05 
MYL12A 0.329292 5.92E-05 
ARL8A 0.33201 5.1E-05 
SYS1 0.33403 4.56E-05 
SSFA2 0.340979 3.08E-05 
MAP2K6 0.34147 3E-05 
PIM1 0.34503 2.44E-05 
GPER 0.3577 1.15E-05 
LONRF1 0.380004 2.85E-06 
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Gene List 2. Genes identified in functional analysis of the SAMRA gene list. 
Genes R P Pathway(s) 
ACTB 0.273504 0.000949 Actin related 
ACTG1 0.28918 0.00046 Actin related 
ACTR2 0.28478 0.00057 Actin related 
ACTR3 0.26851 0.00119 Actin related 
ADAM17 0.29669 0.00032 Immune system development, Positive 
regulation of protein processing 
ADAM9 0.27953 0.00072 Positive regulation of protein processing 
ADAR 0.26806 0.00121 RNA splicing 
ANAPC11 0.27995 0.00071 Positive regulation of protein processing 
ARF6 0.25491 0.00212 Ras GTPase 
ARL8A 0.33201 5.10E-05 Ras GTPase 
B2M 0.32566 7.22E-05 Antigen processing, Antigen presentation 
BCL11A -0.27 0.00111 Immune system development 
BPGM 0.25899 0.00179 Immune system development 
C19ORF29 -0.2557 0.00206 RNA splicing 
CALM2 0.25876 0.00181 Regulation of DNA binding 
CD1C -0.2507 0.00253 Antigen processing, Antigen presentation 
CD79A -0.2637 0.00146 Immune system development 
CDC42 0.31138 0.00015 Immune system development, Ras 
GTPase 
CDC5L 0.28535 0.00055 RNA splicing 
CHD7 0.25709 0.00194 Immune system development 
CHUK 0.28122 0.00067 Immune system development 
CLN8 -0.2507 0.00253 Ubiquitin regulation 
CRADD 0.26099 0.00164 Antigen presentation 
CRNKL1 0.26556 0.00135 RNA splicing 
DNAJA3 -0.2968 0.00032 Immune system development, Positive 
regulation of protein processing, Negative 
regulation of transcription, Ubiquitin 
regulation, Regulation of DNA binding 
DNAJC27 -0.2889 0.00047 Ras GTPase 
FAS 0.2674 0.00124 Immune system development 
GEMIN4 -0.2524 0.00235 RNA splicing 
HDAC4 0.28025 0.0007 Immune system development, Positive 
regulation of protein processing, Negative 
regulation of transcription, Regulation of 
DNA binding 
HLA-B 0.31888 0.0001 Antigen processing, Antigen presentation 
HLA-C 0.26212 0.00156 Antigen processing, Antigen presentation 
HLA-E 0.25894 0.00179 Antigen processing, Antigen presentation 
HLA-G 0.3124 0.00015 Antigen processing, Antigen presentation 
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HLA-H 0.25433 0.00217 Antigen processing, Antigen presentation 
HLA-J 0.26581 0.00133 Antigen processing, Antigen presentation 
HNRNPA3 -0.2794 0.00073 RNA splicing 
IFI16 0.26744 0.00124 Immune system development 
JAK2 0.25915 0.00178 Immune system development, Positive 
regulation of protein processing, Negative 
regulation of transcription, Regulation of 
DNA binding 
LMO2 0.25908 0.00178 Immune system development 
LOC150786 0.2561 0.00202 Ras GTPase 
LOC389901 -0.2511 0.00248 Immune system development 
LOC399804 -0.2578 0.00188 Regulation of DNA binding 
LOC644063 0.26768 0.00123 RNA splicing 
LRPAP1 0.26459 0.00141 Negative regulation of transcription, 
Regulation of DNA binding 
NBN 0.26463 0.0014 Immune system development 
NFKBIA 0.31836 0.00011 Positive regulation of protein processing, 
Negative regulation of transcription, 
Regulation of DNA binding 
NHP2L1 -0.2587 0.00181 RNA splicing 
NOTCH2 0.25952 0.00175 Immune system development 
P704P 0.27984 0.00071 Actin related 
PCBP1 0.26104 0.00164 RNA splicing 
PEMT -0.3029 0.00024 Positive regulation of protein processing 
PIM1 0.34503 2.44E-05 Negative regulation of transcription, 
Regulation of DNA binding 
PMS2 -0.3281 6.3E-05 Immune system development 
POTEKP 0.27314 0.00096 Actin related 
PPP3CB 0.2742 0.00092 Immune system development 
PPP4R2 0.26028 0.00169 RNA splicing 
PRDX3 0.27033 0.00109 Immune system development 
PRPF31 -0.2639 0.00145 RNA splicing 
PRPF8 -0.26 0.00172 RNA splicing 
PSMA6 0.2509 0.00251 Positive regulation of protein processing, 
Ubiquitin regulation 
PSMC1 0.28519 0.00056 Positive regulation of protein processing, 
Ubiquitin regulation 
PSMC6 0.2667 0.00128 Positive regulation of protein processing, 
Ubiquitin regulation 
 
PSMD12 
 
0.28097 
 
0.00068 
 
Positive regulation of protein processing, 
Ubiquitin regulation 
PSMD4 0.28826 0.00048 Positive regulation of protein processing, 
Ubiquitin regulation 
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PSME1 0.26958 0.00113 Antigen processing, Positive regulation of 
protein processing, Ubiquitin regulation 
RAB10 0.25152 0.00244 Ras GTPase 
RAB11A 0.25196 0.0024 Ras GTPase 
RAB35 0.26587 0.00133 Ras GTPase 
RAB8B 0.30738 0.00019 Ras GTPase 
RAC2 0.25093 0.0025 Ras GTPase 
RAP2C 0.3138 0.00014 Ras GTPase 
RBM17 -0.2685 0.00118 RNA splicing 
RBM25 -0.2575 0.0019 RNA splicing 
RHOT1 0.318 0.00011 Ras GTPase 
RIT1 0.27209 0.00101 Ras GTPase 
RRAGC 0.26076 0.00166 RNA splicing 
SFRS14 -0.2585 0.00182 RNA splicing 
SGSM3 -0.2596 0.00174 Positive regulation of protein processing 
SMAD2 0.26337 0.00148 Regulation of DNA binding 
SMURF1 0.253 0.0023 Positive regulation of protein processing, 
Ubiquitin regulation 
SNRPN -0.2601 0.00171 RNA splicing 
SP100 0.29474 0.00035 Negative regulation of transcription, 
Regulation of DNA binding 
SRP14 0.26905 0.00116 Ubiquitin regulation 
SRPK1 0.2673 0.00125 RNA splicing 
SUMO1P3 0.26605 0.00132 Negative regulation of transcription, 
Regulation of DNA binding 
TGFBR2 0.26727 0.00125 Immune system development 
TRPT1 -0.2644 0.00142 RNA splicing 
UBC 0.25649 0.00199 Positive regulation of protein processing, 
Ubiquitin regulation 
UPF1 0.26076 0.00166 RNA splicing 
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Gene List 3. Overlap of genes identified in the CATHEN/PREDICT analysis and the 
SAMARA analysis. 
ACTB MARCH9 
APBB1 MCL1 
B2M METTL9 
BCL7A MYL6 
C11orf2 NDRG2 
C16orf57 NMI 
C20orf24 PPP4R2 
CALM3 RAC2 
CASP4 RIT1 
CLIC1 RPL34 
DYNLT1 RPS10 
EIF1AX S100P 
EXOC6 SAMSN1 
FAU SEC22B 
GLRX SERPINB1 
GMFG SLC37A3 
GRB10 SP100 
GYG1 SRPK1 
HDAC4 TALDO1 
HLA-E TXN 
HTATIP2 UBC 
ITM2C YOD1 
MAPK14  
  
 
 
 
 
 
 
 
CHAPTER III 
EVALUATION OF ARACHIDONIC ACID METABOLISM GENE EXPRESSION IN 
HUMANS WITH OBSTRUCTIVE CORONARY ARTERY DISEASE  
 
Introduction 
 
Vascular inflammation is integral to the development and progression of coronary artery 
disease (CAD), and activation of the inflammatory cascade contributes to plaque instability 
and rupture, resulting in acute coronary syndrome (ACS) events.2 4 In addition, CAD patients 
with advanced vascular inflammation have poor disease prognosis and have higher risk of 
all-cause mortality.12, 13 Peripheral blood mononuclear cells (PBMCs) are integral mediators 
of vascular inflammation, and infiltration of monocytes into the vessel wall is a key event in 
the pathogenesis of atherosclerosis. PBMCs express numerous signaling molecules 
regulating interactions between the vessel wall and circulating leukocytes, and drive 
monocyte recruitment and infiltration into the vessel, ultimately leading to plaque 
development and obstructive CAD.114 Moreover, the presence of obstructive CAD is 
associated with higher risk of cardiovascular events and poor prognosis in CAD patients 
with advanced age.1 Therefore, identification of biological pathways that are dysregulated in 
the presence of obstructive CAD in older individuals may provide insight into pathogenesis 
and progression of atherosclerosis, and facilitate the development of targeted therapeutic 
strategies for this high-risk population subset.  
Arachidonic acid derived eicosanoids regulate key processes in the pathophysiology of 
atherosclerosis including inflammation, platelet aggregation and vascular tone.34, 39 Genetic 
epidemiology studies indicate the cytochrome P450 (CYP), cyclooxygenase (COX), and 
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lipoxygenase (LOX) pathways of arachidonic acid metabolism are associated with coronary 
artery disease (CAD) risk.48, 80, 123 For example, a polymorphism in EPHX2 (K55R) is 
associated with higher epoxide hydrolase activity in vivo and higher risk of CAD81 and 
endothelial dysfunction82 in Caucasians. In addition, a CYP2J2 promoter polymorphism 
(CYP2J2 -50G>T) is associated with lower CYP2J2 promoter activity in vitro and higher risk 
of CAD in humans.83 Similarly, the CYP2C8 K399R variant allele has lower CYP 
epoxygenase activity in vitro84 and is associated with higher risk of acute myocardial 
infarction (MI) in humans.85 In the COX pathway, single nucleotide polymorphisms in 
TBXAS1 and PTGIS have been associated with risk for MI and ischemic stroke and 
common polymorphisms in PTGS2 have been associated with risk for ACS events.124, 125 
Similarly, in the LOX pathway a variable nucleotide tandem repeat polymorphism in the 
ALOX5 promoter has been associated with the development of subclinical atherosclerosis60 
and certain haplotypes in ALOX5AP and LTA4H have been associated with risk of MI.126, 127  
Collectively, these studies demonstrate that inter-individual variation in the arachidonic 
acid metabolism pathway is an important predictor of cardiovascular disease (CVD) risk. 
Moreover, PBMCs express numerous genes that contribute to the metabolism of 
arachidonic acid to biologically active eicosanoids, including components of the CYP, COX, 
and LOX pathways, suggesting that dysregulation of arachidonic acid metabolism may 
regulate monocyte activation and infiltration into the vessel wall.99, 128 Since inflammation 
and monocyte infiltration into the vessel wall are key events in the pathogenesis and 
progression of atherosclerosis, and the CYP, COX and LOX pathways are known to 
regulate systemic and vascular inflammation in preclinical models, we hypothesize that 
dysregulation of arachidonic acid metabolism is a key driver of inflammation and the 
subsequent development and progression of atherosclerosis in humans. However, the 
contribution of inter-individual variation in the expression of genes that metabolize 
arachidonic acid to biologically active eicosanoids to CAD risk remains unknown. Therefore, 
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the objective of this analysis is to determine if genes in the arachidonic acid metabolism 
pathway are differentially expressed in PBMCs of older individuals with obstructive CAD, a 
population at high-risk for CAD clinical events. 
 
Methods 
Study Population 
The Supporting A Multidisciplinary Approach to Researching Atherosclerosis (SAMARA) 
study enrolled consecutive patients who were at least 65 years of age and undergoing 
diagnostic cardiac catheterization as part of their routine care. Between March 2007 and 
February 2009 we enrolled 143 individuals from the University of North Carolina (UNC) 
Cardiac Catheterization Laboratory. Subjects with HIV or HCV infection, lymphoma, 
leukemia, anemia, history of rheumatoid arthritis or lupus, history of solid organ 
transplantation and individuals undergoing current cancer treatment or chronic 
immunosuppressive therapy were not eligible to participate. This study was approved by the 
UNC Institutional Review Board and conducted according to institutional guidelines; all 
participants provided written informed consent. 
 
Sample Collection and Processing 
All catheterizations took place in the morning following an overnight fast; at the start of 
the procedure 30 mL of blood was drawn from the femoral artery into Na-EDTA Vacutainer 
tubes (Becton, Dickinson and Co., Cockeysville, MD). Following blood collection RNA was 
isolated from PBMCs as described.101 RNA was purified using the RNeasy mini-kit (Qiagen, 
Valencia, CA). RNA quantity, purity and integrity were assessed by spectrophotometry and 
microcapillary electrophoresis on an Agilent BioAnalyzer 2100 (Agilent Technologies, Inc., 
Santa Clara, CA). Only RNA with an A260/280 ratio of ≥ 1.8, and an electrophoretic profile 
consistent with only minimal degradation was considered acceptable for use. An additional 8 
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mL of blood collected in tubes containing EDTA and proteinase inhibitor was processed to 
plasma, aliquoted, and stored at -80ºC pending analysis. 
 
CAD Severity 
Subjects underwent diagnostic left-heart catheterization as part of their routine medical 
care. Following the procedure, coronary angiography was utilized to classify subjects as 
obstructive CAD patients (≥70% stenosis in ≥1 major epicardial coronary artery); individuals 
with <70% occlusion in any vessel were considered free of obstructive CAD and were 
utilized as the comparator group. 
 
Gene Expression Microarray 
RNA was co-hybridized to Agilent G4112A Whole Human Genome 44K oligonucleotide 
arrays in the presence of Cyanine-3 labeled Universal Human Reference RNA (Stratagene, 
LaJolla, CA) for array normalization, as described.101 Slides were hybridized and washed, 
then scanned on an Axon 4000b microarray scanner; data were processed using Agilent 
software. Only probes flagged “detected” in at least 85% of all samples were included, 
resulting in 18,411 probes in the final dataset. In addition, only samples with at least 90% of 
probes flagged detected were included in the analyses. Missing data were imputed using 
the k-nearest neighbor algorithm (k=10). MIAME-compliant datasets were deposited with the 
Gene Expression Omnibus of the National Center for Biotechnology Information (GEO 
Series accession number GSE12959). 
Microarray expression data was corrected to account for scan-date batch effects using 
the remove batch-effect feature in Partek Genomics Suite v6.6. Unsupervised analyses 
determined the primary signal contributing to gene expression was gender. In addition, 
diabetes was found to be a potential confounder to CAD severity. Therefore we conditioned 
 68 
 
the dataset using an analysis of variance (ANOVA) linear model to account for gender and 
diabetes. 
 
Gene Set Enrichment Analysis 
Gene set enrichment analysis (GSEA) is a powerful analytical tool for the detection of 
gene expression differences in coordinated biological processes, such as metabolic 
signaling pathways.129, 130 Therefore, GSEA (Version 2.0) was used to determine if the 
arachidonic acid metabolism pathway is “enriched” in individuals with obstructive CAD 
compared to individuals without obstructive CAD.  
GSEA ranks a preselected list of genes according to their correlation with the phenotype 
being tested then calculates an enrichment score that represents the degree to which the 
candidate gene list is overrepresented at the top or bottom of all genes on the microarray. 
Significance (p-value) is determined by comparing the enrichment score of the candidate 
gene list to the null distribution, which is obtained from a series of random phenotype 
permutations. The leading-edge or “core enrichment” subset is defined as the gene(s) that 
appear at or before the maximum deviation of the gene set from zero, and thus is the core 
subset of candidate genes that accounts for the observed enrichment signal relative to 
global gene expression. 
Genes involved in the metabolism of arachidonic acid to biologically active eicosanoids 
were identified using the Kyoto Encyclopedia of Genes and Genomes (KEGG)131 
‘arachidonic acid metabolism pathway’ map00590, and limited to genes encoding proteins 
involved in arachidonic acid liberation from the cell membrane and metabolism (Table 3.1). 
Of the 43 genes in the arachidonic acid metabolism pathway, 40 (93%) were represented on 
the microarray, and 14 (33%) passed our quality control standards (indicating that they were 
expressed in at least 85% of all SAMARA subjects) and were included in the final processed 
dataset used for the GSEA (Table 3.2).  
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The primary GSEA was completed in the entire cohort of 143 subjects; due to the known 
confounding effects of race and gender on genes expression,132, 133 secondary analyses 
were conducted using the subset of male subjects (n=75), Caucasian subjects (n=111), and 
Caucasian male subjects (n=64). The number of permutations for each analysis was set at 
1000, with a p-value of <0.05 considered significantly enriched.  
 
Results 
Study Population 
We enrolled 143 subjects undergoing diagnostic cardiac catheterization; the study 
population characteristics are shown in Table 3.3. Subjects were on average 74±6 years of 
age and a total of 93 subjects (65%) had obstructive CAD while 50 (35%) did not have 
obstructive CAD. The majority of subjects were Caucasian (78%), male (52%) and had 
multiple comorbidities including hyperlipidemia (71%) and hypertension (88%). Use of 
medications for the treatment of CAD was common including statins (68%), aspirin (78%) 
and clopidogrel (27%). Population characteristics were similar in subjects diagnosed with 
obstructive CAD and subjects without an obstructive CAD diagnosis (Table 3.3). However, 
individuals with obstructive CAD were more likely to be male (61%) compared to individuals 
without obstructive CAD (36%). Consistent with current clinical practice guidelines, 
individuals with obstructive CAD were also more likely to be receiving medications used in 
the treatment of CAD, including aspirin, clopidogrel, and statins (Table 3.3).  
 
Arachidonic Acid Metabolism Pathway Expression in Obstructive CAD 
The results of the arachidonic acid metabolism pathway GSEA are summarized in Table 
3.4. The arachidonic acid metabolism pathway was not significantly enriched in subjects 
with obstructive CAD (p=0.526), indicating that relative to global gene expression changes, 
the arachidonic acid metabolism pathway as a whole was not dysregulated in individuals 
 70 
 
with obstructive CAD compared to individuals without obstructive CAD. Similar to the 
analysis in the entire cohort, significant enrichment of the arachidonic acid pathway was not 
observed after stratifying the cohort and limiting the analysis to Caucasians (p=0.255), 
males (p=0.288), or Caucasian male subjects (p=0.425, Table 3.4). 
Table 3.5 lists each gene in the arachidonic acid metabolism pathway in rank order of its 
correlation with obstructive CAD. The overall rank of the correlation of each gene relative to 
the 10,096 unique annotated genes in the correlation analysis, the direction of the 
association with CAD (positive indicates higher expression in individuals diagnosed with 
obstructive CAD) and whether or not the gene was part of the core enrichment subset are 
displayed. Although the overall GSEA was not statistically significant, the core enrichment 
subset for this analysis shows that the enrichment signal was strongest for EPHX2, PTGS1, 
and PLA2G12A, which were negatively correlated with the presence of obstructive CAD 
(Table 3.5).  
Since EPHX2 was found to demonstrate one of the strongest inverse correlations 
relative to all genes expressed in PBMCs (rank 9,975 out of 10,096), we conducted an 
exploratory analysis using ANOVA to determine whether this individual gene in the 
arachidonic acid pathway was differentially expressed in subjects with obstructive CAD. We 
found that EPHX2 was significantly suppressed by 18±4% (p=0.007) in individuals with 
obstructive compared to individuals without obstructive CAD (Figure 2.1). 
 
Discussion 
Preclinical and epidemiologic studies have demonstrated that arachidonic acid 
metabolism is important in the regulation of vascular inflammation, and the subsequent 
development and progression of CAD. In this study, we utilized GSEA to determine whether 
arachidonic acid metabolism pathway gene expression is “enriched” in PBMCs of older 
individuals with obstructive CAD. Our analysis did not demonstrate significant enrichment of 
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arachidonic acid metabolism pathway gene expression in individuals with obstructive CAD. 
Similarly, GSEA of population subsets including Caucasians, males, and Caucasian male 
subjects did not demonstrate significant enrichment in individuals with obstructive CAD, 
suggesting that the coordinated dysregulation of key genes involved in the metabolism of 
arachidonic acid in PBMCs is not associated with the development of obstructive CAD in 
older humans.  
It is well-established that 5-lipoxygenase (5-LO) pathway derived leukotrienes are pro-
inflammatory chemoattractant molecules that activate leukocytes and contribute to 
recruitment of monocytes to the vessel wall.51 Conversely, COX pathway enzymes 
metabolize arachidonic acid to prostaglandins which may have pro- or anti-inflammatory 
effects.42, 134 While COX-derived prostaglandins generally increase vascular permeability 
and leukocyte infiltration, their actions are tissue specific and inhibition of prostaglandin 
biosynthesis has yielded conflicting effects on cardiovascular inflammatory responses and 
atherosclerosis in pre-clinical models.134 Similar to the COX pathway, CYP-mediated 
arachidonic acid metabolism drives both pro- and anti-inflammatory processes in the 
vasculature. CYP ω-hydroxylase derived 20-hydroxyeicosatetraenoic acid (HETE) elicits 
pro-inflammatory vasoconstrictive effects, while CYP epoxygenase derived 
epoxyeicosatrienoic acids (EETs) are anti-inflammatory and cardioprotective.74, 86 Therefore, 
although our results demonstrated that arachidonic acid metabolism pathway gene 
expression was not dysregulated as a whole in subjects with obstructive CAD, we cannot 
dismiss the possibility that the individual (i.e. COX, LOX, and CYP) pathways of arachidonic 
acid metabolism may be important mediators of systemic and vascular inflammation, and 
the subsequent development and progression of CAD. 
Our analysis has limitations that must be noted. First, our cohort consisted only of 
individuals ≥65 years of age. While our findings cannot be extrapolated to other population 
subsets, older individuals are at high-risk for CAD and the pathophysiology of the 
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development and progression of CAD has previously remained largely unexplored in this 
population subset. Second, PBMC RNA expression is a surrogate for capturing biological 
processes taking place at the site of the atherosclerotic lesion, and the CYP, COX, and LOX 
pathways are metabolically active in other cell types that also are important in CAD, 
including endothelial cells, platelets, cardiomyocytes, and hepatocytes.34 Furthermore, 
multiple arachidonic acid metabolism pathway genes either were not on the microarray or 
did not pass our quality control analysis and therefore were not included in the GSEA. 
Moreover, some proteins including CYPs are regulated at the post-transcriptional level.135 
Therefore, it is possible that individual components of the arachidonic acid metabolism 
pathway that are important in the pathophysiology of CAD may not have been captured in 
our pathway analysis of genes that metabolize arachidonic acid to biologically active 
eicosanoids in PBMCs. Furthermore, previous genetic association studies have 
demonstrated that individual pathways of arachidonic acid metabolism (i.e. COX, LOX, and 
CYP) are important in the development of CAD. Lastly, although our analysis is one of the 
largest microarray studies conducted in patients at high-risk for CAD, some of the subgroup 
comparisons contained small numbers of subjects and therefore had limited power to detect 
enrichment of the arachidonic acid metabolism pathway. The absence of a significant 
association at the RNA level between arachidonic acid metabolism pathway gene 
expression in PBMCs and obstructive CAD, suggests that the parallel components of the 
overall arachidonic acid metabolism pathway are not coordinately dysregulated in the 
presence of obstructive CAD in older individuals. However, the limitations described above 
highlight the need for candidate pathway approaches to rigorously evaluate the functional 
relationship between individual pathways of arachidonic acid metabolism and the 
pathogenesis and progression of CAD. 
Accumulating preclinical and epidemiologic evidence suggests that CYP-mediated 
eicosanoid metabolism is important in the regulation of vascular inflammation. The CYP-
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epoxygenase pathway exerts potent anti-inflammatory effects while the CYP ω-hydroxylase 
pathway exerts pro-inflammatory effects.74, 86 In our study, only two genes from the CYP 
pathway were found two be expressed on PBMCs, the CYP ω-hydroxylase CYP4F2 and the 
CYP-epoxygenase pathway gene EPHX2 which encodes soluble epoxide hydrolase (sEH), 
the enzyme responsible for metabolizing EETs to the less biologically active 
dihydroxyeicosatrienoic acids (DHETs). While our analysis of gene expression in PBMCs did 
not demonstrate significant dysregulation of the arachidonic acid metabolism pathway as a 
whole, our exploratory analysis found that EPHX2 was suppressed in subjects with 
obstructive CAD. It is important to note that the association between EPHX2 expression and 
CAD score did not exceed the a priori absolute correlation coefficient of ≥0.25 in our global 
analysis of gene expression (rs=-0.20, p=0.020) and therefore was not included in our list of 
512 differentially expressed genes (Chapter II). In addition, this exploratory finding requires 
validation by quantitative real time-polymerase chain reaction (qRT-PCR) and replication in 
an independent cohort; however, suppression of EPHX2 in the presence of CAD is 
consistent with our previous report that sEH metabolic function is suppressed in stable CAD 
patients under 65 years of age compared to healthy volunteers.136 Moreover, previous 
studies have demonstrated that myocardial EPHX2 expression is suppressed in individuals 
with ischemic heart failure compared to control subjects.137 These findings suggest that the 
presence of CVD may lead to a compensatory suppression of sEH-mediated EET hydrolysis 
in humans that was not captured by our global analysis of arachidonic acid pathway gene 
expression in PBMCs. Given the emerging importance of CYP-mediated eicosanoid 
metabolism in the regulation of pathological processes integral to CAD in preclinical 
models,74 future studies evaluating the association between inter-individual variation in CYP-
derived eicosanoids at the metabolite level and the pathogenesis and progression of CAD in 
humans are warranted.  
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Conclusions 
In summary, our analysis in older individuals presenting for coronary angiography did not 
demonstrate that arachidonic acid metabolism pathway gene expression is coordinately 
dysregulated in PBMCs of individuals with obstructive CAD. However, future studies are 
warranted to define the functional link between candidate pathways of arachidonic acid 
metabolism and the pathogenesis and progression of CAD.  
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Tables 
 
Table 3.1. Genes in the arachidonic acid metabolism pathway from the KEGG 
database. 
PLA CYP COX LOX  
PLA2G10 CYP2B6 PTGDS ALOX12 
PLA2G12A CYP2C18 PTGES  ALOX12B 
PLA2G12B CYP2C19 PTGES2  ALOX15 
PLA2G1B CYP2C8 PTGIS   ALOX15B 
PLA2G2A CYP2C9 PTGS1  ALOX5 
PLA2G2C* CYP2E1 PTGS2  ALOX5AP 
PLA2G2D CYP2J2 TBXAS  LTA4H 
PLA2G2E CYP2U1  LTC4S 
PLA2G2F CYP4A11 
PLA2G3 CYP4A22* 
PLA2G4A CYP4F2 
PLA2G4B CYP4F3 
PLA2G4E* EPHX2 
PLA2G5 
PLA2G6 
*Included in the arachidonic acid metabolism pathway from the KEGG database but not 
represented on the microarray. 
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Table 3.2. Arachidonic acid pathway genes in final analysis. 
PLA CYP COX LOX 
PLAG4A CYP4F2 PTGS1 ALOX5 
PLA2G12A EPHX2 PTGS2 ALOX5AP 
PLA2G4B  PTGES2 LTA4H  
PLA2G6  PTGDS 
  TBXAS1 
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Table 3.3. Demographics are presented for all subjects, and according to obstructive 
CAD status. 
Characteristic All Obstructive No Obstructive
  CAD CAD  
N  143 93 50   
Age (years) 73.9±6.3 74±6.3 73±6.2  
Male gender (%) 75 (52%) 57 (61%) 18 (36%)*  
Caucasian (%) 111 (78%) 74 (80%) 37 (74%)  
Body mass index (kg/m2) 29±6.6 29±6.3 30±7.1  
Current smoker (%) 7 (5%) 4 (4%) 3 (6%)  
Diabetes (%) 55 (38%) 38 (41%) 17 (34%)  
Hyperlipidemia (%) 102 (71%) 74 (80%) 28 (56%)*  
Hypertension (%) 126 (88%) 82 (88%) 44 (88%)  
Previous myocardial infarction 44 (31%) 41 (44%) 3 (6%)*  
Multivessel disease 62 (43%) 62 (67%) 0 (0%)*  
Systolic blood pressure (mmHg) 142±20 143±20 141±20  
Diastolic blood pressure (mmHg) 78±13 77±13 78±12  
Statin use (%) 97 (68%) 74 (80%) 23 (46%)*  
Aspirin use (%) 111 (78%) 78 (84%) 33 (66%)*  
Clopidogrel use (%) 39 (27%) 33 (36%) 6 (12%)*  
Data presented as mean ± standard deviation or count (proportion). 
*P<0.05 vs. individuals with obstructive CAD. 
Age, body mass index, and diastolic blood pressure were not normally distributed and were 
log-transformed prior to analysis. 
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Table 3.4. Results of Arachidonic Acid Metabolism Pathway Gene Set Enrichment 
Analysis. 
Population Obstructive CAD   
 (yes vs. no)  
All (n=143) 0.526  
Caucasians only (n=75) 0.255  
Males only (n=111) 0.288  
Caucasian Males only (n=64) 0.425  
P-values are presented for each of the Gene Set Enrichment Analyses. 
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Table 3.5. Summary of GSEA results for the arachidonic acid metabolism pathway in 
patients with obstructive CAD. 
Rank  Gene Overall Rank* Direction Core Enrichment^ 
1 PLA2G4A 827 Positive No 
2 CYP4F2 1950 Positive No 
3 LTA4H 2540 Positive No 
4 ALOX5 2703 Positive No 
5 ALOX5AP 2830 Positive No 
6 PTGDS 3463 Positive No 
7 TBXAS1 3882 Positive No 
8 PLA2G6 4615 Positive No 
9 PTGS2 5062 Negative No 
10 PTGES2 6079 Negative No 
11 PLA2G4B 6577 Negative No 
12 PLA2G12A 8965 Negative Yes 
13 PTGS1 9216 Negative Yes 
14 EPHX2 9975 Negative Yes 
*Overall rank of 10,096 unique annotated genes in correlation analysis with obstructive 
CAD. The direction of the association indicates whether the gene was expressed at higher 
(positive) or lower (negative) levels in subjects with obstructive CAD. 
^The Core Enrichment subset of genes is the core of a gene set that accounts for the 
observed signal. Since the overall GSEA was not statistically significant (p=0.526), the core 
enrichment subset for this analysis indicates that the enrichment signal was strongest in 
EPHX2, PTGS1, and PLA2G12A, which were inversely correlated with the presence of 
obstructive CAD. 
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Figures 
 
Figure 3.1. EPHX2 expression in PBMCs according to obstructive CAD status.  
The expression of EPHX2 in PBMCs is displayed relative to individuals without obstructive 
CAD. The horizontal line within the box represents the median, the edges of the box 
represent the 25th and 75th percentiles, and the error bars represent the 10th and 90th 
percentiles. EPHX2 was found to be significantly lower in individuals with obstructive CAD 
(n=93) compared to individuals without obstructive CAD (n=50). *P=0.007 vs. subjects 
without obstructive CAD.  
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CHAPTER IV 
CYTOCHROME P450-DERIVED EICOSANOIDS AND VASCULAR DYSFUNCTION IN 
CORONARY ARTERY DISEASE PATIENTS1 
 
Introduction 
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide 
and despite recent advances, novel therapies are needed to further improve outcomes. 
Inflammation and impaired arterial vasodilation (endothelial dysfunction) are key drivers of 
the pathogenesis and progression of CAD in preclinical models and humans.9 It is well 
established that elevated circulating biomarkers of systemic (C-reactive protein)24 and 
vascular (chemokines, cellular adhesion molecules [CAMs])12, 13 inflammation and impaired 
physiologic measures of endothelial function (brachial artery flow-mediated dilation [FMD])22 
are predictive of poor prognosis in patients with established CAD. Therefore, CAD patients 
with persistent vascular inflammation and/or endothelial dysfunction, despite treatment with 
current standards of care, may be candidates for adjunct therapeutic strategies specifically 
designed to improve vascular function. Identification of the key pathways that regulate these 
phenotypes in humans, however, is essential to facilitate the development of targeted 
therapies for these high-risk subsets of the population. 
Accumulating preclinical and epidemiologic evidence has emerged to suggest that 
modulation of cytochrome P450 (CYP)-mediated eicosanoid metabolism may be a viable 
                                               
1
 Schuck RN, Theken KN, Edin ML, Caughey M, Bass A, Ellis K, Tran B, Steele S, Simmons BP, Lih 
FB, Tomer KB, Wu MC, Hinderliter AL, Zeldin DC, Stouffer GA, and Lee CR. Atherosclerosis, 
2013;227(2):442-448. 
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clinical therapeutic strategy for the management of cardiovascular disease.74, 86 The CYP2J 
and CYP2C epoxygenases metabolize arachidonic acid to four epoxyeicosatrienoic acid 
(EET) regioisomers (5,6-, 8,9-, 11,12-, and 14,15-EET), which possess potent vasodilatory 
and anti-inflammatory effects. The EETs, however, are rapidly metabolized to less active 
dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolase (sEH). In parallel, 
CYP4F and CYP4A ω-hydroxylases generate 20-hydroxyeicosatetraenoic acid (20-HETE), 
which exhibits potent vasoconstrictive and pro-inflammatory effects. Inhibition of sEH 
mediated EET hydrolysis and CYP ω-hydroxylase mediated 20-HETE biosynthesis each 
elicit potent protective effects in preclinical models of endothelial dysfunction and 
hypertension, nuclear factor (NF)-κB dependent vascular inflammation, atherosclerosis, and 
myocardial ischemia-reperfusion injury.73-75, 77, 78, 88, 138 In humans, genetic epidemiology 
studies have shown that functional polymorphisms in CYP epoxygenases (CYP2J2 and 
CYP2C8), sEH (EPHX2), and CYP ω-hydroxylases (CYP4F2 and CYP4A11) are associated 
with the development of cardiovascular disease.81, 83, 92 
Furthermore, we recently reported that patients with established atherosclerotic 
cardiovascular disease exhibit higher plasma EET levels and higher 14,15-EET:DHET ratios 
compared to healthy individuals at low risk for cardiovascular disease.136 Conversely, no 
significant differences in 20-HETE levels were observed. Due to the vascular protective 
effects of EETs in preclinical models, these data suggest that the presence of 
cardiovascular disease may lead to a compensatory suppression of sEH-mediated EET 
hydrolysis in humans. Importantly, pharmacologic inhibitors of sEH139 and CYP ω-
hydroxylase metabolism140 are currently in development. Although these novel therapies are 
hypothesized to improve prognosis in CAD patients by eliciting protective effects in the 
vasculature via increasing EET and decreasing 20-HETE levels, respectively, it remains 
unknown whether CAD patients with dysregulated CYP-mediated eicosanoid metabolism 
exhibit more advanced vascular dysfunction. A more thorough understanding of the role of 
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CYP-derived EETs and 20-HETE in the regulation of vascular function in patients with 
established CAD offers enormous potential to identify subsets of the population with 
dysregulated eicosanoid metabolism (i.e., low EET and/or high 20-HETE levels) who may be 
most likely to derive benefit from these novel therapies in development.  
Therefore, the primary objective of this study was to characterize the relationship 
between inter-individual variation in CYP-mediated eicosanoid metabolism and key vascular 
function phenotypes in patients with stable atherosclerotic cardiovascular disease, and 
determine whether the subset of individuals with enhanced sEH and CYP ω-hydroxylase 
metabolic function exhibit endothelial dysfunction and advanced inflammation.  
 
Methods 
Study Population 
A cohort of 106 individuals with established and stable CAD, defined as ≥50% stenosis 
in one or more major epicardial coronary arteries by coronary angiography, were identified 
in the University of North Carolina (UNC) Cardiac Catheterization Laboratory between 
October 2007 and November 2010.136, 141 Exclusion criteria included pregnancy, atrial 
fibrillation, left-ventricular systolic dysfunction (ejection fraction ≤35%), current use of long-
acting nitrates or insulin, active autoimmune disease, history of severe aortic stenosis, 
history of solid organ transplant or dialysis, or history of cancer within the previous 5 years. 
Eligible participants provided written informed consent and returned to the UNC Clinical and 
Translational Research Center 65±35 days after their index catheterization for a single 
morning study visit and blood sample collection after fasting overnight and withholding their 
morning medications. All study visits took place at least 7 days following the index 
catheterization, and all participants were clinically stable and chest pain free at the time of 
their study visit. 
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Participants were instructed to refrain from tobacco products, caffeine, and vigorous 
exercise the morning of the study visit, and from use of vitamin C, vitamin E, fish oil, niacin 
or arginine supplements, oral decongestants, non-steroidal anti-inflammatory drugs (other 
than low-dose aspirin), or phosphodiesterase-5 inhibitors for at least seven days prior to the 
study visit. Individuals who experienced a respiratory tract infection within four weeks of the 
study visit were not eligible to participate, but could be scheduled at a later date. The study 
protocol was approved by the UNC Biomedical Institutional Review Board and conducted in 
accordance with institutional guidelines. 
 
Evaluation of Endothelial Function 
Endothelial dysfunction is a physiologic manifestation of vascular inflammation 
secondary to impaired nitric oxide availability and function that is associated with future 
cardiovascular events in multiple patient populations.142 
Endothelium-dependent vasodilation was assessed by brachial artery FMD using a 12.5 
MHz linear-array transducer (Philips HDI 5000 system) as previously described.141, 143 All 
recordings were taken in the morning in a dimly lit room by the same sonographer. Following 
10 minutes of rest, baseline brachial artery diameter was measured at end diastole from the 
lumen-intimal interface of the proximal and distal walls and calculated by averaging 10 
consecutive frames. Reactive hyperemia was induced by inflating a blood pressure cuff 
around the right forearm for five minutes to a pressure of at least 70 mmHg greater than the 
systolic blood pressure. Upon cuff release, recordings were taken for 90 seconds and peak 
brachial artery diameter was assessed by averaging three consecutive frames. FMD was 
calculated as the peak percent change in brachial artery diameter from baseline [= 
100*(diameter Peak – diameter Baseline) / (diameter Baseline)]. Following 10 minutes of rest, 
endothelium-independent vasodilation was quantified as the percent change in arterial 
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diameter five minutes after sublingual administration of a 0.4 mg nitroglycerin tablet. All data 
were analyzed by Brachial Tools software (Medical Imaging Applications, Coralville, IA). 
 
Quantification of Inflammatory Biomarkers 
It is well-established that circulating biomarkers of inflammation are associated with 
prognosis in patients with established CAD.9 Individuals with elevated high sensitivity C-
reactive protein (hs-CRP, a systemic inflammatory mediator produced in the liver that 
correlates with cytokines including interleukin-6),144 CAMs (inflammatory mediators 
expressed on endothelial cells that mediate leukocyte and platelet adhesion) and monocyte 
chemoattractant protein-1 (MCP-1, a chemokine synthesized in monocytes and endothelial 
cells that drives monocyte recruitment to the vascular wall) levels, and genetic predisposition 
to higher epithelial neutrophil-activating protein (ENA)-78 levels (a chemokine synthesized in 
neutrophils and endothelial cells that drives neutrophil recruitment to the vascular wall) have 
each been associated with poorer survival in patients with established CAD.12, 13, 17  
Venous blood was collected from each study participant, and plasma and serum were 
separated by centrifugation. In fresh serum, hs-CRP was quantified by latex-enhanced 
turbidimetric immunoassay using the VITROS® 5600 Chemistry System (Ortho-Clinical 
Diagnostics, Inc., Rochester, NY) by UNC McLendon Clinical Laboratories. The remaining 
serum and plasma were aliquoted and stored at -80°C pending analysis. Plasma 
concentrations of CAMs (E-selectin and P-selectin) and the neutrophil (ENA-78) and 
monocyte (MCP-1) chemokines were quantified using the Human Adhesion Molecule and 
Human Cytokine Fluorokine® Multi-Analyte Profiling Kits (R&D Systems, Minneapolis, MN), 
respectively, with fluorescence detection on the Bio-Plex 200 System (Bio-Rad, Hercules, 
CA) according to the manufacturer’s instructions. 
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Quantification of Plasma Eicosanoids 
Plasma eicosanoids were quantified after solid phase extraction by high-performance 
liquid chromatography followed by tandem mass spectrometry (HPLC-MS/MS) as previously 
described.81, 136, 145 HyperSep Retain PEP SPE cartridges (Thermo Scientific, Rockford, IL) 
were pre-conditioned with a solution of 0.1% acetic acid/5% methanol and spiked with 30 ng 
each of 10,11-epoxyheptadecanoic acid and 10,11-dihydroxynonadecanoic acid (internal 
standards). Plasma (0.25 mL) was diluted in 0.1% acetic acid/5% methanol containing 0.009 
mmol/L butylated hydroxytoluene and added to the column. Samples were then washed with 
two volumes of 0.1% acetic acid/5% methanol, eluted in 1 mL of acetonitrile, dried under 
nitrogen gas at 37°C, and reconstituted in 40% ethanol.  
Arachidonic acid derived metabolites from the CYP epoxygenase pathway (8,9- EET, 
11,12-EET, 14,15-EET, 5,6- DHET, 8,9-DHET, 11,12-DHET, and 14,15-DHET) and CYP ω-
hydroxylase pathway (20-HETE), and linoleic acid derived metabolites from the CYP 
epoxygenase pathway (12,13-epoxyoctadecenoic acid [EpOME] and 12,13-
dihydroxyoctadecenoic acid [DHOME]) were separated by reverse phase HPLC on a 1x150 
mm, 5μm Luna C18(2) column (Phenomenex, Torrance, CA)  and quantified using a MDS 
Sciex API 3000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) 
with negative mode electrospray ionization and multiple reaction monitoring. Data were 
captured and analyzed using Analyst 1.5.1 software. Relative response ratios of each 
analyte were used to calculate concentrations and extraction efficiency for each sample was 
calculated based on recovery of the internal standards. For samples in which the 
concentration fell below the lowest standard, a value of one half the lowest standard was 
imputed. Analytes for which more than 20% of the values were imputed were dropped from 
the statistical analysis.146 Consistent with prior analyses,147 plasma 11,12-EET 
concentrations were below the lower limit of detection in 68 of 106 samples (64%), and 
therefore excluded from the analysis. 
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Statistical Analysis 
Data are presented as mean ± standard deviation or median (interquartile range) unless 
otherwise indicated. CYP-derived eicosanoids and circulating biomarkers of inflammation 
did not follow the normal distribution and therefore were log-transformed prior to analysis. In 
order to account for batch variation in the quantification of inflammatory biomarkers, data 
within each batch were standardized using a z-score [i.e. (subject value – batch 
mean)/batch standard deviation], as described.105 Correlations among each vascular 
function phenotype were determined by Pearson’s correlation. A significant correlation was 
observed between E-selectin and P-selectin (r=0.599, P<0.001). In order to minimize 
redundancy in our analysis, a consolidated ‘CAM score’ phenotype was calculated in each 
individual, as described,105 by summing the z-scores of E-selectin and P-selectin. No 
significant correlations were observed among the final five biomarkers of vascular function 
(Table 4.1), indicating these biomarkers represent five distinct phenotypes.  
In order to characterize the association between inter-individual variation in CYP-
mediated eicosanoid metabolism and key vascular function phenotypes, plasma 20-HETE 
levels (the bioactive metabolite of the CYP ω-hydroxylase enzymes) were utilized as a 
biomarker of CYP ω-hydroxylase pathway function. The plasma 14,15-EET:DHET ratio (a 
sensitive in vivo biomarker of sEH metabolic function)73, 81 and the sum of EET levels in 
plasma (the bioactive metabolites of CYP epoxygenase enzymes) were utilized as 
biomarkers of CYP epoxygenase pathway function as previously described (Figure 4.1).136  
For the primary analysis, associations between circulating biomarkers of CYP-mediated 
eicosanoid metabolism (20-HETE, 14,15-EET:DHET ratio, and sum EETs) and five distinct 
phenotypic indices of vascular function (FMD, CAM score, MCP-1, ENA-78, and hs-CRP) 
were evaluated by Pearson’s correlation. A secondary analysis was conducted using a 
model that adjusted for potential demographic (age, race, gender) and clinical (smoking 
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status, diabetes, obesity, multivessel disease, hypertension, renin-angiotensin system 
inhibitor use, time post-catheterization [7-30 days, 31-90 days, >90 days]) confounders that 
associated with the biomarkers of CYP eicosanoid metabolism and/or phenotypic indices of 
vascular function in our population.136 In order to account for the potential confounding 
effects of medications that may impact vascular function and/or CYP-mediated eicosanoid 
metabolism, each analysis was repeated after adding aspirin, clopidogrel, beta-blocker, or 
statin use to the adjusted model. We also conducted stratified analyses limited to subjects 
receiving aspirin (n=103), clopidogrel (n=83), beta-blockers (n=89), or statins (n=83).  
In order to further assess the eicosanoid-vascular function relationships, vascular 
phenotypes were compared across eicosanoid metabolism tertiles by analysis of variance 
(ANOVA) and a post-hoc Student Newman-Keuls test. To minimize the impact of the 
multiple statistical tests required for this analysis, a false discovery rate (FDR) q-value was 
calculated for each comparison in our primary analysis, which is defined as the expected 
proportion of statistical tests deemed significant that are actually false-positives.148 Only q-
values for statistically significant findings (p<0.05) are presented. A post-hoc power analysis 
was completed to assess the statistical power of our study. All statistical analyses were 
performed using SAS Version 9.2 (SAS Institute, Cary, NC). 
 
Results 
Study Population 
The population characteristics are shown in Table 4.2. The majority of patients had 
advanced CAD, with 66% exhibiting multivessel disease at their index catheterization, and 
comorbidities including hypertension (81%), obesity (54%), and diabetes (24%). Medication 
utilization and revascularization rates were consistent with current clinical practice 
guidelines.  
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CYP ω-hydroxylase Pathway 
The relationships between inter-individual variation in CYP-derived eicosanoid levels 
and vascular function are provided in Table 4.3. Plasma 20-HETE levels were significantly 
associated with endothelial dysfunction, such that patients with higher levels of 20-HETE 
had lower FMD (Figure 4.2A, r=-0.255, p=0.010, q=0.048). A significant inverse association 
was also observed in the adjusted model (r=-0.223, p=0.033). Similarly, a stepwise trend of 
lower FMD was observed across increasing tertiles of 20-HETE (Figure 4.2B, p for 
trend=0.080); however, statistically significant differences were not observed between each 
tertile. Circulating 20-HETE levels were not associated with either nitroglycerin-mediated 
dilation (r=-0.068, p=0.495) or baseline brachial artery diameter (r=0.074, p=0.455), 
indicating that the mechanism underlying the association between 20-HETE and FMD is 
endothelium-dependent and is not explained by differences in arterial size.  
A positive relationship between 20-HETE levels and the CAM score was also observed 
(unadjusted: r=0.191, p=0.051; adjusted model: r=0.222, p=0.031); however, the association 
was not statistically significant in the primary analysis. In contrast, no association was 
observed between 20-HETE and either hs-CRP or chemokine levels (Table 4.3). Similar 
relationships between 20-HETE levels and each vascular function phenotype were observed 
after adjusting for or stratifying by aspirin, clopidogrel, beta blocker, or statin use (data not 
shown).  
 
CYP Epoxygenase Pathway 
In contrast to the observed relationship between 20-HETE and endothelial function, no 
association was observed between FMD and either 14,15-EET:DHET ratios or sum EETs  
(Table 4.3). Lower 14,15-EET:DHET ratios (indicative of higher sEH metabolic function) 
were, however, significantly associated with higher circulating levels of MCP-1 (Figure 4.3A, 
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r=-0.252, p=0.009, q=0.048). This association was also significant in the adjusted model (r=-
0.260, p=0.011), and across tertiles (Figure 4.3B). A significant inverse correlation was also 
observed between MCP-1 levels and both the sum EET:DHET ratio (r=-0.245, p=0.012) and 
12,13-epoxyoctadecenoic acid (EpOME):dihydroxyoctadecenoic acid (DHOME) ratio (r=-
0.201, p=0.040). In addition, lower 14,15-EET:DHET ratios were associated with higher 
CAM scores (Figure 4.3C, r=-0.216, p=0.027, q=0.101), such that those in the lowest tertile 
had a significantly higher CAM score compared to tertiles 2 and 3 (Figure 4.3D). The inverse 
relationship between CAM score and 14,15-EET:DHET ratio, however, was not statistically 
significant in the adjusted model (r=-0.190, p=0.065). Similar results were observed with the 
sum EET:DHET ratio and 12,13-EpOME:DHOME ratio (data not shown).  
Consistent with the relationship observed with 14,15-EET:DHET ratios, lower sum EET 
levels were associated with higher MCP-1 levels (Figure 4.4A, r=-0.283, p=0.003, q=0.045). 
A significant inverse association was also observed in the adjusted model (r=-0.243, 
p=0.017). Furthermore, those with sum EET levels in the lowest two tertiles exhibited 
significantly higher MCP-1 levels compared to those in the highest tertile (Figure 4.4B). 
When analyzed separately, a significant inverse relationship was observed between MCP-1 
and both 8,9-EET (r=-0.244, p=0.012) and 14,15-EET (r=-0.284, p=0.003) levels. No 
association was observed between sum EETs or 14,15-EET:DHET ratio and either hs-CRP 
or ENA-78 levels (Table 4.3). Similar relationships between both 14,15-EET:DHET ratio and 
sum EETs and each vascular function phenotype were observed after adjusting for or 
stratifying by aspirin, clopidogrel, beta-blocker, or statin use (data not shown). 
 
Discussion 
Preclinical and genetic epidemiologic studies suggest that increasing CYP-derived EETs 
and/or decreasing 20-HETE levels may have utility as a vascular protective therapeutic 
strategy in patients with cardiovascular disease. The functional relationship between CYP-
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mediated eicosanoid metabolism and vascular dysfunction in humans with established 
cardiovascular disease, however, has not been studied to date. This study demonstrated 
that higher 20-HETE levels were associated with lower brachial artery FMD and higher CAM 
levels and lower 14,15-EET:DHET ratios were associated with elevated MCP-1 and CAM 
levels in a population of patients with stable CAD. These findings are consistent with the 
vascular effects of 20-HETE and EETs in preclinical models, and suggest that enhanced 
CYP ω-hydroxylase and sEH metabolic function predispose stable CAD patients to more 
advanced endothelial dysfunction and vascular inflammation, respectively.  
It is well-established that biomarkers of vascular function are associated with prognosis 
in patients with established CAD.9 For example, persistently elevated circulating levels of hs-
CRP, CAMs and MCP-1, or genetic predisposition to higher ENA-78 levels, have each been 
associated with poorer survival in patients with established CAD.12, 13, 17, 24 Similarly, CAD 
patients with persistently impaired FMD despite optimized therapy have a higher risk of 
cardiovascular events, suggesting that adjunct therapies that improve FMD may 
subsequently improve prognosis.22 Identification of key regulators of these distinct vascular 
phenotypes predictive of prognosis offers enormous potential to facilitate the development of 
targeted therapies designed to improve vascular function and prognosis in high-risk subsets 
of the population.  
The observed inverse association between circulating 20-HETE levels and brachial 
artery FMD is consistent with preclinical studies in which 20-HETE directly induces reactive 
oxygen species (ROS) production and endothelial nitric oxide synthase uncoupling, reduces 
NO availability, and impairs endothelial-dependent vasodilation.88 An inverse association 
between urinary excretion of 20-HETE, which is reflective of renal 20-HETE biosynthesis,138 
and FMD has previously been reported in humans without known CAD.94 Our findings with 
circulating 20-HETE are consistent with this report; however, we are the first to demonstrate 
an association between 20-HETE and FMD in humans with established CAD. We also 
 92 
 
observed a positive relationship between plasma 20-HETE levels and circulating CAMs that 
is consistent with preclinical studies demonstrating that 20-HETE directly induces CAM 
expression in endothelial cells through activation of NF-κB.87 In our previous case-control 
analysis, we did not observe a significant difference in 20-HETE levels in stable CAD 
patients compared to healthy individuals; however, CAD patients who were not treated with 
a renin-angiotensin system inhibitor exhibited modestly higher 20-HETE levels compared to 
healthy individuals.136 Our current findings suggest that despite being treated with current 
standard of care therapies (including renin-angiotensin system inhibitors), CAD patients with 
the highest 20-HETE levels may be predisposed to more advanced endothelial dysfunction 
and vascular inflammation, and therapeutic strategies that directly decrease 20-HETE 
biosynthesis may improve vascular function in this high-risk population. 
Consistent with a series of preclinical studies and our hypothesis, we are also the first to 
report that lower EET:DHET ratios, a biomarker of enhanced sEH metabolic function, were 
associated with higher plasma MCP-1 and CAM levels. Indeed, EETs exert potent anti-
inflammatory effects in the vasculature in preclinical models via attenuation of NF-κB 
activation and chemokine and CAM expression,75, 77 and these effects are potentiated via 
inhibition of sEH.74 These data are consistent with a recent report demonstrating that 
CYP2J2 and CYP2C8 are expressed in human monocytes, and CYP epoxygenase 
metabolic function attenuates monocyte/macrophage activation.149 In addition, a recent 
study in mice demonstrated that sEH activity in bone marrow-derived cells, the primary site 
of chemokine biosynthesis, is a key regulator of plasma epoxide:diol ratios.150 We previously 
reported that plasma epoxide:diol ratios were significantly higher in patients with established 
CAD compared to healthy individuals at low risk for cardiovascular disease.136 Due to the 
aforementioned vascular protective effects of EETs, these data suggest that the presence of 
cardiovascular disease may lead to a compensatory suppression of sEH metabolic function 
and higher EET levels in humans. However, our current findings suggest that, in spite of a 
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potential compensatory increase in EET levels overall, the subset of CAD patients with the 
highest sEH metabolic function may be predisposed to more advanced vascular 
inflammation. Consequently, therapeutic strategies that further increase EET levels, most 
notably sEH inhibitors, may represent an effective secondary prevention strategy by 
attenuating vascular inflammation and improving prognosis in this high-risk population.  
In contrast, we did not observe an association between 14,15-EET:DHET ratio and FMD 
which is surprising given the known vasodilatory properties of EETs in preclinical models 
and our previous finding that EPHX2 genotype is associated with vasodilator responses in 
healthy individuals.82 In addition to the different populations, it should be noted that brachial 
artery FMD (an index of NO bioavailability and conduit arterial function) was evaluated in the 
current study while bradkyinin-induced changes in forearm blood flow (a phenotype more 
reflective of microvascular function) was evaluated in the previous study. Although these 
contrasting results may not be surprising given the more prominent role of EETs in the 
regulation of microvascular compared to macrovascular tone in preclinical models,86 it is 
important to note that our current findings are consistent with previous studies 
demonstrating that CYP epoxygenase inhibition does not impair endothelium-dependent 
vasodilator responses in CAD patients in vivo,151 or in isolated coronary arterioles from 
patients undergoing cardiac surgery, 152 due to the presence of enhanced oxidative stress. 
Collectively, these data suggest that the vasodilatory effects of CYP-derived EETs may be 
overwhelmed and masked by the presence of ROS in populations with underlying vascular 
inflammation and remodeling, such as atherosclerotic cardiovascular disease. This 
hypothesis requires rigorous investigation in prospective interventional studies.  
No associations were observed between biomarkers of CYP-mediated eicosanoid 
metabolism and hs-CRP. While chemokines and CAMs mediate inflammation in the 
vasculature, hs-CRP is an acute-phase reactant released from the liver indicative of 
systemic inflammation.153 Consequently, our findings indicate that CYP-derived eicosanoids 
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may be important in the regulation of vascular, but not hepatic or systemic, inflammation in 
humans. This is consistent with previous observations in preclinical models demonstrating 
that the hepatic inflammatory response to endotoxin is not attenuated in Ephx2 knockout 
mice.154 Furthermore, no relationship between CYP-mediated eicosanoid metabolism and 
the neutrophil chemokine ENA-78 was observed. We have reported that genetic potentiation 
of the CYP epoxygenase pathway attenuates induction of ENA-78 expression and 
neutrophil infiltration in mice.77 In contrast, CYP epoxygenase enzymes are not expressed in 
human polymorphonuclear cells,149 suggesting the presence of species differences in the 
contribution of CYP-derived eicosanoids to the regulation of neutrophil activation. 
Our analysis has limitations that must be acknowledged. First, although the observed 
associations were consistent with prior preclinical studies, the cross-sectional design does 
not allow us to establish a cause-and-effect relationship between eicosanoid metabolism 
and vascular function. Second, our analysis included multiple statistical comparisons and 
was limited by its relatively small sample size. To account for the possibility of false-positive 
findings, we calculated a FDR for each comparison. All statistically significant associations 
had a FDR of 10% or less, and were in directions consistent with prior preclinical evidence, 
giving us a higher level of confidence in our results. Furthermore, at α=0.05, there was 
greater than 80% power to detect an r2 of 0.07 for each eicosanoid metabolism-vascular 
phenotype relationship, which is similar in magnitude to the well-established and clinically 
relevant association observed between body mass index and hs-CRP in previous studies.153 
This demonstrates that we had ample statistical power to detect biologically meaningful and 
clinically relevant relationships in the current study. Importantly, validation of the observed 
relationships in an independent cohort will ultimately be necessary. Lastly, the population 
under investigation had established atherosclerotic cardiovascular disease and thus was 
being treated according to current clinical practice guidelines, including multiple medications 
that impact vascular function (i.e., statins, low-dose aspirin, clopidogrel, beta-blockers). 
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Moreover, the impact of these medications (most notably aspirin which modifies prostanoid 
levels) on CYP-mediated eicosanoid metabolism has not been rigorously evaluated in 
preclinical models or humans, and thus remains unknown. Therefore, we cannot elucidate 
whether the observed relationships were modified by medication use. Although our adjusted 
and stratified analyses showed similar associations between biomarkers of CYP-mediated 
eicosanoid metabolism and vascular function phenotypes irrespective of medication use, 
evaluation of the direct impact of medication use on EET and 20-HETE levels, as well as the 
modifying effect of medication use on the observed eicosanoid-vascular function 
relationships, is beyond the scope of the current investigation and requires further study. 
Importantly, since pharmacologic agents in development that increase EETs (sEH inhibitors) 
or decrease 20-HETE (CYP ω-hydroxylase inhibitors) would most likely be used as a 
secondary prevention strategy for CAD, in addition to these standard of care medications, 
our study was designed to specifically characterize associations between biomarkers of 
CYP-mediated eicosanoid metabolism and vascular function in a population of stable, 
appropriately treated patients with established CAD. These data lay a foundation for the 
rational design of subsequent studies that aim to directly evaluate the effects of novel 
therapies that decrease 20-HETE and increase EET levels on vascular function in patients 
with established CAD. 
 
Conclusions 
This cross-sectional analysis demonstrates that higher circulating 20-HETE levels are 
associated with lower brachial artery FMD and higher CAMs and lower 14,15-EET:DHET 
ratios are associated with elevated MCP-1 and CAM levels in a population of patients with 
stable CAD. These findings suggest that enhanced CYP ω-hydroxylase and sEH metabolic 
function may predispose patients with established atherosclerotic cardiovascular disease to 
more advanced endothelial dysfunction and vascular inflammation despite current standards 
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of care. These findings lay a critical foundation for future clinical research in this area, 
including the rational design of interventional proof-of-concept studies that seek to define the 
vascular protective effects and safety of decreasing CYP-mediated 20-HETE biosynthesis 
and/or decreasing sEH-mediated EET hydrolysis in patients with established CAD. 
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Tables 
Table 4.1. Correlation between vascular function phenotypes. 
 FMD CAM score MCP-1 ENA-78 hs-CRP 
FMD == -0.064 (0.526) -0.101 (0.313) -0.013 (0.901) 0.002 (0.984) 
CAM score   ==  0.120 (0.225) 0.115 (0.244) 0.071 (0.474) 
MCP-1     ==  0.017 (0.863) -0.093 (0.345) 
ENA-78       ==  0.094 (0.338) 
hs-CRP        == 
Data presented as Pearson’s correlation coefficient (p-value).
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Table 4.2. Study population characteristics. 
Characteristic   
N  106   
Age (years) 58 ± 10    
Female (%) 35 (33%)      
African-American (%) 18 (17%)   
Body mass index (kg/m2) 30 ± 6     
Obese (BMI ≥ 30 kg/m2; %) 57 (54%)   
Current smoker (%) 23 (22%)   
Diabetes (%) 25 (24%)   
Hypertension (%) 86 (81%)   
Previous myocardial infarction 39 (37%) 
Multivessel disease 70 (66%) 
Recent revascularization procedurea 70 (66%) 
Systolic blood pressure (mmHg) 136 ± 17    
Diastolic blood pressure (mmHg) 80 ± 10  
Total cholesterol (mmol/L) 4.04 (1.32)    
LDL cholesterol (mmol/L) 2.20 (0.96)    
HDL cholesterol (mmol/L) 1.22 (0.41)     
Triglycerides (mmol/L) 1.11 (0.84)  
ACE inhibitor or ARB (%) 66 (62%)   
Beta-blocker (%) 89 (84%)    
Statin (%) 99 (93%)   
Aspirin (%) 103 (97%)    
Clopidogrel (%) 83 (78%) 
Data presented as mean ± standard deviation, median (interquartile range) or count 
(proportion). 
ACE=angiotensin-converting enzyme, ARB=angiotensin receptor blocker, HDL=high density 
lipoprotein, LDL=low density lipoprotein. 
a59/106 underwent a percutaneous coronary intervention and 11/106 underwent a coronary 
artery bypass grafting procedure between screening and the study visit. 
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Table 4.3. Correlation between biomarkers of CYP-mediated eicosanoid metabolism and vascular function. 
CYP Eicosanoid FMD CAM Score MCP-1 ENA-78 hs-CRP 
20-HETE -0.255 (0.010) 0.191 (0.051) 0.020 (0.843) 0.105 (0.287) -0.090 (0.357) 
   
Sum EETs  -0.095 (0.345) -0.053 (0.599) -0.283 (0.003) 0.115 (0.244) 0.045 (0.645) 
  
14,15-EET:DHET 0.120 (0.229) -0.216 (0.027) -0.252 (0.009) 0.035 (0.723) 0.100 (0.307) 
Data presented as Pearson’s correlation coefficient (p-value).
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Figures 
 
Figure 4.1. Overview of CYP-mediated arachidonic acid metabolism. 
After release from the cell membrane by cytosolic phospholipase A2, free arachidonic acid is 
metabolized by CYP ω-hydroxylases (CYP4A11 and CYP4F2) to 20-HETE or by CYP 
epoxygenases (CYP2J2, CYP2C8, and CYP2C9) to one of four EET regioisomers (5,6-, 
8,9-, 11,12-, and 14,15-EET). The EETs (epoxides) are subsequently hydrolyzed by sEH to 
their corresponding DHET (diol) metabolites, which generally have less biological activity. 
Structures for the 14,15-EET regioisomer, the preferred EET substrate for sEH, and the 
14,15-DHET metabolite are provided since the 14,15-EET:DHET (epoxide:diol) ratio is an 
established biomarker of sEH metabolic function. 
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Figure 4.2. Association between 20-HETE and FMD. 
(A) The correlation between 20-HETE and FMD is displayed. (B) The distribution of FMD 
across 20-HETE tertiles is displayed using box plots (tertile 1: 0.40-1.29 ng/mL, tertile 2: 
1.30-1.85 ng/mL, tertile 3: 1.86-6.97 ng/mL). The horizontal line within the box represents 
the median, the edges of the box represent the 25th and 75th percentiles, and the error bars 
represent the 10th and 90th percentiles. The ANOVA p-value for the trend is provided. 
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Figure 4.3. Association between 14,15-EET:DHET ratios and biomarkers of vascular 
inflammation. 
The correlation between 14,15-EET:DHET ratio and (A) MCP-1 and (C) CAM score is 
displayed. The distribution of (B) MCP-1 and (D) CAM score across 14,15-EET:DHET ratio 
tertiles is displayed using box plots (tertile 1: 0.040-0189 ng/mL, tertile 2: 0.190-0.541 
ng/mL, tertile 3: 0.542-1.82 ng/mL). The ANOVA p-value for the trend is provided. *P<0.05 
versus tertile 3. †P<0.05 versus tertile 2.  
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Figure 4.4. Association between sum EETs and MCP-1 levels. 
(A) The correlation between sum EETs and MCP-1 is displayed. (B) The distribution of 
MCP-1 across sum EETs tertiles is displayed using box plots (tertile 1: 0.086-0.251 ng/mL, 
tertile 2: 0.252-0.375 ng/mL, tertile 3 0.376-1.26 ng/mL). The ANOVA p-value for the trend is 
provided. *P<0.05 versus tertile 3. 
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CHAPTER V 
EVALUATION OF THE FUNCTIONAL ROLE OF THE CYTOCHROME P450 
EPOXYGENASE PATHWAY IN FATTY LIVER DISEASE-ASSOCIATED INFLAMMATION 
 
Introduction 
Non-alcoholic fatty liver disease (NAFLD) affects approximately 30% of the general 
population in the United States, and nearly 70% of individuals with type 2 diabetes 
mellitus.155 NAFLD begins with simple steatosis, and may progress to non-alcoholic 
steatohepatitis (NASH), and ultimately to advanced fibrosis and cirrhosis of the liver.27 
Although the progression from NAFLD to NASH is poorly understood, the development and 
progression of hepatic inflammation is a key pathological mediator in this transition and is 
associated with disease progression and the development of concomitant disease states 
including cardiovascular disease.156, 157  
In the early stages of NAFLD, an imbalance between hepatocyte uptake and export of 
lipids leads to lipid accumulation within liver. Increased hepatic cholesterol levels activate 
toll-like receptors (TLRs) which signal through myeloid differentiation factor 88 (Myd88) to 
drive activation of nuclear factor-κB (NF-κB) mediated inflammatory responses.158 NF-κB 
subsequently drives transcription of pro-inflammatory cellular adhesion molecules (which 
mediate monocyte adhesion to the endothelium), chemokines (which drive monocyte and 
macrophage recruitment), and cytokines (which propagate the local and systemic 
inflammatory response). Activation of the hepatic inflammatory response leads to monocyte 
activation and macrophage infiltration into the liver, ultimately causing fibrosis and hepatic 
injury.159 Furthermore, this pathologic process drives systemic inflammation, and leads to 
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endothelial activation and the subsequent development of atherosclerosis.26 Consistent with 
the pathological link between hepatic inflammation and atherosclerosis, the high-fat/high-
cholesterol “atherogenic” diet model of steatohepatitis induces dyslipidemia, hepatic 
inflammation, and fibrosis, through an innate immune-mediated mechanism, which precedes 
the development of atherosclerosis.160, 161   
Cytochrome P450 (CYP) enzymes are abundantly expressed in the liver where they 
catalyze the oxidative biotransformation of most exogenous drugs.64 In addition, certain CYP 
isoforms are expressed in extrahepatic tissues and metabolize endogenous substrates 
including fatty acids, steroids, and retinoids to biologically active molecules.65 Notably, CYP 
epoxygenase enzymes from the CYP2C and CYP2J subfamilies are highly expressed in 
endothelial cells and the liver, where they metabolize arachidonic acid to the biologically 
active 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid (EET) regioisomers;66 however, 
EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to their corresponding 
DHETs, which have much less biological activity.66 Previous studies have shown that 
hepatic CYP epoxygenase expression and metabolic activity is suppressed in response to 
lipopolysaccharide (LPS) induced inflammation in a time-dependent manner, an acute 
inflammation model driven by innate immune system activation through TLR4.162 In addition, 
increased endothelial EET biosynthesis, or decreased global sEH mediated EET hydrolysis, 
attenuates NF-kB activation and the acute vascular and systemic inflammatory response to 
LPS.76, 77  
Collectively, these studies demonstrate that hepatic CYP epoxygenase activity is 
suppressed in response to activation of the innate immune system, and potentiation of the 
CYP epoxygenase pathway attenuates innate immune-dependent acute vascular and 
systemic inflammatory responses in vivo. However, the functional relevance of the CYP 
epoxygenase pathway in the development and progression of fatty liver disease-associated 
sustained inflammation has not been rigorously evaluated. Therefore, the objective of our 
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study was to 1) investigate the contribution of innate immune signaling to induction of 
steatohepatitis by the atherogenic diet, 2) characterize the effect of atherogenic diet-induced 
steatohepatitis on CYP epoxygenase expression and EET biosynthesis, and 3) determine if 
genetic and/or pharmacologic potentiation of the CYP epoxygenase pathway attenuates 
fatty liver disease-associated hepatic inflammation and injury. 
 
Materials and Methods 
Animals 
Mice with targeted disruption of Ephx2 (Ephx2-/-) were rederived and backcrossed onto a 
C57BL/6 genetic background for more than 10 generations at the National Institute of 
Environmental Health Sciences (NEHS/NIH), as described.73 Transgenic mice that express 
the human CYP2J2 enzyme in endothelial cells downstream of the murine Tie2 promoter 
(CYP2J2-Tr) were developed on a C57BL/6 background as previously described.163 We 
have previously reported significantly higher endothelial EET biosynthesis and circulating 
EET levels in CYP2J2-Tr mice compared to wild-type (WT) littermates, consistent with CYP 
epoxygenase overexpression.77, 163 All experiments with CYP2J2-Tr mice used transgenic 
mice from multiple founder lines and WT littermates were included as controls; additional 
age-matched WT C57BL/6 mice and Myd88-/- mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Mice were male, 8-20 weeks of age at the initiation of the 
experiments, had free access to food and water and were housed in temperature and 
humidity controlled rooms using a 12 hour light/dark cycle. All studies were completed in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals, and were 
approved by the Institutional Animal Care and Use Committee at the University of North 
Carolina-Chapel Hill (UNC). 
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Experimental Protocol 
Mice were fed ad libitum an atherogenic (ATH) diet164, 165 containing 40% kilocalories 
from fat, 1.25% cholesterol and 0.5% cholic acid (D12109c, Research Diets Inc., New 
Brunswick, NJ) or a standard chow (STD) diet containing 14% kilocalories from fat and 
0.02% cholesterol (ProLab RMH 3000, PMI Nutrition International, Brentwood, MO). An 
initial pilot experiment was conducted to assess the relative induction of hepatic 
inflammation following two, four, or eight weeks of atherogenic diet administration. All 
subsequent studies were conducted over four weeks to evaluate the effects of 1) 
atherogenic diet feeding on CYP-mediated eicosanoid metabolism; 2) abrogation of 
signaling through Myd88 on atherogenic diet induction of hepatic inflammation and 
dysregulation of CYP-mediated eicosanoid metabolism; and, 3) CYP epoxygenase pathway 
potentiation on atherogenic diet induced hepatic inflammation and injury.  
A subset of WT mice administered the atherogenic diet were concurrently administered 
the sEH inhibitor trans-4-[4-(3-adamantan-1-ylureido)-cyclohexyloxy]-benzoic acid (t-AUCB, 
kindly provided by Dr. Bruce Hammock, University of California-Davis) or vehicle (0.5% 
polyethylene glycol 400 [PEG 400]) in drinking water for the four week duration of the 
experiment.166 t-AUCB was dissolved in PEG 400 then diluted in tap water to a final 
concentration of 10 mg/L (t-AUCB group) or 50 mg/L (high-dose [HD]-t-AUCB group) in 
0.5% PEG 400 and provided ad libitum.  
Four independent studies were completed with 6-14 mice per group in each experiment 
plus 3-6 WT mice fed the standard diet (control group). Aggregate results are presented with 
a total of 19 WT mice fed the standard diet, 45 WT mice fed the atherogenic diet, 24 Ephx2-/- 
mice, 15 CYP2J2-Tr, 14 mice administered standard dose t-AUCB (10 mg/L) and 14 mice 
administered high-dose t-AUCB (50 mg/L). At study termination, mice were euthanized by 
CO2 asphyxiation. Blood was collected via cardiac puncture, plasma was separated by 
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centrifugation and liver tissue was harvested and snap-frozen in liquid nitrogen. Plasma and 
tissue were stored at -80°C pending analysis.  
 
Biochemical Analysis 
Plasma total cholesterol and alanine aminotransferase (ALT) levels were quantified 
using a Vitros 350 automated chemical analyzer (Ortho-Clinical Diagnostics, Rochester, NY) 
at the UNC Animal Clinical Laboratory Core Facility. Total cholesterol and triglyceride levels 
were quantified in homogenized liver tissue using the Biovision Cholesterol Ester 
Quantification Kit II and the Biovision Triglyceride quantification Kit, respectively, according 
to the manufacturer’s instructions (Biovision Incorporated, Milpitas, CA).  
 
Formation of CYP-Derived Eicosanoids in Liver Microsomes  
Microsomal fractions were isolated from hepatic tissue as previously described.162 
Frozen liver was homogenized in 0.25 M sucrose-10 mM Tris HCl buffer (pH 7.5) containing 
protease inhibitors. The resulting homogenates were centrifuged at 4°C at 2,570 g for 20 
minutes followed by 10,300 g for 20 minutes; supernatants were collected and centrifuged at 
100,000 g at 4°C for 90 minutes, and the resulting microsomal pellets were resuspended in 
50 mM Tris-1 mM DTT-1 mM EDTA buffer (pH 7.5) containing 20% glycerol. Microsome 
protein concentrations were determined using the BCA method.167 As previously described, 
300 µg microsomal protein was diluted 10-fold with incubation buffer (0.12 M potassium 
phosphate buffer containing 5 mM magnesium chloride) then incubated with 50 µM 
arachidonic acid in 1 mL of incubation buffer.162 Incubations were completed at 37°C for 20 
minutes; reactions were initiated by adding 1 mM NADPH and terminated by placing the 
samples ice. The incubation procedure was repeated using a fresh aliquot of microsomal 
protein in the presence of 5 µM t-AUCB. Following termination of the reaction 12.5 ng of 
internal standard (20-HETE-d6) was added and metabolites were extracted with diethyl 
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ether, dried under a stream of nitrogen gas and reconstituted in 80% methanol in deionized 
water for analysis. Incubations were performed under saturating concentrations of 
arachidonic acid, and preliminary incubations demonstrated formation was linear with 
respect to incubation time and microsomal protein quantity. Under these saturating 
conditions, formation rates reflect the amount of biologically active protein and are 
significantly correlated with CYP mRNA and protein levels.162, 168  
Metabolites of arachidonic acid were then quantified by ultra-performance liquid 
chromatography-tandem mass spectrometry (UPLC-MS/MS), as described.162 Analytes 
were separated using a UPLC BEH C-18 1.7 µM (2.1 x 100 mm) reverse-phase column 
(Waters Corporation, Milford, MA). Mass spectrometry was performed using a TSQ 
Quantum Ultra triple-quadrupole mass spectrometer coupled with heated electrospray 
ionization operated in negative selective reaction monitoring mode (Thermo Fisher 
Scientific, San Jose, CA). Data were acquired and analyzed using Xcaliber software version 
2.0.6 (ThermoFinnigan, San Jose, CA) and metabolite concentrations were calculated from 
a standard curve and expressed relative to the standard diet treated group.  
 
Direct Quantification of CYP-Derived Eicosanoids in Plasma and Liver 
Arachidonic acid metabolites from the CYP epoxygenase pathway (8,9-, 11,12- 14,15-
EET, 5,6-, 8,9- 11,12-, 14,15-DHET), CYP ω-hydroxylase pathway (20-
hydroxyeicosatetraenoic acid [HETE]) and linoleic acid metabolites from the CYP 
epoxygenase pathway (12,13-epoxyoctadecenoic acid [EpOME] and 12,13-
dihydroxyoctadecenoic acid [DHOME]) were quantified in plasma and tissue as previously 
described.145 Plasma (200 uL) was diluted in 250 uL of a 0.1% acetic acid/5% methanol 
solution containing 0.009 mM butylated hydroxytoluene (BHT) and spiked with 30 ng each of 
PGE2-d4, 10,11-DiHN, and 10,11-EpHep (Cayman Chemical, Ann Arbor, MI) which served 
as internal standards. Samples were loaded onto HyperSep Retain PEP SPE cartridges 
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(ThermoFisher Scientific, Waltham, MA) that were conditioned with 0.1% acetic acid/5% 
methanol. Columns were then washed twice with 0.1% acetic acid/5% methanol and dried 
for 10 minutes under a full vacuum. Samples were eluted into glass tubes containing 6 uL of 
30% glycerol using 0.5 mL of methanol followed by two consecutive additions of 0.5 mL 
ethyl acetate. 
Liver tissue (approximately 20 mg) was homogenized in 0.1% acetic acid/5% methanol 
solution containing 0.009 mM BHT and 100 µM t-AUCB (5% w/v). Internal standards (10,11-
DiHN, and 10,11-EpHep) were added to glass tubes and liver lysates were vortexed with 2 
ml of ethyl acetate for 10 minutes and the organic layer was removed and added to a glass 
collection tube containing 6 uL of 30% glycerol. The remaining lysate was vortexed with an 
additional 2 ml of ethyl acetate for 10 minutes and the organic layer was again added to the 
collection tube.  
Metabolites were dried under a stream of nitrogen gas while heated to 37°C; tubes were 
purged with argon gas and stored at -80°C pending analysis. Samples were reconstituted 
using 50 uL of 30% ethanol, vortexed, and centrifuged at 2000 g for 2 minutes; 50 uL of the 
reconstituted sample was injected in triplicate. Liquid chromatography of extracted samples 
was performed with an Agilent 1200 Series capillary HPLC (Agilent Technologies, Santa 
Clara, CA). Separations were performed using a Phenomenex Luna C18(2) column (5 um, 
150x1 mm, Phenomenex, Torrance, CA) while held at 40°C. Eicosanoid concentrations 
were quantified using a MDS Sciex API 3000 triple quadrupole mass spectrometer (Applied 
Biosystems, Foster City, CA) with negative mode electrospray ionization. The plasma 14,15-
EET:DHET ratio was calculated as an in vivo biomarker of sEH metabolic function73 and the 
sum of EET levels (8,9-, 11,12- 14,15-EET) in plasma were calculated as a biomarker of 
CYP epoxygenase pathway function as previously described.163 
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Gene Set Enrichment Analysis  
Total RNA was isolated from homogenized tissue (n=4 per group) using the RNeasy 
mini-prep kit (Qiagen, Valencia, CA). Global gene expression analysis was conducted using 
the Agilent Whole Mouse Genome 4x44 multiplex array (Agilent Technologies, Inc., Santa 
Clara, CA) according to the manufacturer’s protocol. Briefly, 1.65 micrograms of Cy3 labeled 
cRNAs were fragmented and hybridized for 17 hours in a rotating hybridization oven. Slides 
were then washed and scanned, data was acquired using the Agilent Feature Extraction 
software version 9.5 (Agilent Technologies) using 1-color defaults for all parameters. The 
resulting data were processed and analyzed using Genespring version 12.1 (Agilent 
Technologies). Only probes flagged “detected” in at least 75% of samples from at least one 
treatment group were included, resulting in 31,643 probes in the final dataset.  
Gene set enrichment analysis (GSEA) Version 2.0 was used to determine if the 
arachidonic acid metabolism pathway is “enriched” in WT mice administered the atherogenic 
compared to WT mice administered the standard diet. Genes involved in the metabolism of 
arachidonic acid to biologically active eicosanoids were identified using the Kyoto 
Encyclopedia of Genes and Genomes (KEGG)131 ‘arachidonic acid metabolism pathway’ for 
mice map00590, and limited to genes encoding proteins involved in arachidonic acid 
liberation from the cell membrane and metabolism.  
 
Quantitative RT-PCR 
Quantitative RT-PCR was performed by reverse transcribing RNA to cDNA using the 
ABI high-capacity cDNA reverse transcription kit (Applied Biosystems) with a reaction 
temperature of 25°C for 10 min followed by 37°C for 120 min. Quantitative RT-PCR 
reactions were performed in triplicate using the ABI 7300 Real-Time PCR system. 
Expression of  hepatic Tlr2, Tlr4, Cyp2c29, Cyp2c50, Cyp2j5, Ephx2, Saa1, Tnfα, Ccl2 
Nfκb1, and Cd68 was quantified using Taqman® Assays on Demand (Applied Biosystems), 
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normalized to Gapdh (endogenous control) and expressed relative to the control group 
using the  2-ΔΔCt method.169 
 
ELISA 
Liver tissue was homogenized in lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 
1 mM EDTA, 1% Triton X, 1 mM NaF, 0.25% Na deoxycholate and protease inhibitors) and 
the S9 fraction was separated by centrifugation. Protein concentrations of the homogenate 
were quantified using the BCA method.167 Monocyte chemoattractant protein-1 (MCP-1), 
and vascular cellular adhesion molecule-1 (VCAM-1) protein levels were quantified in liver 
homogenates using the mouse CCL2/JE/MCP-1 and VCAM-1/CD106 Quantikine®  ELISA 
kits (R&D Systems, Minneapolis, MN, USA), respectively, after loading equal amounts of 
protein into each well. Concentrations were normalized to mg of liver protein and expressed 
relative to the atherogenic diet group. Plasma concentrations of MCP-1 were quantified 
using the mouse CCL2/JE/MCP-1 Quantikine® ELISA kit (R&D Systems) following a four-
fold dilution.  
 
Histology and Immunohistochemistry 
Liver tissue (left lobe) was fixed in 4% paraformaldehyde for 24 hours, processed, 
embedded in paraffin, and cut into 5 μm sections. Immunohistochemistry was performed by 
treating slides with pH 6.0 sodium citrate buffer (Dako North America, Carpinteria, CA) and 
endogenous peroxide was quenched by placing slides in a solution of 3% H2O2 for 15 
minutes. Sections were blocked using 0.25% casein in PBS (Dako North America) then 
incubated with a rabbit anti-F4/80 polyclonal antibody at a 1:200 dilution (Santa Cruz 
Biotechnology, Santa Cruz, CA) followed by a goat anti-rabbit secondary antibody at a 1:500 
dilution (Jackson Immunoresearch, West Grove, PA). Antibody binding was detected using 
Vectastain Elite ABC Kit (Vector Laboratories, Burlingame, CA) and visualization was 
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performed with 3,3-diaminobenzidine (Vector Laboratories). Sections were then 
counterstained with hematoxylin, dehydrated, and mounted. Digital images were acquired 
with the ScanScope CS slide capture device (Aperio, Vista, CA) and analyzed using 
ImageScope Version 11.1 (Aperio).  
Macrophage infiltration was quantified by counting the number of inflammatory foci per 
10x field, as described.170 All analyses were performed in duplicate by the same individual 
who was blinded to treatment group. Three fields were analyzed in each of three sections 
which were cut 200 µm apart; the number of foci were then summed and averaged to obtain 
an estimate for each animal.  
The presence and extent of NAFLD was evaluated on hematoxylin and eosin (H&E) 
stained slides according to a standardized histological scoring system (NAFLD Activity 
Score) that evaluates the presence and severity of steatosis, lobular inflammation, 
hepatocyte ballooning, and fibrosis.171 Steatosis (the accumulation of fatty deposits in the 
liver) is graded by quantifying the percentage of the surface area with fat droplets (0-3), 
hepatocyte ballooning is graded by the number of ballooned (i.e. enlarged) hepatocytes (0-
2), and fibrosis is graded according to the extent and location of collagen deposition (0-4). 
Lobular inflammation, which is most the most relevant histological consequence of the 
atherogenic diet,161 is graded according to the number of inflammatory infiltrates per 200x 
field as follows: 0 (no infiltrates); 1 (<2 infiltrates per field); 2 (2-4 infiltrates per field); and 3 
(>4 infiltrates per field). 
 
Statistical Analysis 
Data were normalized to the atherogenic diet treated WT control group and pooled 
across experiments, unless otherwise indicated, and expressed as mean ± standard error of 
the mean (SEM). For continuous variables, rank-transformed mean values were compared 
using a one-way ANOVA followed by Fisher's LSD post hoc test with p<0.05 considered 
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statistically significant. Lobular inflammation score was analyzed by Chi-squared test with a 
post hoc logistic regression analysis. Correlation between continuous variables was 
evaluated using Spearman’s rank correlation. All statistical analyses were performed using 
SAS version 9.3 (SAS Institute, Cary, NC).  
 
Results 
 
Section 1: Characterization of the CYP Epoxygenase Pathway in NAFLD/NASH 
 
Characterization of the Atherogenic Diet Model of NAFLD/NASH 
Inflammation was evaluated in liver tissue following two, four, or eight weeks of 
atherogenic diet administration by quantifying mRNA expression of Saa1, (serum amyloid A, 
an acute phase reactant), Ccl2, (MCP-1, a chemokine that recruits monocytes to the vessel 
wall), and Cd68 (a glycoprotein highly expressed on macrophages). Hepatic Saa1, Ccl2, 
and Cd68 were significantly induced at two, four, and eight weeks (Figure 5.1A-C). Similarly, 
plasma ALT levels, a biomarker of hepatic injury, were significantly increased after two, four, 
and eight weeks of atherogenic diet administration (Figure 5.1D). Since inflammation and 
hepatic injury were not further increased with longer duration administration of the 
atherogenic diet, the four-week time-point was utilized for all follow-up studies.  
Plasma total cholesterol (Figure 5.2A), hepatic total cholesterol (Figure 5.2B), and 
hepatic triglyceride levels (Figure 5.2C) were significantly higher in mice administered the 
atherogenic diet compared to mice administered the standard chow diet. Body weight did 
not change significantly from baseline (-0.18±0.21 grams, p=0.397) in response to the 
atherogenic diet; however, mice administered the standard diet experienced modest weight 
gain (1.16±0.16 grams, p<0.001). Collectively, these data demonstrate that the atherogenic 
diet model induces hepatic lipid accumulation, inflammation, macrophage infiltration and 
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injury, which are key drivers of the development and progression of NAFLD/NASH in 
humans.   
 
Differential Expression of the Arachidonic Acid Metabolism Pathway in NAFLD/NASH 
Gene set enrichment analysis was utilized to determine if the arachidonic acid 
metabolism pathway was enriched in WT mice administered the atherogenic diet. Of the 82 
genes in the arachidonic acid metabolism pathway, 67 (82%) were included on the 
microarray and passed our quality control standards (indicating that they were expressed in 
75% samples within at least one treatment group). The arachidonic acid metabolism 
pathway was significantly enriched in mice administered the atherogenic diet (p<0.001). The 
core enrichment subset, which is the subset of genes accounting for the observed signal, 
was down-regulated in mice administered the atherogenic diet compared to mice 
administered the standard chow diet (Figure 5.3), indicating that relative to global gene 
expression changes, the arachidonic acid metabolism pathway was suppressed in mice 
administered the atherogenic diet. Twenty-two of the 28 (79%) genes included in the core 
enrichment subset were CYP transcripts, and 10 of the 22 CYPs (46%) were from the 
CYP2C and CYP2J subfamilies, which are CYP epoxygenases.  
 
CYP Eicosanoid Metabolism 
Administration of the atherogenic diet for four weeks significantly decreased plasma and 
liver EET levels (Figure 5.4A and 5.4D), which were highly correlated (rs=0.876, p<0.001). In 
addition, formation rates of sum EETs and sum EETs+DHETs were significantly suppressed 
in liver microsomes from mice fed the atherogenic diet compared to mice fed the standard 
chow diet both with and without t-AUCB in the incubation (Figure 5.4B-C and 5.4E-F). 
Consistent with suppression of hepatic CYP epoxygenase activity, liver Cyp2c29 mRNA 
levels, were significantly suppressed in mice administered the atherogenic diet (Figure 
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5.5A). Similar results were observed with liver mRNA levels of the Cyp2c50, Cyp2c55, and 
Cyp2j5 epoxygenases (data not shown). However, no significant differences in hepatic 
Ephx2 mRNA levels (Figure 5.5B) were observed. 
In contrast to the atherogenic diet induced suppression of the CYP epoxygenase 
pathway, plasma 20-HETE levels (0.45±0.15 vs. 0.45±0.05 ng/ml, p=0.940), liver 20-HETE 
levels (9.7±4.6 vs. 6.7±1.4 ng/g, p=0.689) and liver microsome 20-HETE formation rates 
(342±14 vs. 374±19 pmol/mg protein/minute, p=0.689) were similar in mice fed the standard 
and atherogenic diets, respectively. 
 
Role of the Innate Immune System in Fatty Liver Disease-Associated Inflammation 
Hepatic expression of Tlr2 and Tlr4 was significantly induced in mice fed the atherogenic 
diet for four weeks compared to mice fed the standard chow diet (Figure 5.6), indicating that 
the innate immune system is activated in response to atherogenic diet feeding. 
Administration of the atherogenic diet significantly increased plasma MCP-1, hepatic MCP-1 
and hepatic VCAM-1 protein levels, and macrophage infiltration into liver tissue, all of which 
were attenuated in Myd88-/- mice (Figure 5.7 and Figure 5.8).  
Consistent with the results of our previous experiment, administration of the atherogenic 
diet significantly suppressed plasma and liver sum EET levels in WT mice; a similar level of 
suppression was observed in Myd88-/- mice (Figure 5.9A and 5.9C). The 14,15-EET:DHET 
ratio was not significantly different in WT or Myd88-/- mice fed the atherogenic diet compared 
to standard diet fed mice in either plasma or liver (Figure 5.9B and 5.9D). Consistent with 
suppression of hepatic CYP epoxygenase activity, liver Cyp2c29 mRNA levels were 
significantly suppressed in WT mice administered the atherogenic diet (37% of control), and 
were partially restored in Myd88-/- mice fed the atherogenic diet (54% of control, Figure 
5.9E). However, Ephx2 mRNA levels were not significantly different in WT or Myd88-/- mice 
administered the atherogenic diet (Figure 5.9F).  
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Administration of the atherogenic diet increased hepatic mRNA expression of Tlr4, 
Nfκb1, and Tnfα; induction of Tlr4, Nfκb1, and Tnfα was significantly attenuated in Myd88-/- 
mice, but remained significantly higher in Myd88-/- mice compared to WT mice fed the 
standard diet (Figure 5.10A, 5.10D, and 5.10G). Hepatic Tlr4, Nfκb1, and Tnfα mRNA levels 
each exhibited a significant inverse correlation with hepatic Cyp2c29 expression and sum 
EET levels in liver tissue (Figure 5.10). Similar correlations were observed between hepatic 
Tlr4, Nfκb1, and Tnfα mRNA levels and Cyp2c50, Cyp2c55, and Cyp2j5 mRNA levels (data 
not shown).  
 
Summary (Section 1) 
The atherogenic diet model of NAFLD/NASH increases circulating and hepatic 
cholesterol levels and hepatic triglycerides, activates the innate immune system, and 
induces hepatic inflammation and injury. In addition, hepatic expression of CYP 
epoxygenase enzymes, hepatic EET biosynthesis, and hepatic and plasma EET levels are 
significantly suppressed in response to atherogenic diet feeding, and this suppression is 
correlated with activation of the innate immune response. However, changes in hepatic 20-
HETE biosynthesis, and hepatic and plasma 20-HETE levels were not altered in mice 
administered the atherogenic diet. Moreover, abrogation of signaling through Myd88 
attenuates, but does not completely reverse, the induction of hepatic inflammation, and does 
not restore hepatic CYP epoxygenase expression or hepatic and plasma EET levels. 
 
Section 2: Potentiation of the CYP Epoxygenase Pathway in NAFLD/NASH 
 
Genetic Disruption and Pharmacologic Inhibition of sEH 
In order to evaluate sEH inhibition as a therapeutic target to attenuate fatty liver disease-
associated inflammation, we administered the atherogenic diet for four weeks and quantified 
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plasma and liver eicosanoid levels in Ephx2-/- mice, WT mice administered t-AUCB at 10 
mg/L (t-AUCB group) and WT mice administered high-dose t-AUCB at 50 mg/L in drinking 
water (HD t-AUCB group). Consistent with inhibition of sEH mediated EET hydrolysis, the 
14,15-EET:DHET ratio and the 12,13-EpOME:DHOME ratio were significantly higher in 
Ephx2-/- mice and in each of the t-AUCB treated groups compared to WT mice fed the 
atherogenic diet in both plasma and liver (Figure 5.11A-B and 5.11D-E). In addition, 
inhibition of sEH resulted in a significant increase in sum EET levels in both plasma and liver 
tissue in Ephx2-/- mice and in each of the t-AUCB treated groups compared to WT mice fed 
the atherogenic diet (Figure 5.11C and 5.11F). However, plasma epoxide:diol ratios and 
sum EETs were higher in the Ephx2-/- mice compared to each of the t-AUCB treated groups, 
indicating that pharmacologic inhibition did not decrease epoxide hydrolysis to the degree 
observed in Ephx2-/- mice. However, these differences were less pronounced in liver. The 
increase in EET levels was similar for both the 8,9- and 14,15-EET regioisomers; however, 
significant differences were not observed across groups for the 11,12-EET regioisomers 
(Figure 5.12). Plasma and liver total cholesterol levels were significantly increased in 
response to atherogenic diet administration (p<0.001 vs. standard diet); however, sEH 
inhibition did not impact cholesterol levels (data not shown). 
 
Expression of Inflammatory Mediators 
Compared to the standard chow diet, administration of the atherogenic diet significantly 
increased plasma MCP-1 (2.3±0.3-fold), hepatic MCP-1 (8.6±1.5-fold), and hepatic VCAM-1 
(4.4±0.5-fold) protein levels (Figure 5.13A-C, p<0.001 vs. standard diet group for each). The 
induction of chemokine and CAM expression was significantly attenuated in the Ephx2-/- 
mice (P<0.01 vs. atherogenic diet group for each), and plasma MCP-1 levels were 
significantly attenuated in the high-dose t-AUCB group (p=0.037). However, no significant 
differences were observed in the CYP2J2-Tr and t-AUCB treated groups (Figure 5.13A-C). 
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Hepatic Macrophage Infiltration 
Administration of the atherogenic diet resulted in significant infiltration of macrophages 
into liver tissue as demonstrated by F4/80 staining (Figure 5.14). Mice fed the atherogenic 
diet had an average of 3.4±0.41 inflammatory foci per 10x field compared to only 0.14±0.02 
inflammatory loci per field in the standard diet fed mice (p<0.001). Macrophage infiltration 
into liver tissue was significantly attenuated in the Ephx2-/- mice (2.0±0.50 foci) compared to 
the atherogenic diet group (p=0.022). In contrast, pharmacologic inhibition of sEH and 
endothelial overexpression of CYP2J2 did not significantly attenuate macrophage infiltration 
(Figure 5.14G). 
 
Pathological Assessment of Hepatic Damage  
NAFLD severity was assessed by quantifying steatosis, lobular inflammation, hepatocyte 
ballooning and fibrosis.171 In response to four weeks of atherogenic diet administration, 
steatosis was present in <5% of all samples, hepatocyte ballooning was absent in all 
samples, and fibrosis was minimal or absent in all samples. Therefore, our analysis focused 
on lobular inflammation, which was noted in the majority of mice administered the 
atherogenic diet (Figure 5.15A-G, Table 5.1).171 Chi-square analysis of lobular inflammation 
indicated atherogenic diet administration induced a significant increase in lobular 
inflammation (p<0.001). A post hoc ordinal logistic regression analysis demonstrated that 
Ephx2-/- mice were significantly more likely to have lower levels of lobular inflammation than 
WT mice administered the atherogenic diet (p=0.011); however no other treatment groups 
were significantly different than the atherogenic diet group (Table 5.1). When analyzed as a 
continuous variable, the atherogenic diet group (1.44±0.17) had a significantly higher 
inflammation score than the standard diet group (0.00±0.00, p<0.001), and Ephx2-/- mice 
(0.71±0.19) had significantly lower inflammation scores than WT mice fed the atherogenic 
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diet (p=0.006). Similar to the ordinal logistic regression analysis, no other treatment groups 
were significantly different than the atherogenic diet group (Figure 5.15G) 
 
 
Hepatic Injury 
 
Plasma ALT levels, a biomarker of hepatic injury and necrosis, increased 6.2±0.87-fold 
in mice fed the atherogenic diet compared to mice fed the standard diet, and Ephx2-/- mice 
had significantly lower plasma ALT levels than WT atherogenic diet fed mice (Figure 5.16, 
p=0.017 vs. the atherogenic diet group); however the CYP2J2-Tr mice (p=0.480), and mice 
administered t-AUCB (p=0.339) and high-dose t-AUCB (p=0.275) were not significantly 
different than the atherogenic diet group.  
 
Summary (Section 2) 
Our analysis of the therapeutic effects of CYP epoxygenase pathway potentiation in fatty 
liver disease-associated inflammation demonstrated that genetic disruption of sEH 
significantly attenuated the induction of key inflammatory mediators, macrophage infiltration 
into liver and liver injury in response to atherogenic diet administration. However, 
pharmacologic inhibition of sEH and endothelial overexpression of CYP2J2 did not produce 
a similar anti-inflammatory effect.  
 
Discussion 
 
Potentiation of the CYP epoxygenase pathway elicits potent anti-inflammatory effects in 
preclinical models of acute and chronic vascular inflammation, and has been proposed as 
an anti-inflammatory therapeutic strategy for the treatment of inflammatory diseases.74 
Chronic hepatic inflammation is a key pathologic mediator in the progression of NAFLD; 
however, the contribution of CYP-mediated eicosanoid metabolism to fatty liver disease-
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associated inflammation has not been rigorously evaluated in preclinical models of 
NAFLD/NASH. This study is the first to demonstrate that 1) expression of hepatic CYP 
epoxygenase enzymes, hepatic EET biosynthesis and circulating EET levels are 
significantly suppressed in an atherogenic diet model of NAFLD/NASH and 2) genetic 
disruption of sEH restores hepatic and systemic EET levels and attenuates atherogenic diet 
induced hepatic inflammation and injury. These findings demonstrate that suppression of 
EET biosynthesis is a key pathological consequence of NAFLD/NASH, and therapeutic 
restoration of EET levels is an anti-inflammatory therapeutic strategy with potential utility for 
the treatment of fatty liver disease-associated inflammation. Future studies will seek to 
define the mechanism underlying the suppression of EET biosynthesis in the presence of 
NAFLD/NASH. In addition, the observed differences between genetic disruption and 
pharmacologic inhibition of sEH highlight the need for rigorous characterization of the 
mechanisms by which EETs attenuate hepatic inflammation, and to evaluate the utility of 
therapeutic strategies that increase EETs as a treatment for NAFLD/NASH. 
Previous studies have demonstrated that inflammatory stimuli suppress hepatic CYP-
mediated xenobiotic metabolism.172 In addition, we have reported that the hepatic EET 
biosynthesis is suppressed in a LPS model of acute inflammation and a high-fat diet model 
of insulin resistance.162, 173 Our microarray analysis demonstrated that, relative to global 
gene expression changes, the arachidonic acid metabolism pathway (including numerous 
CYP epoxygenase enzymes) is significantly suppressed in response to atherogenic diet 
administration. Moreover, we observed suppression of hepatic Cyp2c29, Cyp2c50, 
Cyp2c55, and Cyp2j5, the most abundant CYP epoxygenases in mouse liver.162 This finding 
suggests that suppression of CYP epoxygenase enzymes is an important event in the 
pathogenesis of NAFLD/NASH, and is consistent with a previous report demonstrating that 
expression of hepatic Cyp2c29 is suppressed in response to choline- and folate-deficient 
diet administration, a model of NAFLD/NASH that induces hepatic steatosis and 
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inflammation.174 Consequently, we investigated the effects of atherogenic diet administration 
on CYP-mediated eicosanoid metabolism in WT mice. We observed that CYP epoxygenase 
pathway activity is suppressed in liver microsomes following four weeks of atherogenic diet 
administration. In addition, both plasma and liver EET levels were suppressed in mice fed 
the atherogenic diet compared to mice fed a standard chow diet. Our study is the first to 
demonstrate that EET biosynthesis in liver microsomes, and hepatic and plasma EET levels, 
are suppressed in the presence of NAFLD/NASH. Collectively, these data suggest that 
suppression of hepatic CYP epoxygenase-mediated EET biosynthesis is a key pathological 
consequence of NAFLD/NASH. 
Previous studies have demonstrated that LPS induced inflammation suppresses hepatic 
CYP epoxygenase expression in vivo.162 In addition, inflammatory cytokines including IL-1, 
IL-6 and TNFα suppress CYP expression in hepatocytes, and cytokine-mediated 
suppression of CYPs is dependent on NF-κB activation.175, 176 Despite this clear effect, the 
contribution of specific nuclear receptors known to regulate CYP expression on the cytokine-
mediated suppression of CYPs appears isoform and species specific and model dependent, 
suggesting that upstream activation of the innate immune response is the most important 
factor in CYP suppression. Therefore, we hypothesized that abrogation of Myd88-dependent 
activation of NF-κB would prevent the atherogenic diet induced suppression of CYP 
epoxygenase expression and EET biosynthesis. Genetic disruption of Myd88 attenuated the 
atherogenic diet induced increase in plasma and liver inflammatory biomarkers and 
macrophage infiltration into liver demonstrating a significant inhibition, but not complete 
abrogation, of the inflammatory response. However, despite a partial attenuation of Cyp2c29 
suppression in liver tissue, disruption of Myd88 did not restore the atherogenic diet induced 
suppression of plasma or hepatic EETs.  
To further investigate the mechanism underlying the atherogenic diet induced 
suppression of the CYP epoxygenase pathway, we quantified mRNA expression of Tlr4, 
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Nfκb1, and Tnfα. Induction of Tlr4, Nfκb1, and Tnfα transcript levels were attenuated in 
Myd88-/- mice, but remained significantly elevated compared to WT mice administered the 
standard diet. Interestingly, a strong inverse correlation was observed between Tlr4, Nfκb1, 
and Tnfα expression and CYP epoxygenase expression. Moreover, a significant inverse 
association was also observed between hepatic Tlr4, Nfκb1, and Tnfα expression and EET 
levels in liver. Collectively, these data suggest that innate immune system activation is 
associated with suppression of the CYP epoxygenase pathway, and that the mechanism 
driving CYP epoxygenase suppression is, at least in part, independent of signaling through 
Myd88. Future studies directly evaluating the role of Myd88-independent activation of NF-κB 
in atherogenic diet induced CYP epoxygenase pathway suppression are warranted. 
CYP derived EETs have potent anti-inflammatory effects in preclinical models of NF-κB 
mediated vascular inflammation.75, 77 In addition, recent reports indicate that sEH inhibition 
may attenuate the development of insulin resistance and hepatic steatosis in response to a 
high-fat diet.177, 178 However, the anti-inflammatory effects of CYP epoxygenase pathway 
potentiation have not been rigorously evaluated in an atherogenic diet model of 
NAFLD/NASH, which induces hepatic inflammation via an innate immune system dependent 
mechanism. Since our studies demonstrated that suppression of CYP mediated EET 
biosynthesis is a pathological consequence of atherogenic diet feeding, we hypothesized 
that restoring CYP epoxygenase pathway activity by increasing EET biosynthesis via 
endothelial CYP2J2 overexpression, or globally decreasing EET hydrolysis by targeted 
disruption of Ephx2 or pharmacologic inhibition of sEH, would attenuate atherogenic diet 
induced hepatic inflammation. Consistent with our hypothesis and the anti-inflammatory 
effects of EETs, genetic disruption of sEH attenuated macrophage infiltration into liver 
tissue, hepatic expression of inflammatory mediators, and hepatic injury in response to 
atherogenic diet feeding. 
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Surprisingly, endothelial CYP2J2 overexpression and pharmacologic inhibition of sEH 
did not result in an anti-inflammatory effect similar to that observed in the Ephx2-/- mice. 
Previous studies have shown that endothelial CYP2J2 overexpression and genetic 
disruption of sEH each attenuate the LPS induced inflammatory response in lung tissue to a 
similar degree,77 and pharmacologic inhibition of sEH attenuates the LPS induced increase 
in circulating inflammatory biomarkers.76 Similarly, administration of t-AUCB attenuated 
hepatic induction of TNFα in response to high fat diet feeding for 16 weeks.177 However, 
while genetic disruption of sEH attenuated the induction of inflammation in response to 8 
weeks of high fat diet feeding, administration of t-AUCB to WT mice for the final 4 weeks of 
the experiment had no effect.177 Interestingly, similar differences in phenotypic response to 
genetic disruption and pharmacologic inhibition of sEH have also been reported in a mouse 
model of hypoxia-induced pulmonary hypertension.179 Collectively, these data suggest that 
the anti-inflammatory effects of sEH inhibition may be model dependent, and that 
pharmacologic inhibition and genetic disruption of sEH may not always produce consistent 
phenotypes. 
The atherogenic diet model increases circulating cholesterol levels and induces hepatic 
and systemic inflammation; therefore, therapies that reduce plasma cholesterol levels may 
have an anti-inflammatory effect. Of note, sEH is a bifunctional enzyme with both an 
epoxide hydrolase and lipid phosphatase domain.180 Previous studies have shown that 
genetic disruption of sEH, which abolishes activity in both domains, results in lower plasma 
cholesterol levels, whereas pharmacologic inhibition of sEH, which inhibits only hydrolase 
activity, has no effect on cholesterol.181 In the present study, neither genetic disruption nor 
pharmacologic inhibition of sEH had an effect on the atherogenic diet induced increase in 
plasma or hepatic cholesterol levels; therefore, it is unlikely that differences in cholesterol 
metabolism account for the differences in anti-inflammatory phenotypes. The differences in 
anti-inflammatory effect observed between genetic disruption and pharmacologic inhibition 
 125 
 
of sEH may be secondary to insufficient inhibition of sEH with administration of t-AUCB. The 
14,15-EET:DHET ratio was significantly increased 4.0±0.26-fold and 4.6±0.24-fold in mice 
administered t-AUCB at 10 mg/L and 50 mg/L, respectively, compared to mice fed the 
atherogenic diet only, which is similar to the level of sEH inhibition observed in previous 
studies.166 In addition, sum EET levels were significantly higher in mice administered t-
AUCB at both 10 mg/L and 50 mg/L compared to mice fed the atherogenic diet only, 
demonstrating inhibition of sEH led to a significant increase in circulating EETs. However, 
Ephx2-/- mice had significantly higher 14,15-EET:DHET ratio and sum EET levels in plasma 
compared to each of the t-AUCB groups, suggesting that t-AUCB at these doses did not 
inhibit EET hydrolysis to the same degree as Ephx2-/- disruption. In addition, high-dose, but 
not standard dose, t-AUCB administration significantly attenuated the induction of plasma 
MCP-1 levels, suggesting that more potent inhibition may be necessary to achieve an 
increase in EET levels (i.e. EET “dose”) that is sufficient to produce an anti-inflammatory 
effect. These findings are consistent with the absence of an anti-inflammatory phenotype in 
the CYP2J2-Tr mice, which demonstrate only a modest ~1.5-fold elevation in circulating 
EETs despite significantly higher EET biosynthesis in isolated endothelial cells,163 
suggesting that higher EETs specifically in endothelial cells does not produce a high enough 
EET “dose” to attenuate macrophage infiltration into liver tissue.  
Collectively, these findings suggest that the CYP epoxygenase pathway is an important 
regulator of atherogenic diet induced chronic hepatic inflammation. EETs exhibit anti-
inflammatory, anti-apoptotic, and anti-fibrotic properties in preclinical models;71, 74, 182 
therefore the observed suppression of hepatic CYP epoxygenase pathway activity and 
circulating EET levels may be detrimental in the pathological progression of fatty liver 
disease. Indeed, Ephx2-/- mice fed an atherogenic diet had circulating EET levels greater 
than WT mice fed a standard diet, and exhibited significantly attenuated macrophage 
infiltration into liver tissue, lower hepatic and circulating mediators of inflammation, and 
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reduced hepatic injury, suggesting that restoration of the CYP epoxygenase pathway 
attenuates the development and progression of fatty liver disease. Importantly, these effects 
were independent of changes in circulating and hepatic cholesterol levels. Pharmacologic 
inhibition of sEH, however, did not produce a similar effect, suggesting the need for more 
potent inhibitors, which are currently in development,183 or other therapeutic strategies that 
potentiate the effects of CYP-derived EETs. Additional studies are warranted to further 
investigate the mechanisms underlying the observed differences between genetic disruption 
and pharmacologic inhibition of sEH. 
Our study has limitations that must be acknowledged. We evaluated the contribution of 
the CYP epoxygenase pathway to the regulation of fatty liver disease-associated 
inflammation following four weeks of atherogenic diet administration. The relatively short 
duration of our study has limitations as a model of human NAFLD/NASH, where chronic 
obesity leads to accumulation of fat within the liver (NAFLD) which eventually results in 
activation of the inflammatory response (NASH). However, four weeks of atherogenic diet 
administration significantly induced hepatic inflammation and macrophage infiltration which 
allowed us to evaluate fundamental pathological role of inflammation in this disease model, 
without the confounding effects of weight gain, adipose tissue inflammation, and insulin 
resistance. Follow-up studies in the diet-induced obesity and methionine/choline deficient 
diet models of NAFLD/NASH remain necessary. In addition, although circulating levels of 
anti-inflammatory EETs were significantly higher in Ephx2-/- mice compared to mice 
administered t-AUCB, suggesting a “dose response” effect with complete abrogation of sEH 
activity producing a greater effect than partial pharmacologic inhibition, we have not fully 
evaluated this hypothesis. Moreover, the inability of high-dose administration of t-AUCB to 
produce a significant anti-inflammatory effect, despite clear inhibition of sEH, suggests that 
in order to have utility as an anti-inflammatory therapeutic approach to prevent the 
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progression of fatty liver disease, pharmacologic inhibition of sEH must increase EETs to 
levels similar to those achieved by Ephx2 disruption.  
 
Conclusions 
In summary, we have demonstrated that in response to an atherogenic diet hepatic CYP 
epoxygenase activity, and both hepatic and circulating levels of anti-inflammatory EETs are 
suppressed. These data suggest that suppression of hepatic CYP-mediated EET 
biosynthesis is an important pathological consequence of NAFLD/NASH in vivo. In addition, 
genetic disruption of sEH restored hepatic and circulating EET levels, and attenuated 
hepatic inflammation. Collectively, these data indicate that the CYP epoxygenase pathway 
is an important regulator of the NAFLD/NASH-associated hepatic inflammatory response. 
Future studies are needed to improve our understanding of the mechanisms underlying the 
role of sEH and EETs in the regulation of NAFLD/NASH-associated chronic hepatic 
inflammation. 
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Tables 
Table 5.1. Hepatic inflammation scores by treatment group.  
Group 0 1 2 3 
Standard Diet  
 WT (control) 18 (100%) 0 (0%) 0 (0%) 0 (0%)   
Atherogenic Diet 
 WT 12 (28%)  9 (21%) 13 (30%) 9 (21%) 
 Ephx2-/- 14 (58%) 4 (17%) 5 (21%) 1 (4%)  
 CYP2J2-Tr  2 (13%) 5 (33%) 3 (20%) 5 (33%) 
 WT + t-AUCB 1 (8%) 3 (23%) 6 (46%) 3 (23%)  
 WT + HD t-AUCB 3 (21%) 4 (29%) 1 (7%) 6 (43%) 
Data presented as the n (percentage) of mice from each group having an inflammation 
score of 0, 1, 2, or 3. 
Note: percentages may not equal 100% due to rounding. 
The overall chi-square analysis demonstrated a significant induction of inflammation 
(p<0.001). 
Ephx2-/- mice were significantly more likely to have lower levels of inflammation (p=0.007), 
no other treatment groups were significantly different from WT mice administered the 
atherogenic diet using ordinal logistic regression. 
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Figures 
 
 
 
 
 
Figure 5.1. Time course of atherogenic diet-induced inflammation and liver damage. 
(A) Serum amyloid A, (B) MCP-1, and (C) CD-68 mRNA levels were significantly induced in 
mice administered the atherogenic diet for 2, 4, or 8 weeks (n=6 per group) relative to STD 
diet fed mice (n=15). (D) Plasma ALT was significantly increased in mice administered the 
atherogenic diet for 2, 4, or 8 weeks (n=6 per group) compared to mice administered the 
STD diet (n=15). Data presented as mean ± SEM. *P<0.05 vs. STD diet group. 
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Figure 5.2. Plasma and hepatic lipid levels in response to atherogenic diet 
administration. 
(A) Plasma total cholesterol levels, (B) liver total cholesterol levels, and (C) liver triglyceride 
levels were significantly higher in mice administered the atherogenic diet for 4 weeks 
compared to mice administered the STD diet (plasma total cholesterol STD diet: n=10, 
atherogenic diet: n=22; liver cholesterol STD diet: n=6, atherogenic diet: n=14; liver 
triglycerides STD diet: n=6, atherogenic diet n=13). Data presented as mean ± SEM. 
*P<0.05 vs. STD diet group. 
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Figure 5.3. Arachidonic acid metabolism pathway gene expression in response to 
atherogenic diet administration.  
Gene expression profiling was completed using the Agilent Whole Mouse Genome 
Microarray (n=4 per group). To generate the enrichment plot, each gene on the microarray 
is rank-ordered (left to right) according to its correlation with atherogenic diet administration 
(most positive on the far left, most negative on the far right). The enrichment plot for the 
arachidonic acid metabolism pathway GSEA indicates the position of each gene (vertical 
lines) within the pathway in the overall rank-order of the correlation (top of figure). A heat-
map is provided illustrating gene expression levels for each gene in the core enrichment 
subset (bottom of figure), blue indicates the gene is down-regulated and red indicates the 
gene is up-regulated. The p-value for the GSEA is provided.  
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Figure 5.4. Atherogenic diet administration suppresses the CYP epoxygenase 
pathway. 
(A) Plasma sum EET levels (STD diet: n=6, atherogenic diet: n=13) and (D) liver sum EET 
levels (STD diet: n=3, atherogenic diet n=5) were significantly lower in mice administered 
the atherogenic diet compared to mice administered the STD diet. Formation rates for (B, E) 
sum EETs and (C, F) sum EETs+DHETs are suppressed in liver microsomes of mice 
administered the atherogenic diet compared to mice administered the STD chow diet in the 
presence and absence of the sEH inhibitor t-AUCB (n=8 per group). Data presented as 
mean ± SEM. *P<0.05 vs. STD diet group.  
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Figure 5.5. Effects of Atherogenic diet feeding on CYP epoxygenase pathway mRNA 
levels. 
(A) Liver Cyp2c29 mRNA levels were significantly lower but (B) Ephx2 mRNA levels were 
not significantly different in mice administered the atherogenic diet compared to mice 
administered the STD diet (n=6 per group). Data presented as mean ± SEM. *P<0.05 vs. 
STD diet group. 
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Figure 5.6. Toll like receptor expression in response to atherogenic diet 
administration. 
Hepatic (A) Tlr2 and (B)  Tlr4 mRNA levels were significantly induced following four weeks 
of atherogenic diet administration (STD diet group n=9, atherogenic diet group n=6). Data 
presented as mean ± SEM. *P<0.05 vs. STD diet group. 
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Figure 5.7. Myd88 disruption attenuates atherogenic diet induced inflammation. 
Disruption of Myd88 signaling attenuates atherogenic diet induced protein expression of (A) 
plasma MCP-1 (B) liver MCP-1, and (C) liver VCAM-1, (STD Diet: n=6, atherogenic diet: 
n=5, Myd88-/-: n=5). Data presented as mean ± SEM. *P<0.05 vs. atherogenic diet group. 
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Figure 5.8. Myd88 disruption attenuates atherogenic diet induced macrophage 
infiltration into hepatic tissue. 
Representative images of F4/80 stained slides from (A) STD diet (n=6), (B) atherogenic diet 
(n=5), and (C) Myd88-/- (n=5) mice are provided. (D) The number of inflammatory foci per 
10x field was significantly increased in mice administered the atherogenic diet and 
significantly attenuated in Myd88-/- mice. Data presented as mean ± SEM. *P<0.05 vs. 
atherogenic diet group. 
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Figure 5.9. Effect of Myd88 disruption on atherogenic diet induced changes in the 
CYP epoxygenase pathway.  
(A) Plasma and (C) liver sum EET levels were significantly lower in WT mice administered 
the atherogenic diet compared to the STD diet group; however, genetic disruption of Myd88 
had no effect on sum EET levels. The 14,15-EET:DHET ratio was not significantly impacted 
by the atherogenic diet in (B) plasma or (D) liver tissue. (E) Hepatic Cyp2c29 expression 
was significantly suppressed in mice administered the atherogenic diet, and partially 
restored in Myd88-/- mice. (F) No differences were observed in Ephx2 expression (STD Diet: 
n=6, atherogenic diet: n=5, Myd88-/-: n=5). Data presented as mean ± SEM. *P<0.05 vs. 
atherogenic diet group. 
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Figure 5.10. Residual inflammation and immune activation correlates with CYP 
epoxygenase pathway activity.  
(A, D, G) Administration of the atherogenic diet increases hepatic Tlr4, Nfκb1, and Tnfα 
mRNA levels, and each is significantly attenuated in Myd88-/- mice but remain significantly 
elevated compared to STD diet fed mice. (B, E, H) Hepatic expression of Cyp2c29 is 
inversely correlated with hepatic expression of Tlr4, Nfκb1, and Tnfα. (C, F, I) Liver sum 
EET levels are inversely correlated with hepatic expression of Tlr4, Nfκb1, and Tnfα (STD 
Diet: n=6, atherogenic diet: n=5, Myd88-/-: n=5). Data presented as mean ± SEM, or 
individual data points for log-transformed gene expression and liver EET levels. *P<0.05 vs. 
atherogenic diet group, #P<0.05 vs. STD diet.   
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Figure 5.11. Genetic disruption and pharmacologic inhibition of sEH restores 
circulating and hepatic EET levels. 
Plasma and liver (A,D) 14,15-EET:DHET and (B,E) 12,13-EpOME:DHOME ratios and (C,F) 
sum EET levels are significantly higher in Ephx2-/- mice and the standard (10 mg/L) and 
high-dose (50 mg/L) t-AUCB treated groups compared to mice administered the atherogenic 
diet. The plasma 14,15-EET:DHET ratio and plasma sum EETs are significantly higher in 
Ephx2-/- mice compared to each of the t-AUCB treated groups and the liver 14,15-
EET:DHET ratio is significantly higher than the standard dose t-AUCB treated group. The 
plasma 12,13-EpOME:DHOME ratio was significantly higher in Ephx2-/- mice and mice 
administered high-dose t-AUCB compared to standard dose t-AUCB (plasma atherogenic 
diet: n=9, Ephx2-/-, n=5, t-AUCB: n=6, HD t-AUCB: n=7; liver atherogenic diet: n=5, Ephx2-/-, 
n=5, t-AUCB: n=3, HD t-AUCB: n=5). Data presented as mean ± SEM. *P<0.05 vs. 
atherogenic diet group, #P<0.05 vs. t-AUCB group, $P<0.05 vs. HD t-AUCB group. 
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Figure 5.12. Plasma and liver concentrations of individual EET regioisomers. 
(A) Plasma and (D) liver levels of 8,9-EET and were significantly higher in Ephx2-/- mice and  
the  standard (10 mg/L) and high-dose (50 mg/L) t-AUCB treated groups compared to the 
atherogenic diet group. (B) Plasma and (E) liver 11,12-EET levels tended to be higher in 
Ephx2-/- mice and in each of the t-AUCB treated groups compared to the atherogenic diet 
group, but the difference did not reach statistical significance. (C) Plasma and (F) liver 
concentrations of 14,15-EET were significantly higher in Ephx2-/- mice and in each of the t-
AUCB treated groups compared to the atherogenic diet group, and plasma 14,15-EET levels 
were significantly higher in Ephx2-/- mice compared to each of the t-AUCB treated groups 
(plasma atherogenic diet: n=9, Ephx2-/-: n=5, t-AUCB: n=6, HD t-AUCB: n=7; liver 
atherogenic diet: n=5, Ephx2-/-, n=5, t-AUCB: n=3, HD t-AUCB: n=5). Data presented as 
mean ± SEM. *P<0.05 vs. atherogenic diet group, #P<0.05 vs. t-AUCB group, $P<0.05 vs. 
HD t-AUCB group, ^P<0.05 vs. Ephx2-/- group.  
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Figure 5.13. Genetic disruption of sEH attenuates hepatic expression of inflammatory 
biomarkers. 
Plasma MCP-1, liver MCP-1, and liver VCAM-1 protein levels are significantly induced in 
atherogenic diet fed mice. The induction of plasma MCP-1, liver MCP-1, and liver VCAM-1 
protein levels is attenuated in Ephx2-/- mice; however, no attenuation was observed in the 
CYP2J2-Tr mice or either of the t-AUCB treated groups (STD diet: n=15-19, atherogenic 
diet: n=38-45, Ephx2-/-, n=22-24, CYP2J2-Tr: n=13-15, t-AUCB: n=13-14, HD t-AUCB: 
n=14). Data presented as mean ± SEM. *P<0.05 vs. atherogenic diet group. 
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Figure 5.14. Genetic disruption of sEH attenuates macrophage infiltration into hepatic 
tissue. 
Representative F4/80 stained images at 10x magnification from (A) STD diet (n=16), (B) 
atherogenic diet (n=38), (C) Ephx2-/- (n=22), (D) CYP2J2-Tr (n=14), t-AUCB (n=14), and HD 
t-AUCB (n=8) groups. (G) The number of inflammatory foci per 10x field was significantly 
increased in mice administered the atherogenic diet and significantly attenuated in Ephx2-/- 
mice, but not CYP2J2-Tr mice or either of the t-AUCB treated groups. Data presented as 
mean ± SEM. *P<0.05 vs. atherogenic diet group.  
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Figure 5.15. NASH lobular inflammation scoring.  
Representative H&E stained images at 20x magnification from (A) STD diet (n=18), (B) 
atherogenic diet (n=43), (C) Ephx2-/- (n=24), (D) CYP2J2-Tr (n=15), (E) t-AUCB (n=13), and 
(F) HD t-AUCB (n=13) groups. (G) Graphical representation of the lobular inflammation 
score for each group demonstrates that Ephx2-/- mice have attenuated lobular inflammation 
score in response to atherogenic diet administration. Data presented as mean ± SEM. 
*P<0.05 vs. atherogenic diet group. 
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Figure 5.16. Genetic disruption of sEH attenuates induction of plasma ALT levels. 
Plasma ALT levels were significantly higher in mice administered the atherogenic diet 
compared to mice administered the STD diet and significantly attenuated in Ephx2-/- mice, 
but not CYP2J2-Tr mice or WT mice treated with either dose of t-AUCB (STD diet: n=13, 
atherogenic diet: n=26, Ephx2-/-: n=14, CYP2J2-Tr: n=8, t-AUCB: n=7, HD t-AUCB: n=13). 
Data presented as mean ± SEM. *P<0.05 vs. atherogenic diet group. 
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CHAPTER VI 
DISCUSSION AND PERSPECTIVE 
 
Summary and Scope 
Cardiovascular disease (CVD) is a major public health problem, accounting for 1 in 
every 3 deaths in the United States.1 Moreover, individuals with established coronary artery 
disease (CAD) are at high risk for acute coronary syndrome (ACS) clinical events, which are 
associated with significant morbidity and mortality. While substantial progress has been 
made in the treatment of CAD in recent decades, novel therapeutic approaches are needed 
to further improve prognosis in CAD patients. However, recent failures in drug development 
indicate that new therapeutics are unlikely to be effective in broadly defined populations. 
Therefore, thorough understanding of the mechanisms underlying the progression of CAD is 
necessary to facilitate the development and rigorous evaluation of novel therapeutic 
strategies, and identify putative responders to targeted therapies for the treatment of CAD.  
Atherosclerosis is a chronic disease with complex underlying pathophysiology; however, 
it is well-established that vascular and systemic inflammation is integral to the development 
and progression of CAD, and the liver is a critical mediator of the initiation and propagation 
of the inflammatory response.3, 4 Moreover, emerging evidence indicates that cytochrome 
P450 (CYP)-derived eicosanoids are key regulators of inflammation and endothelial 
function, and modulation of CYP-mediated arachidonic acid metabolism has emerged as a 
potential therapeutic target for the treatment of CAD. However, the functional association 
between CYP-mediated eicosanoid metabolism, inflammation, and CAD remains poorly 
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understood, and requires rigorous investigation in preclinical models and humans. Thus, the 
overall aim of this dissertation was to characterize the functional contribution of CYP-
mediated eicosanoid metabolism to the regulation of systemic and vascular inflammation 
within the clinical context of CAD. We have taken a translational research approach using 
preclinical models and humans to evaluate the functional relationship between CYP-
mediated eicosanoid metabolism, systemic and vascular inflammation, and CAD. The major 
findings of this work include 1) the identification of key genes associated with the presence 
and severity of CAD, which may represent novel targets for therapeutic strategies that aim to 
prevent CAD development and progression, 2) the observation of an association between 
dysregulation of CYP-mediated eicosanoid metabolism in human CAD patients and vascular 
dysfunction phenotypes that are predictive of prognosis in this patient population, and 3) the 
discovery that suppression of CYP epoxygenase pathway activity is a key pathological 
consequence of fatty liver disease-associated inflammation, an emerging risk factor for 
CAD, and reversal of this suppression by genetic disruption of sEH attenuates fatty liver 
disease-associated inflammation. 
The major implication of this work includes laying a critical foundation for the rational 
design of future studies that seek to rigorously evaluate CYP epoxygenase pathway 
potentiation as an anti-inflammatory approach for the treatment of non-alcoholic fatty liver 
disease (NAFLD)/non-alcoholic steatohepatitis (NASH), as well as CAD.  
 
Key Findings 
Systemic and vascular inflammation are key drivers of the pathogenesis and progression 
of CAD, and the liver is a critical mediator of the initiation and propagation of the 
inflammatory response.115 Therefore, in order to characterize the contribution of systemic 
and vascular inflammation to the development and progression CAD in older adults, we first 
utilized a global systems biology approach to identify the key biological processes that 
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underlie the development and progression of obstructive CAD in humans (Aim 1). Our 
analysis in the Supporting a Multidisciplinary Approach to Researching Atherosclerosis 
(SAMARA) cohort is the first study to rigorously evaluate the key mechanisms underlying the 
pathophysiology of CAD in older adults using a combination of non-biased systems biology 
and candidate biomarker approaches.  
Consistent with our hypothesis, and previous observations in the general population, our 
global gene expression analysis in peripheral blood mononuclear cells (PBMCs) confirmed 
that inflammation is an important pathological mediator underlying the pathogenesis and 
progression of CAD in older adults. We identified multiple genes that may be important in 
the development and progression of CAD in older individuals, including CASP4, HLA-E, and 
MAPK14, which were associated with the presence and severity of CAD in previous studies 
in younger patient populations.104 Since the association between expression of these genes 
and the presence and severity of CAD has now been validated in multiple independent 
patient populations, future studies using preclinical models of atherosclerosis are warranted 
to directly evaluate their functional role in the pathogenesis and progression of 
atherosclerotic CAD. Additional genes identified in our analysis were not found to be 
associated with the presence and severity of CAD in previous studies with younger patient 
populations, and therefore may be unique to the pathophysiology of CAD in older adults; 
however, validation of these findings in an independent cohort remains necessary. Future 
studies directly evaluating the unique mechanisms driving the development and progression 
of CAD in older adults are warranted.  
Our candidate biomarker analysis demonstrated that elevated circulating biomarkers of 
inflammation, which are established biomarkers of CAD risk in the general population, are 
not predictive of CAD status in older adults. These data suggest that circulating biomarkers 
of inflammation have limited clinical utility for risk assessment in this population and more 
advanced biomarker analyses, such as global gene expression profiling in PBMCs, may be 
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necessary to improve the precision with which we assess risk in older adults. Future studies 
evaluating the role of novel circulating biomarkers of CAD risk in older adults remain 
necessary. Collectively, our candidate biomarker and global gene expression analyses 
suggest that the role of inflammation in the pathophysiology of CAD in the elderly is not 
captured by circulating biomarkers, and the mechanism by which inflammation impacts the 
development and progression of CAD in older individuals may be distinct from that in the 
general population. Importantly, inflammation was identified as a key pathological mediator 
of CAD in older adults, indicating that anti-inflammatory therapeutics that are currently in 
development for the treatment of CAD, including those that modulate CYP-mediated 
arachidonic acid metabolism, may have clinical utility in this patient population.  
In order to characterize the contribution of CYP-mediated arachidonic acid metabolism 
to CAD development and progression, we took a candidate pathway approach using gene 
set enrichment analysis (GSEA) in the SAMARA cohort. Our analysis did not demonstrate a 
significant relationship between expression of the arachidonic acid metabolism pathway as a 
whole and CAD in PBMCs of older individuals. However, we observed a signal suggesting 
that expression of individual genes within the arachidonic acid metabolism pathway, most 
notably EPHX2 (a key gene in the CYP pathway of arachidonic acid metabolism), may be 
suppressed in CAD patients. Suppression of EPHX2, which metabolizes 
epoxyeicosatrienoic acids (EETs) to the less biologically active dihydroxyeicosatrienoic 
acids (DHETs), in CVD patients is consistent with our previous report that sEH metabolic 
function is suppressed in stable CAD patients under 65 years of age compared to healthy 
volunteers,136 and studies demonstrating that EPHX2 is suppressed in individuals with 
ischemic heart failure compared to control subjects.137 These findings suggest that the 
presence of CVD may lead to a compensatory suppression of sEH-mediated EET hydrolysis 
in humans that was not captured by our global analysis of arachidonic acid pathway gene 
expression in PBMCs, and demonstrate the need for studies evaluating the association 
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between inter-individual variation in CYP-derived eicosanoids at the metabolite level and the 
pathogenesis and progression of CAD. 
Our analysis of arachidonic acid metabolism pathway gene expression in PBMCs from 
older adults demonstrated that genes from the CYP epoxygenase pathway may be 
important in the development and progression of CAD. Therefore, we utilized a candidate 
pathway approach to characterize the functional relationship between inter-individual 
variation in CYP-mediated eicosanoid metabolism and endothelial dysfunction, vascular 
inflammation, and systemic inflammation in stable obstructive CAD patients (Aim 2). We 
accomplished this by quantifying inter-individual variation in CYP-derived eicosanoids at the 
metabolite level, and biomarkers of vascular function that are predictive of prognosis in CAD 
patients. Our analysis of CYP metabolites in humans identified a subset of individuals with 
established CAD that have dysregulated CYP-mediated eicosanoid metabolism and 
vascular dysfunction, suggesting that inter-individual variation in CYP-derived eicosanoids is 
an important regulator of phenotypes that are associated with prognosis in this population. 
This is the first study in humans to demonstrate that dysregulation of CYP-mediated 
eicosanoid metabolism is associated with vascular dysfunction in this high-risk population. 
Importantly, these associations were identified in patients treated with standard of care 
medications, suggesting that treatment of CAD patients who have enhanced CYP ω-
hydroxylase or sEH metabolic activity with adjunct therapies that inhibit 20-HETE 
biosynthesis and/or EET hydrolysis may improve vascular function and subsequently 
improve prognosis. Future studies remain necessary to validate these findings and evaluate 
the association between CYP ω-hydroxylase and sEH metabolic activity and clinical 
outcomes in CAD patients. In addition, proof-of-concept studies are necessary to define the 
vascular protective effects and safety of decreasing 20-HETE biosynthesis and/or inhibiting 
sEH activity in CAD patients. 
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The association between inter-individual variation in CYP-derived eicosanoids and 
vascular dysfunction in CAD patients suggests that targeted therapies that increase EETs 
and/or decrease 20-HETE may have therapeutic utility in a subset of CAD patients with 
dysregulated CYP-mediated eicosanoid metabolism. Importantly, pharmacologic inhibitors 
of sEH139 and CYP ω-hydroxylase metabolism140 are currently in development. Although 
these novel therapies are hypothesized to improve prognosis in CAD patients by eliciting 
protective effects in the vasculature via increasing EET and decreasing 20-HETE levels, 
respectively, preclinical studies are necessary to directly define the contribution of CYP-
mediated eicosanoid metabolism to vascular and systemic inflammation. Therefore, we 
utilized a preclinical approach to define the contribution of CYP-mediated eicosanoid 
metabolism to the regulation of non-alcoholic fatty liver disease-associated systemic and 
vascular inflammation in mice (Aim 3), a preclinical model of chronic inflammation which is 
relevant to human CAD.  
Similar to the association between dysregulated CYP-mediated eicosanoid metabolism 
and vascular dysfunction that was observed in CAD patients, our studies demonstrated that 
induction of NAFLD/NASH-associated systemic and vascular inflammation resulted in 
suppression of CYP epoxygenase enzymes and EET biosynthesis in the liver. Importantly, 
direct quantification of CYP-derived eicosanoids demonstrated that plasma and hepatic EET 
levels are suppressed in response to induction of NAFLD/NASH, and are highly correlated 
with each other, suggesting that dysregulation of CYP-mediated eicosanoid metabolism in 
the liver regulates circulating metabolite levels. These findings highlight the potential 
importance of hepatic eicosanoid metabolism in the observed relationship between 
circulating eicosanoid levels and vascular dysfunction in human CAD patients, and the need 
to directly evaluate the contribution of CYP-mediated eicosanoid metabolism to the 
regulation of systemic and vascular inflammation in preclinical models of sustained hepatic 
inflammation. Interestingly, dysregulation of the CYP epoxygenase pathway was secondary 
 151 
 
to suppression of CYP enzymes in our preclinical model of fatty liver disease-associated 
inflammation, while enhanced sEH metabolic function was the key mediator of CYP 
epoxygenase pathway dysfunction in our analysis of human CAD patients. These findings 
suggest that different disease pathologies may impact CYP-mediated eicosanoid 
metabolism at distinct levels of the pathway, and highlight the need to rigorously 
characterize the mechanisms underlying dysregulation of CYP-mediated eicosanoid 
metabolism. 
We investigated the role of innate immune system activation, a pathological process key 
in the development and progression of both NAFLD/NASH and CAD, 156 in the suppression 
of the CYP epoxygenase pathway following induction of a sustained inflammatory response. 
Our studies demonstrated that the innate immune system was activated in the atherogenic 
diet model of NAFLD/NASH; however, abolishing signaling through myeloid differentiation 
factor 88 (Myd88) did not restore CYP-mediated eicosanoid metabolism. Interestingly, Tlr4, 
Nfkb1, and Tnfα expression remained significantly elevated in Myd88-/- mice and each were 
inversely correlated with CYP epoxygenase expression and liver EET levels. These findings 
indicate that Myd88-indpendent activation of the innate immune system may have a 
significant role in the suppression of CYP epoxygenase activity; alternatively, Myd88-
indpendent pathways may play an important “reserve” role in the absence of Myd88 
signaling. Follow-up experiments remain necessary to directly evaluate the role of Myd88-
indpendent activation of the innate immune system on suppression of the CYP 
epoxygenase pathway in fatty liver disease-associated inflammation.  
Evaluation of the therapeutic effects of CYP epoxygenase pathway potentiation in fatty 
liver disease-associated inflammation demonstrated that genetic disruption of sEH elicits 
potent anti-inflammatory effects in a preclinical model of inflammation relevant to CAD. Of 
note, genetic disruption of sEH exhibited anti-inflammatory effects in this model despite the 
observation that atherogenic diet administration suppressed CYP epoxygenase expression 
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but had no effect on Ephx2 expression. This is the first in vivo study to demonstrate that 
increasing circulating and hepatic EET levels may have utility as an anti-inflammatory 
therapeutic strategy for the treatment of NAFLD/NASH, and suggests that sEH is a viable 
therapeutic target, even when dysregulation of the CYP epoxygenase pathway is not 
secondary to changes in sEH activity or expression. Our analysis adds to a growing body of 
literature in the eicosanoid field demonstrating that modulation of CYP-mediated arachidonic 
acid metabolism is a rational anti-inflammatory therapeutic strategy for the treatment of 
inflammatory diseases. However, it must be noted that pharmacologic inhibition of sEH and 
endothelial over-expression of CYP2J2, did not produce similar anti-inflammatory effects. 
Future studies remain necessary to determine the mechanism underlying the observed 
absence of an anti-inflammatory effect in mice treated with a pharmacologic inhibitor of sEH. 
Importantly, more potent inhibitors of sEH are currently in development that will facilitate 
these investigations.183  
 
Clinical Implications 
In recent decades considerable progress has been made in the development of 
therapeutics for the treatment of CAD; however, the burden of CAD remains high and the 
associated morbidity and mortality highlights the need for new therapies that target 
biological pathways integral to its pathogenesis and progression. Recent studies evaluating 
adjunct therapies that lower LDL cholesterol, a well-established pathological mediator of 
CAD, have failed to demonstrate an improvement in clinical outcomes in broadly defined 
CAD patient populations (Appendix II). These disappointing results demonstrate a critical 
need for novel adjunct therapies targeting biological pathways that are dysregulated in CAD 
patients, and identifying a subset of putative responders to these therapies.  
Our study identified a subset of CAD patients that have dysregulated CYP-mediated 
eicosanoid metabolism, and demonstrated that this subset of CAD patients exhibited 
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vascular dysfunction, which is predictive of poor outcomes. These findings suggest that 
CAD patients with dysregulated eicosanoid metabolism may represent a subset of putative 
responders to adjunct therapies that inhibit EET hydrolysis and/or 20-HETE biosynthesis. 
Moreover, in a mouse model of hepatic inflammation that precedes the development of 
atherosclerosis, we demonstrated that CYP epoxygenase-mediated EET biosynthesis was 
suppressed, and restoring EET levels by disrupting sEH-mediated EET hydrolysis resulted 
in reduced systemic and hepatic inflammation and liver injury. Collectively, these studies 
suggest that therapeutic interventions that restore CYP epoxygenase pathway metabolic 
function may be a viable anti-inflammatory therapeutic strategy in pathological conditions 
that suppress EET levels, and this therapeutic approach requires more rigorous 
investigation. This dissertation work has laid the foundation for future studies in this area 
that will focus on the critical evaluation of pharmacologic agents currently in development 
that increase EETs (sEH inhibitors), promote the effects of EETs (stable EET analogs), or 
decrease 20-HETE (CYP ω-hydroxylase inhibitors) as targeted anti-inflammatory 
therapeutic strategies for the treatment of CAD patients with enhanced sEH and/or CYP ω-
hydroxylase metabolic function. This personalized medicine approach, which incorporates 
rigorous characterization of therapeutic strategies in preclinical models and identification of 
putative responders in humans, offers enormous potential to develop targeted therapeutic 
strategies with high potential to improve clinical outcomes. 
 
Conclusions 
In summary, the overall aim of this dissertation was to characterize the functional 
contribution of CYP-mediated eicosanoid metabolism to the regulation of systemic and 
vascular inflammation within the clinical context of CAD. Our functional analysis of genes 
associated with the presence and severity of obstructive CAD reflected differential 
expression of genes regulating the inflammatory response. In addition, we identified a 
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subset of stable obstructive CAD patients with enhanced CYP ω-hydroxylase and sEH 
metabolic function who had advanced endothelial dysfunction and vascular inflammation 
despite receiving current standard of care therapies. Moreover, our preclinical studies 
directly demonstrated that fatty liver disease-associated inflammation suppressed hepatic 
CYP epoxygenase activity, and genetic disruption of sEH restored hepatic and circulating 
EET levels, and attenuated hepatic and systemic inflammation. Collectively, this dissertation 
demonstrates that targeted therapeutic strategies that modulate CYP-mediated arachidonic 
acid metabolism represents a rational anti-inflammatory approach for the treatment of CAD, 
and thus lays a critical foundation for future studies that directly evaluate the therapeutic 
effects of modulating CYP-mediated eicosanoid metabolism in CAD patients.
  
 
 
 
 
 
 
 
APPENDIX I 
DEVELOPMENT OF AN INFLAMMATION SCORE AS A COMPREHENSIVE 
PHENOTYPIC INDEX OF INFLAMMATION 
 
Introduction 
It is well-established that systemic and vascular inflammation are important in the 
development and progression of coronary artery disease (CAD) in the general population;1, 2 
however, studies evaluating the association between established biomarkers of 
inflammation and prognosis in older patient populations have not consistently demonstrated 
that elevated biomarkers of inflammation are associated with poorer outcomes.3, 4 Moreover, 
our analysis of candidate circulating biomarkers of inflammation, which are critical mediators 
of systemic and vascular inflammation did not demonstrate that individual biomarkers of 
inflammation were significantly higher in obstructive CAD patients in the SAMARA cohort 
compared to individuals without obstructive CAD (Chapter II). However, analysis of 
individual biomarkers of inflammation captures only isolated components of the inflammatory 
response (i.e. acute phase response, chemoattraction, or adhesion of leukocytes to the 
vessel wall), whereas the pathologic inflammatory response observed in cardiovascular 
disease encompasses all of these processes. Thus, it has been proposed that a combined 
phenotypic index of inflammation or “inflammation score” may provide further insight into the 
relationship between inflammation and cardiovascular disease.5  Therefore, in order to more 
rigorously assess the relationship between systemic and vascular inflammation and CAD in 
older individuals, we 1) developed a comprehensive inflammation score that captures the 
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inflammatory response at multiple levels and 2) characterized the association between the 
inflammation score and the presence and severity of obstructive CAD in older adults.  
 
Methods 
Development of an Inflammation Score 
In an independent cohort of 95 stable CAD patients and 42 healthy volunteers with no 
cardiovascular risk factors,6, 7 we developed a phenotypic index of inflammation 
“inflammation score”. In fresh serum, high-sensitivity C-reactive protein (hs-CRP) was 
quantified by latex-enhanced turbidimetric immunoassay using the VITROS® 5600 
Chemistry System (Ortho-Clinical Diagnostics, Inc., Rochester, NY). Chemokines (monocyte 
chemoattractant protein-1 [MCP-1] and epithelial neutrophil activating protein-78 [ENA-78]) 
and CAMs (intracellular adhesion molecule-1 [ICAM-1], vascular cellular adhesion molecule-
1 [VCAM-1], P-selectin and E-selectin) were quantified using a multianalyte profiling kit 
(R&D Systems, Minneapolis, MN). 
Stepwise multi-variable logistic regression was utilized to determine which biomarkers of 
inflammation independently differentiate a population of patients with advanced 
atherosclerotic cardiovascular disease from healthy volunteers at low risk for cardiovascular 
disease. Thus, this analysis facilitated the development of a phenotypic index of 
inflammation that captures the inflammatory response at multiple levels. In a univariate 
analysis, circulating concentrations of hs-CRP, MCP-1, ICAM-1 and E-selectin were all 
significantly higher in patients compared to healthy volunteers. ICAM-1 was highly 
correlated with E-selectin (rs=0.57, P<0.01) and modestly correlated with hs-CRP (rs=0.24, 
P<0.01). All other biomarkers included in the model were not significantly correlated with 
each other. In a multi-variable logistic regression model, hs-CRP (odds ratio 1.49, P=0.03), 
MCP-1 (odds ratio 4.28, P=0.06), and ICAM-1 (odds ratio 8.09, P<0.01) remained predictors 
of CAD status at the pre-defined α of 0.10. Accordingly, an inflammation score was created 
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in which subjects were assigned one point for each elevated (> median) biomarker of 
inflammation that was a significant predictor of CAD status (hs-CRP, MCP-1, and ICAM-1). 
The inflammation score was subsequently found to be significantly higher in subjects with 
CAD in this cohort of patients with established stable CAD and healthy volunteers with no 
cardiovascular risk factors (Figure 1), suggesting it represents biological mediators of 
inflammation that are key in the pathology of CAD. 
This data reduction process allows us to have an index of inflammation that captures the 
inflammatory response at multiple levels, and thus is a more complete phenotypic index of 
inflammation than individual biomarkers. Consequently, this inflammation score was used as 
a comprehensive phenotypic index of inflammation to characterize the association between 
advanced inflammation and the presence and severity of obstructive CAD in the SAMARA 
cohort. 
 
Quantification of Circulating Biomarkers of Inflammation 
Plasma concentrations of hs-CRP, ICAM-1 and MCP-1 were quantified, and the 
inflammation score was calculated in 143 participants in the SAMARA cohort. ICAM-1 and 
MCP-1 were quantified using the Human Adhesion Molecule and Human Cytokine 
Fluorokine® Multi-Analyte Profiling Kits (R&D Systems, Minneapolis, MN), respectively. hs-
CRP was quantified using the Human C-Reactive Protein Fluorokine® MAP kit for use in 
Cardiac Panel B. All analytes were quantified with fluorescence detection on the Bio-Plex 
200 System (Bio-Rad, Hercules, CA) according to the manufacturer’s instructions. The 
inflammation score was calculated as described above, assigning subjects one point for 
each elevated (> median) biomarker of inflammation (hs-CRP, MCP-1, and ICAM-1).  
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CAD Severity 
Subjects underwent diagnostic left-heart catheterization as part of their routine medical 
care. Following the procedure, CAD severity was quantified in each subject by coronary 
angiography by calculating a CAD score as follows: 0 (<10% stenosis in all major coronary 
arteries); 1 (10-70% stenosis in at least one vessel); 2 (>70% stenosis in one vessel); 3 
(>70% stenosis in two vessels); and, 4 (>70% stenosis in 3 vessels or >70% stenosis in the 
left-main coronary artery).  
Obstructive CAD was defined as >70% stenosis in ≥1 major epicardial coronary artery 
(CAD score 2-4). Subjects with ≤70% occlusion in any vessel (CAD score 0-1) were 
considered free of obstructive CAD and thus were utilized as the comparator group. 
 
Statistical Analysis 
The association between the inflammation score and CAD score was evaluated using an 
unadjusted regression model and a model that adjusted for potential demographic (age, 
race, gender) and clinical (obesity, diabetes mellitus, hyperlipidemia, statin use) 
confounders that associated with biomarkers of inflammation or obstructive CAD status in 
the SAMARA cohort. Similarly, the inflammation score was compared in subjects with and 
without obstructive CAD using both the unadjusted and adjusted regression models. A 
secondary analysis compared the proportion of subjects with an inflammation score of 0, 1, 
2, or 3 in individuals with and without obstructive CAD using a Chi-square analysis. 
 
Results 
The inflammation score was not significantly associated with CAD score or the presence 
of obstructive CAD in this population of older individuals in either the unadjusted or adjusted 
model (Table 1). Similarly, the proportion of individuals with an inflammation score of 0, 1, 2, 
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or 3, was not significantly different in individuals with obstructive CAD compared to 
individuals without obstructive CAD (p=0.236, Figure 2).  
 
Discussion 
Systemic and vascular inflammation are important in the development and progression 
of coronary artery disease (CAD) in the general population.1, 2 However, our analysis of 
candidate circulating inflammatory biomarkers in older adults did not demonstrate a 
significant association between higher levels of circulating inflammatory biomarkers and the 
presence and severity of obstructive CAD (Chapter II). Therefore we developed a 
comprehensive phenotypic index of inflammation “inflammation score” in order to more 
rigorously evaluate the association between systemic and vascular inflammation and 
obstructive CAD in older adults. The inflammation score was a significant predictor of CAD 
status in a younger population of stable, angiographically confirmed CAD patients compared 
to healthy volunteers with no CAD risk factors. However, this comprehensive phenotypic 
index of inflammation was not a significant predictor of the presence or severity of 
obstructive CAD in the SAMARA study, a more heterogeneous population of older 
individuals. These findings suggest that the inflammation score has little clinical utility for 
assessment of the presence of cardiovascular disease, or disease progression, in this 
patient population. 
 
Conclusions 
Our analysis in older adults did not demonstrate a significant association between a 
comprehensive inflammation score that captures the inflammatory response at multiple 
levels and the presence and severity of obstructive CAD. These findings highlight the need 
for more advanced and unbiased methods to identify key processes underlying the 
development and progression of obstructive CAD in older adults. 
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Tables 
Table 1. Association between CAD score and obstructive CAD status and the inflammation 
score. 
Analyte Parameter Standard Partial R2 P 
  Estimate Error 
CAD Score 
Unadjusted 0.057 0.066 0.005 0.388  
Adjusted 0.075 0.074 0.008 0.312 
Obstructive CAD 
Unadjusted 0.168 0.190 0.006  0.376 
Adjusted 0.253 0.208 0.001 0.225 
Adjusted model: adjusted for age, race, gender, obesity, diabetes mellitus, hyperlipidemia, 
statin use. 
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Figures 
 
Figure 1. Development of a multivariate inflammation score that is predictive of CAD 
status. 
The percentage of individuals with stable obstructive CAD (oCAD, black bars) and healthy 
volunteers (HV, white bars) having an inflammation score of 0, 1, 2, or 3. CAD is significantly 
higher in subjects with higher inflammation scores (Chi-Square P<0.0001). 
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Figure 2. Inflammation Score by CAD status in the SAMARA cohort. 
The percentage of individuals with obstructive CAD (oCAD, black bars) and individuals 
without an obstructive CAD diagnosis (No oCAD, white bars) having an inflammation score 
of 0, 1, 2, or 3 is displayed (Chi-Square p=0.236). 
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APPENDIX II 
BEYOND STATINS:  LIPID MANAGEMENT TO REDUCE CARDIOVASCULAR RISK2 
 
Abstract 
 
The discovery that elevated total cholesterol levels and the subsequent understanding that 
low-density lipoprotein cholesterol levels are associated with higher risk for cardiovascular 
disease (CVD) has led to the development of lipid management strategies that seek to 
reduce the burden of CVD. Whereas substantive progress has been made in reducing death 
and cardiovascular events, questions remain regarding the optimal approach to further 
reduce CVD-associated death and disability. Based on current evidence, statins are the 
clear first-line agents for the management of hyperlipidemia in patients at high risk for 
cardiovascular events. However, due to the failure of recent clinical trials evaluating 
antihyperlipidemic drugs, the most appropriate lipid management strategy in patients who 
cannot tolerate statin medications or who warrant antihyperlipidemic therapies in addition to 
statins is a major therapeutic controversy. In this review, we summarize the clinical trial 
evidence evaluating the efficacy of second-line antihyperlipidemic drug classes for reducing 
cardiovascular risk, provide recommendations for appropriate use of nonstatin lipid-altering 
drugs, and identify key areas of future research to support evidence-based lipid 
management. Given the complexity, magnitude, and burden of CVD, opportunities to 
improve processes of care and identify new therapeutic options clearly exist. 
 
 
                                               
2
 Schuck RN, Mendys PM, Simpson RJ Jr., Pharmacotherapy, 2013. 
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Introduction 
Since the discovery that elevated total cholesterol levels and the subsequent 
understanding that low-density lipoprotein (LDL) cholesterol levels are associated with 
higher risk for cardiovascular disease (CVD), scientists and clinicians have worked to 
develop a lipid management strategy to reduce the burden of CVD using a range of 
epidemiological, basic science, and clinical studies. Although we have made substantial 
progress in reducing death and cardiovascular events, questions remain regarding the 
optimal approach to further reduce death and disability associated with CVD, which is the 
leading cause of morbidity and mortality in the United States.1 It is well established that 
elevated circulating levels of LDL cholesterol are associated with higher risk of developing 
CVD and poor clinical outcomes in patients with established coronary disease.2 
Furthermore, numerous clinical trials have demonstrated that lowering LDL cholesterol 
improves clinical outcomes. 
The evidence generated in clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors (statins) convincingly supports their efficacy to improve clinical 
outcomes in patients at high risk for cardiovascular events according to National Cholesterol 
Education Program Adult Treatment Panel (ATP) III guidelines.3  The initial statin trials 
demonstrated that statins reduce cardiovascular events compared to placebo in primary and 
secondary prevention populations with elevated LDL cholesterol levels.4-6 Subsequently, 
trials showed that high-dose statin therapy is associated with greater benefit than low-dose 
statin therapy,7, 8 and more recent trials have demonstrated that statins are beneficial even 
in the range of LDL cholesterol levels that were not previously considered elevated.9 In 
addition, statins have been shown to reduce the risk of stroke after an acute coronary 
syndrome or stroke or transient ischemic attack.10, 11 Although the cost-effectiveness of 
statins in low-risk populations has been questioned,12 based on numerous clinical trials 
demonstrating their ability to reduce cardiovascular events, statins have become the clear 
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first-line antihyperlipidemic agents for prevention of adverse outcomes both in primary and 
secondary prevention populations. In addition, the availability of inexpensive generic 
formulations of potent statins in recent years has made statin use cost-effective in patients 
with a 10-year risk of coronary heart disease (CHD) as low as 5%13; however, the most 
appropriate second-line class of agents remains highly controversial. 
The association between LDL cholesterol and coronary artery disease (CAD) has been 
established in epidemiological and genetic studies as well as clinical trials, and LDL 
cholesterol is integral to the pathophysiology of atherosclerosis.14 Therefore, the ATP III 
guidelines issued by the National Cholesterol Education Program support the practice of 
lowering LDL cholesterol to goal levels based on patient risk for cardiovascular events.15, 16 
However, the clinical trials from which these goals were ascertained evaluated fixed-dose 
statin therapy rather than dose titration to achieve target levels. Although the efficacy and 
safety of treating patients to target LDL cholesterol levels has not been directly evaluated, 
treatment with fixed-dose statin therapy has reduced cardiovascular risk in multiple trials.17 
This has led some experts to conclude that LDL cholesterol goals are not evidence based 
and should not be used to guide clinical decision making.18 New guidelines supported by the 
National Heart, Lung, and Blood Institute (which supports the development of the ATP 
guidelines) will be more narrowly focused and rely solely on recommendations from detailed 
systematic reviews of the available evidence.19 Thus, the upcoming ATP IV guidelines will 
focus heavily on evidence generated from randomized controlled clinical trials. However, 
new guidelines will likely allow for clinical judgment in lipid management, meaning nonstatin 
lipid-modifying agents will continue to have a role in risk reduction, and due to recent clinical 
trials that have failed to demonstrate improved clinical outcomes with antihyperlipidemic 
therapies such as niacin, fibrates, and omega-3 fatty acids, the most appropriate second-
line antihyperlipidemic drug therapies will remain unclear.20-22 Therefore, the objective of this 
review is to summarize the clinical trial evidence evaluating the efficacy of second-line 
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antihyperlipidemic drug classes in reducing cardiovascular risk, provide recommendations 
for appropriate use of nonstatin lipid-altering drugs where clear evidence is lacking, and 
identify key areas of future research to support evidence-based lipid management. 
 
Literature Search 
English-language articles published through July 2012 were identified through the 
PubMed and Cochrane databases. Relevant ongoing trials were identified by searching 
www.ClinicalTrials.gov. Articles were identified by using the search terms statin, niacin, 
ezetimibe, fenofibrate, gemfibrozil, clofibrate, fibrate, cholestyramine, colestipol, 
colesevelam, bile acid sequestrant, omega-3 fatty acid, cholesterol ester transfer protein, 
proprotein convertase subtilisin/kexin 9, and clinical outcomes. Additional articles were 
identified through review of the reference sections of pertinent manuscripts. All English-
language studies identified that evaluated the effect of niacin, ezetimibe, fibrates, bile acid 
sequestrants, or omega-3 fatty acids on clinical outcomes in patients at high risk for CVD 
events were assessed. Articles evaluating the efficacy of investigational or emerging 
therapeutics were also included. 
 
Niacin 
Niacin exerts its effects through inhibition of diacylglycerol acyltransferase-2, which 
decreases triglyceride synthesis, resulting in degradation of hepatic apolipoprotein B and 
lower circulating LDL cholesterol levels.23 In addition, niacin reduces hepatic catabolism of 
high-density lipoprotein (HDL) cholesterol and is the most effective agent available for 
increasing HDL cholesterol levels.23 Niacin results in a mean reduction in total cholesterol 
levels of 10%, LDL cholesterol levels of up to 15%, and triglycerides of 28% while increasing 
HDL cholesterol levels 23%.24 The potent HDL cholesterol–raising effects of niacin make it a 
commonly prescribed agent for patients with suboptimal HDL cholesterol levels.  
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The first study to evaluate the effect of niacin on clinical outcomes was the Coronary 
Drug Project. Between 1966 and 1969 the Coronary Drug Project enrolled men with a 
history of myocardial infarction (MI) and randomized them to one of five lipid-lowering 
regimens or placebo. In the niacin arm of the study, immediate-release niacin 3000 mg daily 
reduced the incidence of nonfatal MI by 27% compared to placebo but showed no effect on 
the primary outcome of all-cause mortality.25 However, an analysis of mortality data 
including fifteen years of patient follow-up was conducted nine years after trial 
discontinuation and showed a significant 11% reduction in all-cause mortality compared to 
placebo.26  
The introduction of extended-release niacin products, which have fewer adverse effects, 
has renewed interest in niacin, and numerous clinical trials have evaluated extended-
release niacin formulations. Multiple trials designed to assess surrogate endpoints have 
suggested that extended-release niacin may improve clinical outcomes in certain patient 
populations.27-29 These findings are hypothesis generating and warrant follow-up with larger 
clinical trials; however, clinicians should be cautioned not to overinterpret the results from 
these small trials of short duration, which were not designed to evaluate clinical outcomes. 
The Atherothrombosis Intervention in Metabolic Syndrome with Low HDL Cholesterol/High 
Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial failed to show an 
improvement with extended-release niacin compared to placebo.20 The AIM-HIGH trial 
enrolled patients with established CAD and an atherogenic lipid profile (defined as HDL 
cholesterol levels <40 mg/dL for men or <50 mg/dL for women, triglyceride levels 150-400 
mg/dL, and LDL cholesterol levels <180 mg/dL if not receiving a statin) and randomized 
them to simvastatin plus either niacin 1500-2000 mg daily or placebo (which contained 50 
mg of niacin to help maintain blinding). After three years of follow-up, the trial was stopped 
early due to lack of efficacy and a higher number of ischemic stroke events in patients 
receiving niacin. No significant difference was observed in the primary endpoint (composite 
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of death from CHD, nonfatal MI, ischemic stroke, hospitalization for an acute coronary 
syndrome, or symptom-driven coronary or cerebral revascularization) which occurred in 282 
patients (16%) receiving niacin and 274 patients (16%) receiving placebo.20 
The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular 
Events (HPS2-THRIVE [NCT00461630]) was designed to assess the effect of niacin-
laropiprant (a prostaglandin D2 receptor antagonist that reduces the incidence of flushing) on 
the primary outcome of nonfatal MI or coronary death, nonfatal or fatal stroke, or 
revascularization procedure. HPS2-THRIVE randomized over 25,000 patients to simvastatin 
40 mg daily plus niacin-laropiprant or placebo. Preliminary results were released in 
December 2012, and indicate that the combination of  niacin-laropiprant is not more 
effective than placebo.30 These disappointing results are consistent with AIM-HIGH another 
study  powered to evaluate clinical outcomes in patients receiving niacin while optimized on 
statin therapy.   
In summary, clinical trials show that niacin effectively lowers LDL cholesterol and raises 
HDL cholesterol levels. Immediate-release niacin monotherapy has been shown to improve 
clinical outcomes, whereas studies demonstrating improved outcomes when niacin is used 
in combination with a statin are lacking, and although niacin is commonly prescribed to raise 
HDL cholesterol, the results of the AIM-HIGH trial demonstrate that this strategy does not 
improve clinical outcomes. Therefore, current data support the use of niacin to lower LDL 
cholesterol; however, as the use of niacin to raise HDL cholesterol levels has been 
evaluated and does not improve patient outcomes, it is not recommended. 
 
Ezetimibe 
Ezetimibe exerts its effects at the brush border of the small intestine through inhibition of 
Niemann–Pick C1-Like 1 (NPC1L1), a key mediator of cholesterol absorption.31 Inhibition of 
NPC1L1 decreases cholesterol absorption and causes a compensatory increase in 
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cholesterol synthesis.32 The net effect is a mean 19% reduction in LDL cholesterol and 4% 
increase in HDL cholesterol, with no significant changes in triglycerides.33  Ezetimibe is 
commonly prescribed to lower LDL cholesterol levels in patients who have not achieved 
therapeutic goals despite optimization of statin therapy and to patients who are intolerant to 
statins. There are currently no clinical trials evaluating the effect of ezetimibe monotherapy 
on cardiovascular outcomes; however, the effect of ezetimibe in combination with 
simvastatin was investigated in the Study of Heart and Renal Protection (SHARP) trial, 
which compared ezetimibe 10 mg plus simvastatin 20 mg daily to placebo in patients with 
moderate-to-severe chronic kidney disease.34 Patients receiving ezetimibe plus simvastatin 
had significantly lower incidence of the primary composite outcome of nonfatal MI or 
coronary death, nonhemorrhagic stroke, or any arterial revascularization procedure. 
However, the SHARP trial did not have a simvastatin monotherapy group, making it 
impossible to distinguish the effects of ezetimibe therapy from the effects of statin therapy. It 
should be noted that a higher incidence of cancer was observed in the simvastatin plus 
ezetimibe group in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, raising 
fears that ezetimibe use may be associated with increased cancer risk.35 A meta-analysis 
published in 2008, which used data from SEAS, SHARP, and Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), did not find that ezetimibe was 
associated with increased cancer risk.36 At the time of publication, SHARP and IMPROVE-IT 
did not have complete follow-up; however, the final analysis of the SHARP did not report 
any association with cancer, suggesting that ezetimibe use is not associated with increased 
cancer risk.34 The IMPROVE-IT trial is scheduled for completion in June 2013 and will 
compare simvastatin monotherapy to simvastatin plus ezetimibe in high-risk patients after an 
acute coronary syndrome.37, 38 The primary outcome is the composite of cardiovascular 
death, nonfatal MI, hospitalization for unstable angina, revascularization, or stroke.. This 
direct comparison of simvastatin to a more intense lipid-lowering regimen of simvastatin plus 
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ezetimibe will provide much-needed evidence regarding the efficacy and safety of ezetimibe 
as an adjunct to statin therapy for reducing cardiovascular events in high-risk patients.  
Collectively, the currently available evidence indicates ezetimibe is a safe and effective 
agent to lower LDL cholesterol as monotherapy or in combination with statin therapy; 
however, there are no clinical trials demonstrating that ezetimibe alone or as an adjunct 
therapy in combination with a statin improves clinical outcomes. Based on current data, the 
use of ezetimibe should be limited to patients who the clinician feels warrant additional LDL 
cholesterol lowering and who are either at their maximum-tolerated statin dose or are unable 
to adhere to statin therapy after multiple attempts. 
 
Fibrates 
Fibrates activate peroxisome proliferator-activated receptor α (PPARα),39, 40 increasing 
transcription of multiple genes involved in cholesterol metabolism, including fatty acid–
binding proteins.41, 42 Transcription of fatty acid–binding proteins leads to an increase in 
lipolysis, induction of fatty acid uptake by the liver, reduction in triglyceride production, and 
an increase in HDL cholesterol production.43 Fibrates produce a mean reduction of 15-20% 
in total cholesterol level, 32-45% in triglyceride level, and 3-20% in LDL cholesterol level, 
and a mean increase in HDL cholesterol of 6-16% in hyperlipidemic patients.44, 45 As a result 
of their potent triglyceride-lowering effects, fibrates are frequently prescribed for patients 
with elevated triglyceride levels. 
Clofibrate was developed in the 1960s whereas gemfibrozil and fenofibrate were 
developed more recently.  Fibrates have been evaluated in multiple clinical trials, with 
inconsistent results. The World Health Organization study compared clofibrate to placebo in 
apparently healthy men with elevated cholesterol levels, and the clofibrate group had a 
lower incidence of major ischemic heart disease, which was driven by a lower incidence of 
nonfatal MI but had higher overall mortality rates.46 These findings persisted in a follow-up 
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report that covered more than nine years of observation.47 In addition, the clofibrate arm of 
the Coronary Drug Project trial did not show a significant difference in mortality or the 
combined endpoint of death due to coronary heart disease or occurrence of definite, 
nonfatal MI in patients receiving clofibrate compared to patients receiving placebo.25 
Similarly, no significant findings were observed in the fifteen-year follow-up study.26  
The Helsinki Heart Study randomized 4081 apparently healthy men with non-HDL 
cholesterol ≥ 200 mg/dL to gemfibrozil 1200 mg daily or placebo. Use of gemfibrozil was 
associated with a significant 34% reduction in the incidence of CHD; however, no significant 
difference in mortality was observed.48 In addition, the Veterans Affairs Cooperative Studies 
Program High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) compared of 
gemfibrozil 1200 mg daily to placebo in men with a history of CHD; the primary composite 
outcome was incidence of nonfatal MI or death from CHD. Subjects randomized to placebo 
experienced 275 events (22%) whereas those randomized to gemfibrozil had 219 events 
(17%), representing a significant 22% relative risk reduction. Gemfibrozil use was also 
associated with nonsignificant reductions in death from CHD (22%, P=0.07) and overall 
mortality (11%, P=0.23).49 The Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study assessed the efficacy of fenofibrate in patients with type 2 diabetes (with or 
without existing coronary disease). In contrast to the Helsinki Heart Study and VA-HIT trials, 
randomization to micronized fenofibrate 200 mg daily did not significantly reduce the primary 
composite outcome of CHD death or nonfatal MI; however, a significant reduction in the 
secondary composite outcome of cardiovascular death, MI, stroke, and coronary and carotid 
revascularization was observed (11% relative risk reduction; P=0.04).50 Similarly, the Action 
to Control Cardiovascular Risk in Diabetes (ACCORD) lipid study compared fenofibrate 165 
mg daily to placebo in patients with type 2 diabetes at high risk for CVD who were also 
being treated with simvastatin; no significant difference was observed in the primary 
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outcome of first occurrence of a major cardiovascular event.21 A possible benefit in patients 
with high triglyceride levels and low HDL cholesterol levels was noted by the authors. 
In summary, early trials evaluating fibrate monotherapy suggested that fibrates may 
improve clinical outcomes in men at moderate-to-high risk for CHD; however, more recent 
trials evaluating fibrates (with or without statin therapy) have not shown compelling evidence 
of benefit. Based on the current literature, we do not recommend the use of fibrates to lower 
LDL cholesterol, alone or in combination with a statin, unless other medications are not 
tolerated by the patient. The efficacy of fibrates in certain subsets of dyslipidemia, including 
individuals with high triglyceride and low HDL cholesterol levels, warrants clinical trial 
evaluation in order to define a clear role for fibrates in treatment of dyslipidemias. 
 
Bile Acid Sequestrants 
Bile acid sequestrants (BAS) include cholestyramine, colestipol, and colesevelam. 
These agents block bile acid reabsorption and reduce its recirculation to the liver, increasing 
conversion of cholesterol to bile acid through the LDL receptor pathway and lowering 
circulating LDL cholesterol levels.51, 52 BAS result in a mean reduction in total cholesterol of 
up to 14% and LDL cholesterol of up to 21% while increasing HDL cholesterol 3% and 
triglycerides 2-5%.53 Despite a positive effect on the overall lipid profile, BAS are not 
commonly prescribed secondary to multiple drug interactions and poor patient tolerance 
resulting in their frequent discontinuation.54  
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was one of 
the first studies to convincingly demonstrate that reduction of circulating cholesterol levels 
with pharmacological agents could improve clinical outcomes in patients at high risk for 
CHD. Beginning in 1973, LRC-CPPT recruited 3806 men with elevated total and LDL 
cholesterol levels and no clinical manifestations of CHD. Individuals randomized to 
cholestyramine 24 g daily had a 19% reduction in the primary composite endpoint of definite 
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CHD death and/or definite nonfatal MI; however, all-cause mortality was not significantly 
different.55 Similarly, in an early study of colestipol in 2278 patients with elevated total 
cholesterol levels, colestipol 5 g daily reduced CHD mortality compared to placebo in men 
but not in women.56  
In summary, BAS have been shown to improve clinical outcomes when used as 
monotherapy, but have not been evaluated in combination with statin therapy. Currently, the 
use of BAS is limited due to their poor tolerability and frequent discontinuation by patients,54 
multiple drug interactions, and lack of trials demonstrating effectiveness when used in 
combination with statins. However, based on the currently available evidence, BAS are a 
reasonable choice to lower LDL cholesterol, either alone or in combination with a statin, in 
patients who are able to adhere to therapy. Additional trials are needed to determine if BAS 
improve clinical outcomes in patients receiving statin therapy in order to better define their 
appropriate role in cholesterol management.  
 
Omega-3 Fatty Acids 
Although omega-3 fatty acids (eicosapentaenoic acid–docosahexaenoic acid; EPA-DHA) 
do not lower LDL cholesterol, dietary supplementation with fish oils or use of prescription 
omega-3 acid ethyl esters is common in patients at high risk for cardiovascular events and in 
patients with elevated triglyceride levels. Although the mechanisms underlying the effects of 
omega-3 fatty acids on cholesterol profiles are not completely understood, they are known 
to reduce hepatic very low–density lipoprotein (VLDL) cholesterol and triglyceride synthesis 
and secretion as well as increase triglyceride clearance.57 When taken in combination with 
statin therapy, prescription omega-3 acid ethyl esters produce a median decrease in total 
cholesterol of 5%, increases in LDL cholesterol of 1% and HDL cholesterol of 3%, and a 
30% decrease in triglycerides.58 Interestingly, there is evidence that purified EPA (icosapent 
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ethyl), which was recently approved for use in the United States, does not increase LDL 
cholesterol and actually reduces these levels.59  
Studies evaluating omega-3 fatty acid supplementation include the Gruppo Italiano per 
lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI) trial, which enrolled post-MI 
patients between 1993 and 1995. The GISSI trial showed that supplementation of EPA-DHA 
resulted in a significant 10% reduction in risk for the combined primary endpoint of death, 
nonfatal MI, and nonfatal stroke (P<0.05); however, less than 5% of patients were taking 
statins at study entry.60 The Japan EPA Lipid Intervention Study (JELIS) randomized 
Japanese patients with elevated cholesterol levels to statin therapy alone (pravastatin 10 
mg/day or simvastatin 5 mg/day) or EPA plus a statin. The combined endpoint of major 
coronary events was reduced 19% in the EPA group (P=0.01), demonstrating that EPA 
supplementation can reduce cardiovascular morbidity when used in combination with statin 
therapy.61 However, it should be noted that the statin doses were much lower than those 
currently used in clinical practice in the United States, and the study exclusively enrolled 
Japanese patients, who have high dietary consumption of omega-3 fatty acids. The Alpha 
Omega Trial randomized patients who had experienced an MI within the previous 10 years 
to supplementation with omega-3 fatty acids or placebo and showed no difference in the 
primary endpoint of major cardiovascular events.62 Similarly, the OMEGA trial randomized 
patients with a recent MI who were receiving current standard of care treatments to omega-3 
acid ethyl esters or placebo and showed no difference in the primary endpoint of rate of 
sudden cardiac death.22 Omega-3 fatty acid supplementation was also evaluated in a 
population at high risk for cardiovascular events who had impaired fasting glucose, impaired 
glucose tolerance, or diabetes mellitus in the Outcome Reduction with an Initial Glargine 
Intervention (ORIGIN) trial. No significant reduction was noted in the primary outcome of 
death from cardiovascular causes (9.1% vs. 9.3%) or the secondary endpoint of major 
vascular events (16.5% vs. 16.3%) in patients randomized to omega-3 fatty acids compared 
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to patients randomized to placebo.63 Of note, statin use was highly prevalent in both the 
Alpha Omega and OMEGA trials, with greater than 80% of subjects receiving statins, and to 
a lesser extent the ORIGIN trial, with over 50% of patients receiving statins. The negative 
results of these trials raise concerns regarding the efficacy of omega-3 acid ethyl esters 
when used in patients who are optimized on statin therapy. In addition, a recent meta-
analysis of trials evaluating the effect of omega-3 fatty acid supplementation on risk of major 
CVD events did not show a significant reduction in all-cause mortality, cardiac death, or any 
cardiovascular events.64 The Reduction of Cardiovascular Events Outcomes Trial 
(REDUCE-IT) will assess the effectiveness of purified EPA to improve cardiovascular 
outcomes in high-risk patients with elevated triglycerides who are optimized on statin 
therapy. Collectively, clinical trials have demonstrated that omega-3 acid ethyl esters are 
safe and may reduce the risk of cardiovascular events in certain populations. Additional 
clinical trials are necessary to evaluate potential disparities in the effects of purified EPA and 
EPA-DHA on cardiovascular outcomes.  
 
Roles of Antihyperlipidemic Drug Classes Beyond the First-Line Statins in Reducing 
Cardiovascular Risk 
 
Cardiovascular disease remains a major public health problem in the United States and 
other developed countries, and reduction of LDL cholesterol improves prognosis in patients 
at high risk for cardiovascular events. Based on current evidence, statins will remain the 
first-line therapy of choice for the foreseeable future; however, the roles of 
antihyperlipidemic drug classes beyond statins remains unclear. New treatment guidelines 
will continue to place an emphasis on evidence-based data to support recommendations, 
making the optimal second-line therapeutic regimen controversial due to recent clinical trials 
assessing antihyperlipidemic therapies that have not demonstrated a benefit. Given the 
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significant number of patients unable to adhere to statin therapy due to the occurrence of 
drug-related adverse events, particularly at high doses,65 and the persistence of high LDL 
cholesterol levels in some patients receiving high-dose statins, second-line 
antihyperlipidemic medications will continue to represent an unmet medical need in the 
management of patients at high risk for cardiovascular events.  
Given the evidence base supporting their use in reducing cardiovascular events, it is 
important that patients be given an adequate trial of statin therapy and titrated to maximum-
tolerated doses prior to adding adjunctive therapies to achieve desired LDL cholesterol 
levels. In addition, all patients should be counseled on proper diet and exercise regimens to 
reduce cardiovascular risk. When initiating statin therapy, we recommend that you 
thoroughly counsel patients on the known risks and benefits of treatment, and provide 
focused education to build long-term adherence to therapy. It is important to review past 
experience with specific agents and acknowledge issues of formulary access and patient 
preferences in order initiate the statin regimen that patients are most likely to accept. In 
cases of past experience of statin intolerance, it may be necessary to employ alternate-day 
dosing or thrice-weekly dosing and gradually increase the frequency and dose as needed to 
optimize treatment benefits.66   
In high-risk patients who require LDL cholesterol–lowering therapy but are unable to 
tolerate statin therapy in spite of adequate trials with more than one agent, we generally 
recommend ezetimibe or niacin as an LDL cholesterol–lowering approach. Although 
ezetimibe is lacking clinical outcomes data in support for its use, it is well tolerated and 
effectively lowers LDL cholesterol. Niacin and BAS also effectively lower LDL cholesterol 
and each has been shown to improve clinical outcomes in CAD patients, making them 
reasonable evidence-based choices that should be considered in all patients who require a 
second-line antihyperlipidemic therapy. 25, 26, 55 However, it should be noted that the 
Coronary Drug Project used an immediate-release formulation of niacin, and both the 
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Coronary Drug Project and LRC-CPPT were conducted when the standard of care in 
cardiology was vastly different than it is today. Given the issues of potential intolerance with 
niacin and BAS,54 ezetimibe is a practical choice in select patients in whom the clinician 
feels that LDL cholesterol lowering is warranted and other medications are not tolerated.  
A significant number of patients will either fail to achieve adequate LDL cholesterol 
lowering or experience cardiovascular events in spite of adhering to high-dose statin 
therapy. Although several antihyperlipidemic drugs have been evaluated in combination with 
statin therapy, to date, none have demonstrated improved outcomes when compared to 
placebo (Table 1).20, 21, 34, 38 As with patients who are unable to tolerate statin therapy, 
ezetimibe and niacin are effective agents to lower LDL cholesterol levels in patients already 
receiving a statin. The IMPROVE-IT trial will provide much-needed data evaluating the 
efficacy of ezetimibe to improve clinical outcomes when used in combination with statin 
therapy. Niacin effectively lowers LDL cholesterol in patients treated with statins and may 
improve outcomes in this patient population; however, clinical trials evaluating niacin in 
combination with statin therapy have been limited to patients who have achieved adequate 
LDL cholesterol lowering but have low HDL cholesterol levels. Since the currently available 
evidence from these trials has demonstrated that niacin does not improve clinical outcomes 
when prescribed to raise HDL cholesterol, this practice is not evidence based and therefore 
is not recommended. Similar to ezetimibe and niacin, BAS effectively lower LDL cholesterol 
but have not been shown to improve outcomes when used in combination with statins; they 
remain a reasonable choice in patients who are able to maintain adherence when the 
clinician feels that combination therapy to lower LDL cholesterol is warranted. Fibrates have 
been evaluated in patients receiving statin therapy and have failed to improve clinical 
outcomes; therefore, the use of fibrates is not recommended unless patients are unable to 
tolerate alternative agents. Although omega-3 fatty acids do not lower LDL cholesterol 
levels, they have been shown to improve clinical outcomes in CAD patients in some studies; 
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however, clinical trials evaluating omega-3 fatty acids in combination with statins have not 
demonstrated benefit, and therefore their routine use is not recommended in the absence of 
elevated triglyceride levels. It should be noted that purified EPA has been shown to 
decrease LDL cholesterol levels, and the differing effects of purified EPA and EPA-DHA 
may impact clinical outcomes. The ongoing REDUCE-IT trial will provide data evaluating the 
effects of purified EPA on cardiovascular outcomes.  
The substantial residual risk of cardiovascular events in patients receiving standard of 
care therapy highlights the need for improved lipid management strategies to reduce 
cardiovascular risk. Several novel therapeutic strategies are currently under investigation 
such as cholesterol ester transfer protein (CETP) and proprotein convertase subtilisin–kexin 
9 (PCSK9) inhibition. To date, two CETP inhibitors have failed phase III clinical trials.67, 68 
The ongoing Randomized Evaluation of the Effects of Anacetrapib Through Lipid-
Modification (REVEAL) trial (Table 1) will provide additional insight into the clinical utility of 
CETP inhibitors (NCT01252953). The development of PCSK9 inhibitors is still in its infancy; 
however, results from phase I trials are encouraging.69 These investigational agents require 
rigorous evaluation in clinical trials to evaluate their safety and efficacy prior to FDA 
approval and use in lipid management. In addition to the investigation of new drug targets 
and therapies, current and future research efforts should focus on improving the precision in 
which we assess risk. This includes clarification of the role of traditional biomarkers of 
cardiovascular risk including LDL cholesterol, HDL cholesterol, and triglyceride levels, and 
investigation of additional biomarkers such as apolipoprotein B, LDL cholesterol particle 
size, and biomarkers of inflammation. In addition, a personalized medicine approach using 
genetic or physiologic biomarker data may prove more efficacious in the management of 
CVD than current lipid management strategies, which are based on global risk.  
In summary, the currently available evidence clearly supports the use of statins as the 
first-line lipid management strategy to lower LDL cholesterol levels and reduce 
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cardiovascular risk, whereas alternative antihyperlipidemic agents have less evidence 
supporting their ability to improve clinical outcomes. It should be noted that LDL cholesterol 
levels are a surrogate marker for cardiovascular risk, and the degree of LDL lowering may 
be an indirect marker of drug efficacy. However, use of second-line agents to achieve 
adequate LDL cholesterol lowering is reasonable in patients who are unable to tolerate 
statins or who do not achieve desired cholesterol levels while taking maximum-tolerated 
doses of statins.15 Current and future research efforts will focus on novel therapeutics and 
risk-assessment strategies, including alternative biomarkers of cardiovascular risk and drug 
efficacy. Findings from these studies may ultimately improve the available selection of 
pharmacologic agents and challenge our current understanding of lipid management. 
 
Conclusion 
We have summarized the current evidence supporting the use of second-line 
antihyperlipidemic therapies, provided clinical recommendations for the appropriate use of 
these therapies, and identified important areas for future research in order to improve lipid-
based management of patients and reduce the burden of CVD. Given the complexity, 
magnitude, and burden of CVD, opportunities to improve processes of care and identify new 
therapeutic options clearly exist.   
 181 
 
Appendix II References 
1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 
update: a report from the American Heart Association. Circulation 2012;125:e2-e220. 
2. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in 
relation to cholesterol level among men with and without preexisting cardiovascular 
disease. N Engl J Med 1990;322:1700-1707. 
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering 
treatment: prospective meta-analysis of data from 90,056 participants in 14 
randomised trials of statins. Lancet 2005;366:1267-1278. 
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart 
disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-
1389. 
5. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with 
pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention 
Study Group. N Engl J Med 1995;333:1301-1307. 
6. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events 
with lovastatin in men and women with average cholesterol levels: results of 
AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. 
JAMA 1998;279:1615-1622. 
7. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in 
patients with stable coronary disease. N Engl J Med 2005;352:1425-1435. 
8. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid 
lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-
1504. 
9. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events 
in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-
2207. 
10. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early 
recurrent ischemic events in acute coronary syndromes: the MIRACL study: a 
randomized controlled trial. JAMA 2001;285:1711-1718. 
11. Amarenco P, Bogousslavsky J, Callahan A, 3rd, et al. High-dose atorvastatin after 
stroke or transient ischemic attack. N Engl J Med 2006;355:549-559. 
12. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of 
cardiovascular disease. Cochrane Database Syst Rev 2011:CD004816. 
 182 
 
13. Mitchell AP, Simpson RJ, Jr. Statin cost effectiveness in primary prevention a 
systematic review of the recent cost-effectiveness literature in the United States. 
BMC research notes 2012;5:373. 
14. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology 
of atherosclerosis. Nature 2011;473:317-325. 
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) final report. Circulation 2002;106:3143-3421. 
16. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the 
National Cholesterol Education Program Adult Treatment Panel III guidelines. 
Circulation 2004;110:227-239. 
17. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended 
low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 
2006;145:520-530. 
18. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein 
targets: an open letter to the Adult Treatment Panel IV of the National Institutes of 
Health. Circ Cardiovasc Qual Outcomes 2012;5:2-5. 
19. Jenkins CM, Cedars A, Gross RW. Eicosanoid signalling pathways in the heart. 
Cardiovasc Res 2009;82:240-249. 
20. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL 
cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-
2267. 
21. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 
2 diabetes mellitus. N Engl J Med 2010;362:1563-1574. 
22. Rauch B, Schiele R, Schneider S, et al. OMEGA, a randomized, placebo-controlled 
trial to test the effect of highly purified omega-3 fatty acids on top of modern 
guideline-adjusted therapy after myocardial infarction. Circulation 2010;122:2152-
2159. 
23. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 
2008;101:20B-26B. 
24. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): 
efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 
1998;82:29U-34U; discussion 39U-41U. 
25. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381. 
 183 
 
26. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug 
Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255. 
27. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or 
the combination for the prevention of coronary disease. N Engl J Med 
2001;345:1583-1592. 
28. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the 
Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a 
double-blind, placebo-controlled study of extended-release niacin on atherosclerosis 
progression in secondary prevention patients treated with statins. Circulation 
2004;110:3512-3517. 
29. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and 
carotid intima-media thickness. N Engl J Med 2009;361:2113-2122. 
30. Merck & Co., Inc. Merck Announces HPS2-THRIVE Study of TREDAPTIVE™ 
(Extended-Release Niacin/Laropiprant) Did Not Achieve Primary Endpoint. 
http://www.mercknewsroom.com/press-release/prescription-medicine-news/merck-
announces-hps2-thrive-study-tredaptive-extended-relea 
31. Garcia-Calvo M, Lisnock J, Bull HG, et al. The target of ezetimibe is Niemann-Pick 
C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005;102:8132-8137. 
32. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of intestinal cholesterol absorption 
by ezetimibe in humans. Circulation 2002;106:1943-1948. 
33. Bays HE, Moore PB, Drehobl MA, et al. Effectiveness and tolerability of ezetimibe in 
patients with primary hypercholesterolemia: pooled analysis of two phase II studies. 
Clin Ther 2001;23:1209-1230. 
34. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with 
simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart 
and Renal Protection): a randomised placebo-controlled trial. Lancet 2011;377:2181-
2192. 
35. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin 
and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356. 
36. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe 
trials. N Engl J Med 2008;359:1357-1366. 
37. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT 
(IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison 
of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular 
outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-832. 
 184 
 
38. Califf RM, Lokhnygina Y, Cannon CP, et al. An update on the IMProved reduction of 
outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. Am Heart J 
2010;159:705-709. 
39. Issemann I, Green S. Activation of a member of the steroid hormone receptor 
superfamily by peroxisome proliferators. Nature 1990;347:645-650. 
40. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, 
and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha 
and delta. Proc Natl Acad Sci USA 1997;94:4312-4317. 
41. Yadetie F, Laegreid A, Bakke I, et al. Liver gene expression in rats in response to the 
peroxisome proliferator-activated receptor-alpha agonist ciprofibrate. Physiol 
Genomics 2003;15:9-19. 
42. Yamazaki K, Kuromitsu J, Tanaka I. Microarray analysis of gene expression changes 
in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists. 
Biochem Biophys Res Commun 2002;290:1114-1122. 
43. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. 
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 
1998;98:2088-2093. 
44. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fenofibrate on plasma 
lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 
1987;83:50-59. 
45. Schaefer EJ, Lamon-Fava S, Cole T, et al. Effects of regular and extended-release 
gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic 
patients with decreased HDL cholesterol levels. Atherosclerosis 1996;127:113-122. 
46. A co-operative trial in the primary prevention of ischaemic heart disease using 
clofibrate. Report from the Committee of Principal Investigators. Br Heart J 
1978;40:1069-1118. 
47. W.H.O. cooperative trial on primary prevention of ischaemic heart disease using 
clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of 
Principal Investigators. Lancet 1980;2:379-385. 
48. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with 
gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in 
risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-
1245. 
49. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of 
coronary heart disease in men with low levels of high-density lipoprotein cholesterol. 
 185 
 
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. 
N Engl J Med 1999;341:410-418. 
50. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on 
cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD 
study): randomised controlled trial. Lancet 2005;366:1849-1861. 
51. Hashim SA, Vanitallie TB. Cholestyramine Resin Therapy for Hypercholesteremia: 
Clinical and Metabolic Studies. JAMA 1965;192:289-293. 
52. Slater HR, Packard CJ, Bicker S, Shepherd J. Effects of cholestyramine on receptor-
mediated plasma clearance and tissue uptake of human low density lipoproteins in 
the rabbit. J Biol Chem 1980;255:10210-10213. 
53. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The 
relationship of reduction in incidence of coronary heart disease to cholesterol 
lowering. JAMA 1984;251:365-374. 
54. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C. Discontinuation of lipid modifying 
drugs among commercially insured United States patients in recent clinical practice. 
Am J Cardiol 2007;99:530-534. 
55. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in 
incidence of coronary heart disease. JAMA 1984;251:351-364. 
56. Dorr AE, Gundersen K, Schneider JC, Jr., Spencer TW, Martin WB. Colestipol 
hydrochloride in hypercholesterolemic patients--effect on serum cholesterol and 
mortality. J Chronic Dis 1978;31:5-14. 
57. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and 
coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 
2008;197:12-24. 
58. Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding 
prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic 
patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 
2007;29:1354-1367. 
59. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and Safety of 
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Statin-Treated Patients 
With Persistent High Triglycerides (from the ANCHOR Study). Am J Cardiol 
2012;110:984-992. 
60. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after 
myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo 
Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999;354:447-455. 
 186 
 
61. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on 
major coronary events in hypercholesterolaemic patients (JELIS): a randomised 
open-label, blinded endpoint analysis. Lancet 2007;369:1090-1098. 
62. Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after 
myocardial infarction. N Engl J Med 2010;363:2015-2026. 
63. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular 
outcomes in patients with dysglycemia. N Engl J Med 2012;367:309-318. 
64. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between 
omega-3 fatty acid supplementation and risk of major cardiovascular disease events: 
a systematic review and meta-analysis. JAMA 2012;308:1024-1033. 
65. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll 
Cardiol 2007;49:1753-1762. 
66. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr 
Atheroscler Rep 2010;12:322-330. 
67. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk 
for coronary events. N Engl J Med 2007;357:2109-2122. 
68. Roche, Inc. Roche provides update on Phase III study of dalcetrapib [press release]. 
http://www.roche.com/media/media_releases/med-cor-2012-05-07.htm 
69. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to 
PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118.
  
 
1
8
7
 
Table 1. Summary of Clinical Trials Evaluating Combination Therapy with Statins 
Trial Population  Intervention Primary Outcome Results  
SHARP
34
 Patients with chronic Simvastatin + ezetimibe Nonfatal MI or coronary death, Simvastatin + 
 kidney disease vs. placebo nonhemorrhagic stroke, or ezetimibe reduced 
   revascularization primary outcome 
ACCORD
21
 Patients with type 2 Simvastatin + fenofibrate First occurrence of nonfatal MI, No significant difference 
 diabetes mellitus vs simvastatin + placebo nonfatal stroke, or death from in the primary outcome 
   cardiovascular causes 
AIM-HIGH
20
 Patients with CAD Simvastatin + niacin Death from CHD, nonfatal MI, Stopped early due to 
 and an atherogenic vs simvastatin + placebo ischemic stroke, hospitalization lack of efficacy 
 profile (secondary  for ACS, or symptom-driven 
 CAD prevention)  revascularization 
IMPROVE-IT
38
 Stabilized, high-risk Simvastatin + ezetimibe Cardiovascular death, nonfatal  Study completion 
 patients after an ACS vs simvastatin + placebo MI, hospitalization for UA, anticipated in June  
  revascularization, or stroke 2013 
HPS2-THRIVE Patients with CAD, Niacin-laropiprant vs. Nonfatal MI or coronary death, Preliminary  
 PAD, diabetes placebo in patients nonfatal or fatal stroke, or results indicate 
 mellitus, or CHD receiving simvastatin revascularization no difference in the 
    primary endpoint   
REDUCE-IT Patients with elevated Icosapent ethyl (EPA ethyl Cardiovascular death, MI, stroke, Study completion 
 triglyceride levels ester) vs. placebo in coronary revascularization, or anticipated in 2016 
 and CHD or at least patients receiving statins hospitalization for UA 
 one risk factor for 
 CHD 
REVEAL Patients ≥ 50 years old Anacetrapib vs. placebo in Cardiovascular death, MI, or Study completion 
 with symptomatic CHD patients receiving coronary revascularization anticipated in 2017 
 and history of MI, atorvastatin  
 cerebrovascular  
 disease, PAD, or  
 diabetes mellitus 
SHARP = Study of Heart and Renal Protection; ACCORD = Action to Control Cardiovascular Risk in Diabetes; AIM-HIGH = Atherothrombosis 
Intervention in Metabolic Syndrome with Low HDL Cholesterol/High Triglycerides: Impact on Global Health Outcomes; IMPROVE-IT = Improved 
Reduction of Outcomes: Vytorin Efficacy International Trial; HPS2-THRIVE = Heart Protection Study 2-Treatment of HDL to Reduce the Incidence 
of Vascular Events; REDUCE-IT = Reduction of Cardiovascular Events Outcomes Trial; REVEAL = Randomized Evaluation of the Effects of 
Anacetrapib Through Lipid-Modification; MI = myocardial infarction
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APPENDIX III 
PERSONAL CONTRIBUTIONS TO DISSERTATION CHAPTERS 
Analyses presented in Chapters II and III utilized the Supporting a Multidisciplinary 
Approach to Researching Atherosclerosis (SAMARA) cohort. Research subjects were 
enrolled in the SAMARA cohort and RNA expression data was generated by members of Dr. 
Cam Patterson’s laboratory. Utilizing this dataset, I subsequently contributed to this project 
by developing the hypotheses tested in Chapters II and III, generating the plasma 
inflammatory biomarker data in collaboration with the UNC Cytokine Analysis Facility, 
conducting the statistical analysis for the candidate biomarker comparison, conducting the 
functional annotation analysis, analyzing and interpreting the data, and writing each chapter. 
Research subjects were enrolled in the coronary artery disease cohort utilized in 
Chapter IV, by multiple members of Dr. Craig Lee’s laboratory. My contributions to this 
project include enrolling a portion of the patients and assisting in study visits, developing the 
hypotheses tested in the analysis, quantifying plasma eicosanoid levels, working with the 
UNC Cytokine Analysis Facility to quantify circulating biomarkers of inflammation, designing 
and conducting the statistical analyses, analyzing and interpreting the data, and writing the 
chapter. 
The preclinical studies included in Chapter V were designed and conducted by myself in 
collaboration with Dr. Craig Lee. My contributions to this project include developing the 
hypotheses tested, generating the phenotypic data presented in the chapter, analyzing and 
interpreting the data, and writing the chapter.  
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